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Chapter 1: Design, synthesis and structural evaluation of peptidomimetics 
containing new δ-amino acids 
 
I. Introduction 
 
1. Generalities about peptides 
 
 Peptides and proteins are at the base of life and are necessary to living organisms as they 
fulfil multiple functions. They are involved in cell recognition, cell adhesion, signal transduction, 
structure in the intracellular and extracellular matrix and are components of hormones and enzymes. 
These multiple roles can be explained by the immense diversity of peptides and proteins coming from 
the unlimited combination of naturally occurring amino acids.  
Natural peptides and proteins are mainly composed of 20 α-amino acids along with a few 
other relatively scarce ones. Amino acids are organic molecules which possess an amine and a 
carboxylic acid. Their nomenclature uses Greek letters according to the number of carbons which 
separate the carboxylic function to the amine function: α (one carbon), β (2 carbons)… α-amino acids 
can be substituted on the Cα giving birth to a great diversity in amino acids’ chemical and physical 
properties. The simplest α-amino acid, glycine or 2-amino ethanoic acid, is the only achiral amino acid 
as it bears no substituent in α-position. All of the other α-amino acids derive from glycine, with 
substituents comprised of aliphatic chains, aromatic chains or polar aliphatic chains. Natural α-amino 
acids have been classified in five categories: acidic, neutral, basic, hydrophobic and hydrophilic. When 
the amino acid is not glycine, the Cα is a chiral center and natural amino acids are all present in the L-
configuration in Fischer nomenclature. A few examples extracted from exotic molluscs or in cell walls 
of some bacterias are in a D-configuration but their occurrence in nature is rare in comparison to the 
supremacy of L-amino acids (Figure 1). 
 
H2N COOH
R COOH
H2N H
R
H2N
COOH
R2
R1
H2N COOH
R3
R2
R1
α-amino acid L-amino acid in Fischer representation
β -amino acid γ -amino acid
αβ γ β α
α
 
 
Figure 1: α-, β-, γ-amino acids and representation of an α-amino acid in Fischer representation 
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Amino acids are the building blocks of peptides and proteins; they are linked together by an 
amide bond resulting from the condensation of the carboxylic acid of an amino acid with the amino 
functionality of another amino acid. Peptides and proteins can be considered as polymers of amino 
acids and those containing less than 10 amino acids are called oligopeptides. Those that contain up to 
50 amino acids are called peptides and beyond 50, they are called proteins. Starting from only 20 
amino acids, there are therefore 20n possibilities of peptide sequences for a peptide containing n 
amino acids. This makes proteins the biggest family of macromolecules existing on Earth and the 
number of combinations can be considered to be unlimited. 
 
a. Primary structure 
To fully describe peptides and proteins, four types of structures are required. The primary 
structure describes the arrangement of amino acids in the peptide starting from the amino acid having 
a free or protected amino residue on the left (N terminus), and finishing with the amino acid having a 
free or protected carboxylic acid (C terminus). The primary structure defines the sequence of amino 
acids composing a peptide. 
 
b. Secondary structure 
Peptides and proteins do not remain linear in liquid phase or in solid state, the interactions 
they have with their environment cause the chain to fold on itself. This folding can be very organised 
and several distinct secondary structures have been described. Folding is not only driven by the 
environment, but it is also favoured and stabilised by intramolecular hydrogen bonding. The amide 
protons composing the peptide can easily be involved in hydrogen bonding with the carbonyl group of 
another amide in the chain. This web of hydrogen bonding can present a periodicity which is typical for 
a subclass of secondary structure. The way the hydrogen bonding is organised determines the 
secondary structure adopted by the peptide. It is important to note that large proteins do not adopt the 
same secondary structure along their backbone. They will present some domains with a defined 
secondary structure and others that will not be organised at all. Three major secondary structures can 
be defined: helices, β-sheets and turns, all of which having their own nomenclature to describe their 
hydrogen bonding. A non organised secondary structure is called random coil. 
 
- Helices 
Helices present a periodic folding having a curly shape. Most of the time, the helix turns 
clockwise and is called right-handed helix. In the other case it is a left-handed helix. Within the family 
of helices, a few subcategories can be described depending on the periodicity of the helix. 
α-helices are the most common helices adopted by proteins and peptides, they are 
characterised by a hydrogen bond between the CO of an i residue and the NH of the i+4 residue 
forming a 13-membered ring. The mean complete helix loop contains 3.6 residues and is 0.54 nm long, 
which corresponds to a translation of 0.15 nm per residue. The dihedral angles ϕ and ψ of the peptidic 
chain are of -184° and -123°. An α-helix is a very compact structure where the maximum of hydrogen 
bonds is formed and the lateral amino acids chains point out of the helix (Figure 2). 
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Figure 2: α-helix and hydrogen bond pattern 
 
The 310 helix is a helix presenting hydrogen bonding between the CO of the residue i and the 
NH of the i+3 residue forming a ten-membered ring. The helix step is 0.60 nm and contains three 
residues, the dihedral angles ϕ and ψ are of -49° and -26° respectively and therefore the helix is more 
narrow and a little longer than an α-helix. This structural type occurs rarely in nature and is usually 
observed on short distances (2-3 steps). 
Some other less common helical structures have been described such as the Π-helix or the 
left-handed type II helix, which are very specific to a few peptides. Other types of helices have been 
observed in β-peptides like the 14-helix or the 2.712-10 helix with β2-β3-peptides which is a helix 
presenting alternation of 10- and 12-membered ring with 2.7 residue per turn.1 
 
- β-sheets 
β-sheets are the result of hydrogen bonding between two fragments that are far from one 
another. They can differ in their orientation which can be parallel (both fragments are oriented in the 
same direction) or antiparallel when a fragment is oriented from the N terminus to the C terminus and 
the other one is oriented from C terminus to the N terminus (Figure 3). In both cases, the sheet is 
stabilised by interfragment hydrogen bonding. 
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Figure 3: Parallel and antiparallel β-sheet 
 
- Turns 
Turns are small secondary structures that form an elbow in the peptide sequence and can 
induce an antiparallel β-sheet conformation by placing two fragments in front of one another. They are 
classified depending on the ring size of the hydrogen bond forming the turn. 
β-turns are the most common turns and involve hydrogen bonding between the i residue and 
the i+3 residue within a ten-membered ring. There are three types of β-turns depending on the 
dihedral angles: I, II and III (the type III corresponds to a single turn of 310 helix). The mirror images of 
these turns are called I’, II’ and III’. On the other hand, γ-turns involve hydrogen bonding between the i 
and i+2 residue by a seven- membered ring. As observed for β-turns, γ’-turns are the mirror image of 
γ-turns and therefore have opposed dihedral angles. 
 
c. Tertiary structure 
The tertiary structure is basically the way proteins fold themselves three-dimensionally so it is 
possible to see how the different secondary structures are organised one to each other. Some 
domains which are very distant in the primary structure can be neighbours when the protein is folded 
in its active form. A protein can fold spontaneously just by hydrophobic and hydrophilic effects, the 
domains containing hydrophobic residues having the tendency to migrate to the centre of the protein 
with hydrophilic residues appearing at the surface of the protein in aqueous environments. Most of the 
time, proteins need to be matured in cells by enzymes which induce their active form. Some disulfide 
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bridges between two cysteines can be created for example to give more stability to the three-
dimensional structure. 
 
d. Quaternary structure 
The quaternary structure exists only in proteins that are composed of at least two polypeptidic 
chains or subunits. The quaternary structure describes the way the subunits are organised relative to 
one another. The quaternary structure is stabilised by non-covalent interactions (e.g. hydrogen 
bonding and hydrophobic interactions). 
 
2. Conformational studies for secondary structure characterisation 
 
As we have seen, secondary structures are mainly stabilised by hydrogen bonding and their 
characterisation involves many different analyses.2 
 
a. NMR characterisation 
NMR spectroscopy is the most useful technique used to characterise secondary structures. 
Since hydrogen bonding is in great part responsible for the secondary structure, the NMR signals of 
the amide protons can give significant information on how the peptide is organised.  
 
- Solvent choice 
The nature of the solvent can strongly affect the secondary structure adopted by a peptide. 
For example, a peptide may not organise itself in one solvent but could have a well defined secondary 
structure in another solvent or even adopt different structures in two different solvents. 1H-NMR 
spectroscopy can give insights into the hydrogen-bonded state of protons: hydrogen-bonded amide 
protons, either intramolecularly or with the solvent, appear downfield in comparison to non-hydrogen-
bonded amide protons. In non-competitive solvents (e.g. CDCl3), significantly deshielded protons often 
indicate that they are in a hydrogen-bonded state.3 
 
- Dilution studies 
NMR spectroscopy can also be used to make dilution analyses as peptides can aggregate 
together by hydrogen bonding, giving misleading information because the intermolecular hydrogen 
bonding could be mistaken with intramolecular hydrogen bonding. A peptide is considered to not be 
aggregated if in a concentration range (typically in the range of 1 to 10 mM) the amide proton chemical 
shifts remain identical. If a variation is observed at a given concentration in comparison to a lower 
concentration, this means that some aggregation occurs at this concentration. This aggregation effect 
is solvent-dependent as a peptide is more prone to aggregation in non competitive solvents like CDCl3. 
For example, a peptide may easily aggregate in CDCl3 at a given concentration whereas it may not 
aggregate in methanol at the same concentration which is a very polar and competitive solvent.  
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- Variation of temperature 
The coefficient of temperature dependence (∆δ/∆T) can also be measured by NMR 
spectroscopy giving information on the hydrogen-bonded or non-hydrogen-bonded state of the amide 
protons. These studies must be made at a concentration where no aggregation occurs. According to 
some authors, amide protons presenting a small temperature dependence coefficient are either locked 
in hydrogen-bonding or non-hydrogen-bonded (0<∆δ/∆T<3 ppb/K) whereas the NH protons with a 
higher coefficient (between -4 and -8 ppb/K) are in an equilibrium between hydrogen-bonded and a 
non-hydrogen-bonded state.4-8 By contrast, some authors conclude that an amide proton is 
intramolecularly hydrogen-bonded if the absolute value of its temperature dependence coefficient is 
lower than 2.6 ppb/K, without taking into consideration other parameters such as the relative chemical 
shift compared to the other NH protons and that coefficients higher than 2.6 ppb/K indicate a non-
hydrogen-bonded state.9 It is generally belived that amide protons having a low temperature 
dependence coefficient (∆δ/∆T<3 ppb/K) are intramolecularly hydrogen-bonded, NH protons exhibiting 
a ∆δ/∆T between 3 and 8 ppb/K are in an equilibrium between hydrogen-bonded and non-hydrogen-
bonded state and that coefficents higher than 8 ppb/K reveal a non-hydrogen-bonded state. Again, the 
solvent nature can affect these measurements as a polar solvent will be more competitive in creating 
hydrogen bonding with the peptide. It is advised to use CDCl3 for these types of experiments, but if the 
peptide is very polar, it will aggregate in this solvent even at low concentrations making the experiment 
invalid. 
 
- Deuterium proton exchange 
Another technique that gives information on intramolecular hydrogen bonding is proton-
deuterium exchange. CD3OD can be added to a peptide dissolved in a solvent possessing no 
exchangeable deuterium and the deuterium on the hydroxyl group of MeOH-d4 can exchange with 
amide protons of the peptide. The more rapidly it exchanges, the less hydrogen bonded NH proton is 
considered to be. Some differences in exchange rates can be observed between protons involved in 
hydrogen bonding and protons not involved because the protons stabilised by hydrogen bonding will 
be almost blocked making the exchange time with deuterium longer.  
 
- 2D NMR 
2D-NMR is a very useful technique as it allows detecting intramolecular long-range couplings, 
therefore giving information on the neighbouring protons involved in hydrogen bonding. If some 
protons are intramolecularly hydrogen bonded, the 2D analysis by NOESY or ROESY will show 
contacts of the NH proton involved in hydrogen bonding with other protons which are far from it in the 
molecule. For example, in the case of an α-peptide forming an α-helix, an amide proton, in addition to 
coupling with the proton in α-position of the same amino acid which can be seen as well by COSY 
experiment, will couple with the Hα of the neighbour amino acid, and with the Hα of the amino acid i-4 
because this amide proton involved in hydrogen bonding with the CO of the amino acid i-4 will be 
close to its Hα (Figure 4). NOESY can detect contact between two protons in a range of 5Ǻ. To 
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analyse a 2D spectrum, it is useful to have a system where the signals are well dispersed to avoid 
errors in the attribution.  
 
Figure 4: Possible couplings by NOESY or ROESY in an α-helix, blue: COSY signal 
 
b. Circular dichroism 
Circular dichroism is a physical measurement that can help in finding the secondary structure 
of peptides.10 This analysis is performed in solution in high dilution (typically <1 mM) in the absorption 
band of amide bonds (180-250 nm). Circular dichroism measures the ellipticity of a peptide in this 
band with polarised UV light. In this band, the pi→pi* absorption of amides can be observed and it will 
vary according to the hydrogen bonded or non hydrogen bonded state of the amides, therefore it will 
give information on the presence of a secondary structure. Indeed, since a peptide is a chiral molecule, 
it will present an optical rotation on polarised light but this optical rotation can vary with the wavelength. 
The analysis is performed in quartz cells of 1 mm length or less as the solvent absorption can create 
some parasite noise. Not all solvents can be used in CD spectroscopy as the circular dichroism must 
be measured in a band where the solvent does not absorb; methanol (limit at 195 nm for a 1 mm-long 
cell), trifluoroethanol (TFE) or mixtures methanol/water can be used. Chloroform or dichloromethane 
can not be used in this case as they absorb in the same region as amides.  
The ellipticity θ follows the Beer-Lambert law and can be calculated as follows: 
θ= CDmeasured/(C x L x n)  
With: θ: ellipticity in deg.cm2.dmol-1 
C. concentration in mol.L-1 
L: length of the cell in dm 
n: number of NH in the molecule 
 
This technique has the advantage of being fast and one can see almost immediately if the 
peptide adopts a secondary structure or not. The limitation is that one can not deduce exactly which 
amides are involved in hydrogen bonding. It is nevertheless very useful since CD curves of α-peptides 
are typical of a certain secondary structure and so new peptide curves can be compared to reference 
spectra. There has been also a lot of work in the field of β-peptides and some references are available 
but when a peptide containing unnatural amino acids is analysed, this comparison can not always be 
performed with certainty as the curves may differ for identical secondary structures. 
 
c. IR in solution 
Solution IR spectroscopy is another simple and fast way to determine if hydrogen bonding is 
present. This measurement can be done in chloroform or dichloromethane at low concentration (1-2 
mM) and the absorption of amides can be observed. The hydrogen bonded amides absorb at wave 
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numbers <3400 cm-1 and non hydrogen bonded amide absorb at >3400 cm-1. This analysis allows 
direct observation of whether or not the molecule undergoes hydrogen bonding in solution.7 The 
disadvantage is that IR in solution can not be performed in solvents like methanol as the OH group of 
methanol absorbs in the same area as amides and their absorption would be masked by the solvent 
absorption. The other disadvantage, as for circular dichroism, is that it does not give any information 
regarding which amide protons are involved in hydrogen bonding. 
 
d. X-ray crystallography 
X-ray crystallography is a direct way of observing the structure of the peptide. The primary 
difficulty of X-ray crystallography is crystallising the peptides, particularly linear ones which have so 
much mobility that getting a stable crystal is quite challenging. In addition, the peptide may not 
crystallise in the same structure as it is in solution, but the crystal structure can give good information 
on how the peptide folds itself, hydrogen bonding taking place and its secondary structure. 
 
e. Computational studies 
Computational studies can give the preferred conformation of a peptide utilising minimisation 
calculations. The result can confirm experimental results or give an idea of what the structure could be. 
The results can be refined by doing calculations with constraints based on observed long range 
coupling by 2D-NMR. 
 
3. Peptide coupling: overview 
 
The synthesis of peptides has interested chemists for many years and the actual knowledge in 
this field is due to decades of research and improvements. An amino acid contains two reactive 
functionalities in the simplest cases, the additional functionalities present on the lateral chain making 
the synthesis more difficult and complex. To form an amide bond, the condensation of the carboxylic 
acid of an amino acid with the amine of another amino acid is required but can be problematic. If one 
considers a mixture of two free amino acids A an B, controlling the reaction to get only the dipeptide 
H2N-A-B-COOH would be impossible as all possible combinations would take place giving dipeptides, 
tripeptides… To avoid these multiple reactions, chemists have examined the reaction of an N-terminal 
protected amino acid with another C-terminal protected amino acid. In this way, the only possible 
reaction would be between the COOH of the first amino acid and the NH2 of the second amino acid. 
Furthermore, if one wanted to elongate this peptide, one should be able to deprotect only one function 
of the new peptide formed. Then, to synthesise a peptide, one must think of using protecting groups 
that can be removed selectively. These types of protecting groups are called orthogonal. 
The condensation of an amine with a carboxylic acid to give an amide is not spontaneous, so 
is it required to use coupling agent that will favour the amide formation. The coupling agents activate 
the carboxylic acid moiety, which then react with the amine to form the amide bond. A multitude of 
coupling reagents and protecting group have been developed to improve peptide synthesis and some 
of them are specific for difficult couplings like with a secondary amine. 
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a. Coupling reagents 
A coupling reagent will react with the free carboxylic acid functionality creating an activated 
carbonyl group which will then react with the free amino group of another amino acid. The coupling 
reagent does not appear in the reaction and a molecule of water is lost in the condensation. The 
coupling reaction also involves the use of a base which deprotonates the free carboxylic acid (Figure 
5). 
 
 
 
Figure 5: General peptide coupling mechanism  
 
Use of carbodiimides is widespread in peptide synthesis as they are a cheap and efficient way 
for classical couplings and many diverse carbodiimides can be used depending on the solvent used 
for the coupling. The most common carbodiimides are EDC (N-ethyl-N’-dimethylaminopropyl 
carbodiimide), DCC (N,N’-dicyclohexyl carbodiimide) and DIC (N,N’-diisopropyl carbodiimide) and 
these can be used in liquid-phase and solid-phase peptide synthesis. But these reagents suffer from 
some drawbacks such as epimerisation of the activated amino acid. Indeed, the activation of the 
carboxylic acid by a carbodiimide leads to the formation of a very reactive O-acylisourea which then 
reacts with the amine to form the amide bond and an N,N’-disubstituted urea (Figure 6). The problem 
of racemisation occurs when the O-acylisourea is formed. The Hα of the activated amino acid 
becomes very acidic and the base present in the reaction mixture can easily deprotonate it since the 
anion formed is stabilised by the O-acylisourea. The anion can then be reprotonated non 
stereoselectively, effecting racemisation of the amino acid. Some additives can be used to diminish or 
suppress racemisation and accelerate couplings, such as HOSu (hydroxysuccinimide), DMAP 
(dimethylaminopyridine), HOBt (hydroxybenzotriazole) or HOAt (hydroxyazabenzotriazole). 
Carbodiimides can also generate symmetrical acid anhydrides by the reaction of the activated amino 
acid with another N-protected amino acid. The solvent nature also has an effect on racemisation 
(Figure 7). Nevertheless, carbodiimides are limited in reactivity and couplings with secondary amine 
are not that efficient so other coupling reagents are required to perform difficult couplings. 
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Figure 6: Peptide coupling mediated by carbodiimides 
 
 
 
Figure 7: Additives in peptide coupling 
 
Uronium salts are very reactive reagents and can be used to perform difficult couplings. The 
most common are uronium salts of HOBt and HOAt and, although they are higher priced compared to 
carbodiimides, are very efficient reagents for difficult couplings. These reagents exist in two forms: 
uronium and guanidinium: the guanidinim is the predominant form but the uronium is the most reactive 
species (Figure 8). HBTU (uronium PF6- salt of HOBt, widely used in solid phase synthesis) and HATU 
(uronium PF6- salt of HOAt, the most active and expensive) are the most commonly used uronium 
salts and generally assure high yields in peptide coupling. They are usually used as a last resort 
(especially HATU) and on small scale as an industrial scale use would not be profitable. Their 
reactivity comes from their saline nature and good solubility in organic solvents, the presence of the 
benzotriazole ring being advantageous for the approach of the free amine to the activated carboxylic 
acid. In the case of HATU, this approach is even more favoured as the nitrogen in position 7 can 
stabilise the free amine close to the activated carboxylic acid (Figure 9). Once they have reacted, 
HOBt or HOAt are released in the solution and are easily removed from the organic phase by aqueous 
washing. 
Some other types of coupling reagents are used such as phosphonium salts which are 
particularly efficient for the coupling of N-methylated amino acids. They are similar to uronium 
reagents but a phosphonium group replaces the uronium group on the HOAt or HOBt ring. 
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Figure 8: Uronium and Guanidinium forms of HATU and HBTU 
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Figure 9: Peptide coupling mediated by HATU 
 
b. Strategies for peptide coupling 
For peptide synthesis, two major approaches can be adopted according to the amount of 
peptide desired and its length.  
 
- Liquid-phase synthesis 
This strategy is adopted when the synthesis of a short peptide is desired. It has the advantage 
of being inexpensive and to be easily applicable on gram-scale. The disadvantage is that it is time 
consuming because purification has to be performed for every step. It can be realised by the Boc or 
Fmoc strategy. The synthesis starts from an N-Boc or N-Fmoc protected amino acid where the C 
terminus is protected as an ester. Removal of the Boc group is achieved in a mixture TFA/DCM or HCl 
in ethyl acetate or dioxane affording the corresponding ammonium salt. The Fmoc group is removed 
by 20-50% piperidine or morpholine in DMF. The N-protected amino acid to be added to the chain is 
then activated and added to the previous ammonium salt. Once the reaction is finished, extraction and 
column chromatography affords the new peptide which is ready to be subjected to the same reaction 
sequence until the desired peptide is obtained.  Subsequent deprotection of the N-terminal and C 
terminal may be required if a non protected peptide is desired. 
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- Solid-phase synthesis 
This technique has revolutionised peptide synthesis as it is particularly convenient for long 
peptide synthesis. The first examples reported by Merrifield11 on resin supported peptide synthesis 
using a modified polystyrene as a support for peptide synthesis allowed the fast synthesis of complex 
and long peptides. The peptide chain being elongated remains attached to the resin through a linker 
allowing an easy separation as a simple filtration of the unsoluble resin permits removal of the excess 
reagents which are soluble in the mixture. The resin can be immediately used for the next step, and, 
when synthesis is achieved, the peptide can be cleaved from the resin support and affords the desired 
peptide with few impurities. Both Boc and Fmoc strategies can be used but the Fmoc strategy is 
usually preferred as it is realised under milder conditions. The most significant advantage of solid 
phase peptide synthesis is that it can be automated and just a single purification is required to obtain 
pure long peptides. Different types of resins and methods have been developed to improve yields and 
resin supported synthesis has been applied to many fields other than peptide chemistry. 
 
4. Synthesis of unnatural amino acids 
 
For many years, chemists have been interested in creating new molecules that could mimic 
natural products in order to create synthetic drugs that would be more efficient than natural products or 
to avoid tedious extraction from natural sources. In the field of peptide chemistry, scientists were also 
curious to know how a peptide or a protein would behave if it was partially or totally constituted of 
synthetic amino acids. Many examples of unnatural α-amino acids exist and the field of β-amino acids 
has been largely investigated, from simple cases to more and more complex applications giving birth 
to the term of “Foldamers” (Foldable polymers) by Gellman who defined them as unnatural peptides or 
polymers that can fold like natural peptides.12 He also described the approach, the scope and the 
possible applications of this new way of obtaining peptides and their secondary structure 
characterisation. The main motivation of creating unnatural amino acids is that they can adopt 
secondary structures like natural peptides and can be designed to be more effective and selective 
towards a given target involved in a disease, but, being partially or totally unnatural, they would be less 
prone to peptide catabolism. Indeed, several drugs are based on a peptide structure but they can be 
quickly cleaved by proteases before arriving to their target, making them useless even if in in-vitro 
tests they had shown a high activity. The presence of unnatural amino acids in these drugs would slow 
down the action of proteases increasing therefore the drug half-life, and consequently, increasing its 
activity and diminishing the dose required for getting the same efficiency. The introduction of unnatural 
amino acid would also have the effect of being more selective than natural peptide drugs. 
The other interest is more fundamental, creating unnatural peptides and study the structure 
they can adopt would give a better knowledge of the parameters that control specific folding of these 
peptides and, as a consequence, this would lead to a better understanding on how natural peptides 
adopt only one conformation and not another one. The final application would be to prepare unnatural 
peptides “on demand” designed to adopt a specific secondary structure and to have a specific activity 
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where every parameter would have been judiciously chosen to obtain the desired peptide with the 
desired secondary structure. 
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II. Syntheses of δ-amino acids  
 
1. Synthesis of linear δ-amino acids 
 
a. Non enantioselective synthesis of linear δ-amino acids 
The substitution of peptide backbone by a totally or partially non-peptidic sequence is 
relatively new and δ-amino acids have proved to be good candidates since a δ-amino acid could be 
seen as an α-dipeptide mimic. The dipeptide isosteric replacement of an amide bond was first 
theorised in 197613 but investigations regarding this had been relatively scarce until it was 
demonstrated to be a powerful concept in 1980 by Sammes et al.14 for the preparation of double bond 
isosteres of peptide bond towards enkephalin analogues. By a simple approach, they showed that the 
spatial disposition of amide and trans-olefin bonds have very similar angles and lengths and that trans-
olefin isosteres, if inserted in strategic positions into peptide backbones, could exhibit an enhanced 
resistance towards peptidases and a better cell permeability (Figure 10). 
 
1.47
1.54 1.54
 
 
Figure 10: Geometric comparison of amide and trans-olefin backbones 
 
To illustrate their theory, they prepared a trans-olefin dipeptide isostere that would substitute 
the enkephalin amide bond Tyr1-Gly2 which is known to be easily hydrolysed in vivo by amino 
peptidases. Starting from L-tyrosine, the O-t-butyl-N-Boc derivative 1 was prepared and submitted to 
reduction in toluene by DIBAL-H giving the resulting aldehyde 2. After purification, 2 was condensed 
with an alkyne ylide. The enyne 3 was obtained primarily in the trans-configuration, only 6.5% of the 
crystalline cis-isomer was formed and could be separated. After hydroboration and oxidation with 
alkaline hydrogen peroxide, the desired trans-alkene dipeptide isostere of Tyr-Gly 4 was obtained for 
further introduction into enkephalin analogues (Scheme 1). This first attempt is considered as a lead in 
the chemistry of trans-alkene dipeptide isosteres and the approach was reused two years later.15 In 
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1985, they adapted their method for preparing Pro-Gly, Pro-Leu and Pro-Phe dipeptide isosteres.16 
Although this method suffered from racemisation of the substituting group of the originally optically 
pure amino acid,17 it was the first to be successfully utilised to mimic peptide proteases sensitive 
domains. 
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Scheme 1: Synthesis of trans-alkene dipeptide isostere by Sammes et al. 
 
After this first example of trans-olefin isosteres, many variations have been proposed with 
various substituents. Later, Cox et al. published another synthesis of that promising genre of δ-amino 
acids.18 Starting from commercial trans-hex-3-enedioic acid, after methyl esterification and a modified 
Curtius reaction, they could access the fully protected δ-amino acid 6 that could subsequently be 
functionalized by enolate formation with LDA and subsequent reaction with alkyl halides or aldehydes 
in a racemic manner. Products 7a and 7b were obtained with moderate yields. Alternatively, the 
monoester of trans-hex-3-enedioic acid 5 can be esterified with MEMCl to give a mixed diester 8 which 
can be regioselectively alkylated in α-position of the MEM ester. Due to the slow nature of the reaction, 
the use of additives like HMPA is required, but, for toxicity reasons, HMPA was substituted by 
tetramethylurea (TMU). Once the diester was alkylated with benzyl bromide and the MEM group 
removed by TiCl4, the acid was submitted to the same modified Curtius reaction giving the 5-
substituted δ-amino acid 11a. Because the selective deprotection of the MEM group revealed 
impossible with classic procedure, the p-tBuOBn analogue was reacted with aqueous TFA and then 
the free OH was acetylated with acetyl chloride. Subsequent modified Curtius reaction gave the final 
p-AcOBn substituted amino acid 11b (Scheme 2). The diester 12, which was formed as a secondary 
product when preparing 5, could also be used to prepare 2,5-dibenzylated dipeptide isostere 13 by a 
double alkylation with LDA in THF/TMU and benzyl bromide. One diastereomer was crystallized and 
the difficult partial hydrolysis was performed using iodotrimethylsilane in dichloroethane at reflux. The 
subsequent Curtius reaction led to the protected isostere 14 (Scheme 3). Despite the lack of 
stereoselectivity of the syntheses, Cox et al. proposed the first route to substituted trans-olefin 
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isosteres that could give new perspectives for the diversity of products and potential medical 
applications. 
 
 
 
Scheme 2: Route for monosubstituted trans-olefin isosteres by Cox et al. 
 
 
Scheme 3: Route for disubstituted trans-olefin dipeptide isostere 
 
 Gellman et al. have also prepared alkene isosteres for studying their secondary structures. 
Starting from 1,4-dibromo-2,3-dimethylbut-2-ene 15 which was reacted with lithio dithiane, the amino 
functionality was introduced by substitution of the remaining bromine by an azido group and 
subsequent Staudinger reaction afforded 16. After coupling the amine with isobutyryl chloride, the 
dithiane ring was removed and the carboxylic end was obtained by oxidation leading to the 
tetrasubsituted dipeptide isostere 17 (Scheme 4).19,20 
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Scheme 4: Gellman’s dipeptide isostere synthesis 
 
 In 1996, Kessler and coworkers developed their own synthesis of Phe-Gly E-alkene dipeptide 
isostere.21 It is distinctive in that they use a β-elimination to generate the E-double bond. Starting from 
Boc-Phe-OH, they prepared the N-methoxy-N-methylcarboxamide derivative 18 using a known 
method bringing into play propylphosphinic anhydride for C-terminus activation. After allylation with 
allylmagnesium bromide and reduction to the allylic alcohol, the alcohol was mesylated giving 19 as a 
diastereomeric mixture. Subsequent reaction with potassium tert-butylate afforded the desired diene 
20 in good yields. The low temperature proved to be essential since higher temperatures led to the 
formation of by-products in non negligible amounts. Regioselective hydroboration of the diene with 9-
BBN and then further oxidation with Jones reagent allowed for the isolation of the desired trans-
dipeptide isostere 21 (Scheme 5). 
 
 
 
Scheme 5: Kessler’s trans-alkene dipeptide isostere 
 
 Although alkene dipeptide isosteres have received a great deal of attention, some groups 
focused on creating non alkene dipeptide isosteres. Kuwahara et al.22 have worked on the synthesis of 
ether dipeptide isosteres that would have the advantage of being more polar than an alkene dipeptide 
isotere. To do so, they started from L-homoserine 22 and after adequate protection of the amine, acid 
and alcohol functionalities, the fully protected homoserine ester 23 was reduced to the corresponding 
alcohol 24. Reaction of the alcohol with sodium hydride and bromoacetic acid tert-butyl ester afforded 
the expected protected δ-amino acid 25 with an ether linkage in β-position (Scheme 6). 
Other groups have tried to replace the amide bond by an ester function as this would mimic 
even better the amide bond polarity. The preparation of this type of derivatives is relatively easy. To 
replace the fragment Pro-Gly, Raines et al. coupled Fmoc-Pro 26 with benzyl 2-hydroxyacetate23 and 
subsequent debenzylation afforded the dipeptide isostere 27 for solid-phase synthesis (Scheme 7). 
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Scheme 6: Ether linkage containing δ-amino acid synthesis 
 
  
 
 
Scheme 7: Synthesis of ester containing dipeptide isosteres 
 
 An alternative replacement of the amide bond can be achieved by introducing a phosphinic 
acid functionality giving birth to phosphino dipeptide isosteres as Kessler et al. reported.24 The 
synthesis is straightforward, using the racemic phosphinic acid 28 derived from Cbz protected leucine, 
it was activated with HMDS and subsequently reacted with α-methyl acrylate in a Michael type 
reaction giving the fully protected phosphino dipeptide isostere 29. Deprotection with aqueous HI 
afforded the deprotected phosphino δ-amino acid 30. The drawback of the synthesis is that the 
dipeptide isostere was obtained under its four diastereoisomeric forms (Scheme 8). 
 
 
 
Scheme 8: Synthesis of phosphino dipeptide isostere 
 
 Fluoroolefin isosteres can also be a good mimic of dipeptide amide bonds regarding geometry 
and polarity. The first example of this type was reported by Allmendinger et al.25 who first calculated 
the geometry of a simple fluoroolefin to compare it with a trans-alkene and an amide and came to the 
conclusion that a fluoroolefin was even closer to the amide backbone than the trans-alkene backbone 
was. Using dihydrofurane as a starting material, it was converted to the cyclic acetal 31. An acid 
catalysed hydrolysis accompanied by concomitant double bond isomerisation and protection of the 
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alcohol by TDS chloride afforded the aldehyde 32. A sequence of reduction, bromination, azidation, 
reduction and Boc protection allowed the introduction of the nitrogen moiety to form 33. A subsequent 
cleavage of the silyl ether and Jones oxidation gave the fluoroolefin Gly-Gly dipeptide isostere 34 in 
good yields. Using 32, they also prepared the Phe-Gly fluoroisostere in E and Z conformations 
(Scheme 9). 
 
 
 
Scheme 9: Synthesis of fluoroolefin isostere 
 
b. Enantioselective synthesis of linear δ-amino acids 
 Synthesising linear δ-amino acids with one or more chiral centers created during the synthesis 
is quite challenging. Most of the time, the chiral centers are introduced using commercially available 
enantiomerically pure starting materials. Nevertheless, many groups have developed enantioselective 
ways of syntheses that could allow a higher efficiency for the preparation of the desired biologically 
active product by the asymmetric introduction of substituents that are difficult to obtain via natural 
amino acids. 
The first stereocontrolled synthesis of trans-alkene dipeptide isosteres was reported by 
Spaltenstein and coworkers who used the Julia olefin synthesis to prepare Tyr-Ala isosteres.26 The 
sulfone 36 was prepared from the protected tyrosine derivative 35. The chiral aldehyde 39 was 
prepared using the Evans oxazolidinone 37. The Julia olefin synthesis proceeded well and afforded 
the dipeptide isostere 41 which led to the corresponding δ-amino acid 42 (Scheme 10). 
A variety of alkyl substituted alkene dipeptide isosteres have been developed and some 
additional efforts have been reported for fluoroalkene isosteres since they were predicted to exhibit 
interesting properties. Allmendinger et al., who were the first to publish the synthesis of fluoroalkene 
isosteres in a racemic form, reported at the same time an enantioselective method for the preparation 
of fluoroolefin isosteres.27 The enol ether 43 was transformed to the chlorofluorocyclopropane 44 
which was then converted to the aldehyde 45. The hydroxyesters 46 and 47 could be obtained by 
addition of chiral reagents giving the compounds with the hydroxyl groups in either configuration 
(Scheme 11). 
46 and 47 could be submitted to the same reaction sequence involving the cleavage of the 
chiral auxiliary and conversion to the bis-iminoester 48. This bis-iminoester was then rearranged by a 
hetero-Cope mechanism to the corresponding acetamide 49 in refluxing xylene with conservation of 
Chapter 1: Design, synthesis and structural evaluation of peptidomimetics containing new δ-amino acids 
 21 
the chirality. The end of the synthesis consisted of adequate deprotection, protection and Jones 
oxidation affording 50 (Scheme 12). 
 
 
 
Scheme 10: First stereocontrolled synthesis of trans-alkene dipeptide isosteres  
 
 
 
Scheme 11: Synthesis of chiral precursors of fluoroolefin isosteres 
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Scheme 12: Enantioselective synthesis of fluoroolefin dipeptide isosteres 
 
Bartlett and Otake have also reported the synthesis of a fluoroalkene. Starting from an 
optically pure oxazolidinone 51,28 they prepared an enantiopure silyl alcohol 52 which was then 
oxidised and condensed with diethyl fluorooxaloacetate to give the fluoroacrylate 53 in a 2.3:1 mixture 
of Z:E isomers. After separation, the Z-isomer could be aminated, reduced to an allylic amine and 
protected to afford the Cbz protected amino group. Deprotection of the silyl ether and further oxidation 
of the alcohol afforded the desired Cbz protected fluoroalkene dipeptide isostere 54 (Scheme 13). 
 
 
 
Scheme 13: Synthesis of fluoroalkene dipeptide isostere 
 
Wipf et al. have been examining the preparation of chiral aziridines and have reported an 
elegant method for the preparation of a variety of polysubstituted (E)-alkene isosteres by a cuprate-
based approach.29 Starting from a substituted allylic alcohol 55, they could synthesize enantiomerically 
pure epoxy alcohols 56 by Sharpless asymmetric epoxidation in the presence of (+)-diisopropyl 
tartrate. The epoxy alcohol was then submitted to a Swern oxidation followed by a Wittig chain 
extension. The epoxide ring was then selectively opened using sodium azide and ammonium chloride 
affording 58 in a high d.r. (19:1). A Staudinger reaction on the azido alcohol 58 allowed the formation 
of the aziridine 59 which was then N-acylated to give the desired alkenylaziridine 60 (Scheme 14). 
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Using this method, the authors prepared a variety of polysubtituted alkenylaziridines with overall yields 
ranging from 24 to 47% from epoxy alcohols. Formation of trans-olefin isostere was then realized by a 
cuprate-based SN2’ reactions which, depending on the substrate and the cuprate used, led to α-
alkylation and subsequent ring opening giving the desired dipeptide isostere 61 and other by-products, 
including the δ-amino acids 62 and 66 (Scheme 15). 
 
 
Scheme 14: Wipf’s route for polysubstituted alkenyl aziridines 
 
 A few years later, the same group applied a similar methodology for a variety E-alkene 
dipeptide isosteres from alkenylaziridines utilising solid phase techniques. The δ-amino acid 70 
synthesized could be cleaved from the resin to give 71, or readily useable for peptide solid phase 
synthesis (Scheme 16).30 
 The authors also prepared, utilizing their aziridine method,31 the optically pure 
(trifluoromethyl)alkene peptide isostere 79 and compared it with the non-fluorinated ones 74 and 83. 
To do so, some α, δ- and α, γ, δ-substituted isosteres were synthesised by different methods having in 
common the use of chiral epoxides and aziridines (Scheme 17). 
Embrey et al. developed a method for synthesising γ-alkylated (E)-olefin dipeptide isosteres 
using the oxazolidinone 84 as a starting material.32 An asymmetric aldol reaction allowed for two chiral 
centers to be created in the presence of dibutylboron triflate and triethylamine in dichloromethane. 
After replacement of the oxazolidinone by a methyl ester with LiOOH and diazomethane, the alcohol 
functionality was converted to the acetimidate 87 with trichloroacetonitrile and DBU in DCM. A 
stereospecific [3,3] rearrangement of the acetimidate 87 in refluxing xylene resulted in the quantitative 
formation of the E-olefin backbone of the product 88. The δ-amino acid 89 could be obtained by 
acetamide and ester hydrolysis and Boc-protection. The good overall yield and the synthesis’ 
efficiency make this a good method for getting enantiomerically pure γ-substituted E-olefin isosteres 
(Scheme 18). 
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Scheme 15: Cuprate based reaction of Wipf leading to substituted (E)-alkene isosteres and 
by-products detected in the reaction 
 
 
 
Scheme 16: Solid-phase synthesis of E-alkene isosteres derived from alkenylaziridines 
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Scheme 17: Stereoselective syntheses of methyl and trifluoromethyl alkene isosteres 
 
 Ghosh et al. have prepared a trisubstituted δ-amino acid in few steps.33 Starting from two 
differently substituted chiral γ-lactones 90, a simple stereoselective alkylation by LiHMDS and methyl 
iodide in THF permitted the introduction of the third substituent with a high diastereoselectivity 
(d.r.>95%). Subsequent saponification of the lactone 91 and protection of the γ-hydroxy group with 
tert-butyldimethylsilyl chloride afforded the desired hydroxyethylene isostere 92 (Scheme 19).  
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Scheme 18: Synthesis of chiral γ-substituted alkene dipeptide isosteres 
 
 
 
 
Scheme 19: Synthesis of chiral trisubstituted δ-amino acid 
 
 In 2004, Haug and Rich have published a long synthesis of Gln-Phe hydroxyethylene 
dipeptide isostere.34 Utilising Boc-Glu-OBn 93 as a starting material, they prepared the succinimide 
ester derivative, which was then reduced to give the free hydroxylated product 94. After protection with 
TBSCl, the reaction with lithio dimethyl methylphosphonate afforded the corresponding keto 
phosphonate 95 which was then utilised for a Horner-Wadsworth-Emmons reaction with methyl 
glyoxolate to give a mixture of cis- and trans-alkenes in a 2/3 ratio. Subsequent hydrogenation led to 
the saturated ketoester 96 in good yields. A stereoselective reduction of the ketone with LiAlH(OtBu)3 
under chelation control conditions gave almost exclusively the anti-amino alcohol derivative 97 which 
was submitted to lactonisation with acetic acid in refluxing toluene and the expected separable lactone 
98 could be obtained with only traces of its diastereomer. Attempts to alkylate the lactone with LDA 
and alkyl halides gave the undesired (2S)-diastereoisomer and another method was envisaged. 
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Thanks to an aldol-elimination-hydrogenation sequence, they could obtain the (2R)-diastereoisomer 
99 and, as a consequence, all the stereocenters they desired were already introduced. Introduction of 
a second Boc group on the amine was required to avoid cyclisation or epimerisation of the substrate 
when submitted to a Jones oxidation which allowed the formation of the carboxylic acid 100 in place of 
the silyl ether. The amide functionality of Gln was then introduced by coupling with 2,4,6-trimethoxy 
benzylamine. Selective removal of one of both Boc groups could be performed by using LiBr affording 
101. The direct use of LiOH to hydrolyse the lactone was accompanied by Boc-cleavage and 
epimerisation of the α-carbon atom. Hydrolysis of the lactone 101 finally gave the expected Gln-Phe 
hydroxyethylene isostere 102a. It is noteworthy that using the benzylated lactone intermediate 99 in 
the same conditions afforded a second hydroxyethylene dipeptide isostere 102b correctly protected for 
peptide synthesis (Scheme 20). 
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Scheme 20: Haug and Rich’s synthesis 
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 Hom et al. also prepared hydroxyethylene dipeptide isosteres containing fluorine.35 They 
prepared the lactone precursor 103 starting from Boc-3,5-difluorophenylalanine and alkylated it by 
classical procedures as in the previous example in order to introduce various substituents. Once 
coupled to dipropylcarbamoyl benzoic acid, the lactone ring was opened with trimethyl aluminium and 
a primary amine affording the fluorinated hydroxyethylene dipeptide isostere 105 already coupled on 
its carboxy and amine ends (Scheme 21). 
 
 
 
Scheme 21: Example of fluorinated hydroxyethylene dipeptide isostere 
 
 The interest for δ-amino acids is not only academic as even Pfizer has worked on a method for 
obtaining chiral imidazole substituted δ-amino acids.36 After testing two routes (crystallisation and 
enantioselective hydrogenation) to obtain the desired enantiomer of 107, they combined these two 
approaches to obtain 107 in high yields and high ee’s. The best compromise found was the 
combination of a rhodium cyclooctadiene complex with a quinidine salt where a total asymmetric 
induction of with 62% ee was observed using only 0.02 mol% of catalyst (Scheme 22). 
 
 
 
Scheme 22: Pfizer’s asymmetric hydrogenation combined to crystallisation 
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 In the synthesis of δ-amino acids, and particularly for dipeptide isosteres, the use of Evans 
oxazolidinone method has been widely accepted because of its efficiency and ease. Kelly et al. used it 
in 2005 37 for preparing the Phe-Phe alkene dipeptide isostere 112. Starting with the aldehyde 108 
obtained from phenylalanine, a Wittig reaction followed by hydroboration afforded the N-Boc-Phe-Gly 
dipeptide isostere 109. The acid, condensed with a chiral oxazolidinone, was diastereoselectively 
alkylated in an 11/1 d.r. and then, the oxazolidinone was cleaved to give the Phe-Phe alkene dipeptide 
isostere 112 (Scheme 23). 
 
 Urones et al. have recently developed an original way to access to highly optically active δ-
amino acids.38 Starting from a variety of acetylated Baylis-Hillman adducts 113, they were reacted with 
a chiral lithium amide in THF at low temperature and the desired δ-amino acid 115 could be obtained 
in high diastereomeric excess (from 72 to 95%) (Scheme 24). 
 
 
Scheme 23: Use of Evans oxazolidinone for chiral induction in alkene dipeptide isostere 
synthesis 
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Scheme 24: δ-amino acid obtained by Ireland-Claisen rearrangement 
 
2. Synthesis of cyclic δ-amino acids 
 
 The syntheses of linear δ-amino acids is very diversified as the methods and reactions used 
are very broad. The preparation of cyclic δ-amino acids has been investigated more thoroughly as 
their inner rigidity is very attractive for obtaining peptides presenting secondary structures. The 
synthesis of cyclic δ-amino acids also involves different types of chemistry and starting materials 
allowing the preparation of cyclic products with various ring sizes and conformations. 
 
 a. Three membered ring δ-amino acids 
 Starting from the linear δ-amino acid 115, Kaltenbrom et al. prepared the three membered ring 
dipeptide isostere 116 as a mixture of diastereomers using an epoxidation with mCPBA (Scheme 
25).39 
 
 
Scheme 25: Synthesis of an epoxide δ-amino acid 
 
 This first example gave rise to similar products having different substituents and 
diastereomeric ratios.40-42 
 In 1996, Mann published another method which had the advantage of affording the epoxide 
isostere in an enantioselective manner.43 The synthesis involved the preparation of the intermediate 
119 from the silylketene 118 and the chiral aldehyde 117 by a Mukaiyama aldol type reaction. The 
intermediate 119 could be cyclised with mCPBA and the ester saponified with sodium hydroxide 
affording the epoxy δ-amino acid 120 as a single diastereomer (Scheme 26). 
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Scheme 26: Enantioselective synthesis of an oxirane δ-amino acid 
 
Wipf et al. also contributed to the synthesis of three-membered ring δ-amino acids by 
preparing the cyclopropane amino acid 125.44 The methyl alkyne 122 was hydrozirconated with 
Cp2ZrHCl, transmetallated to Me2Zn and added to (diphenylphosphinylimino)phenylarene and the 
resulting allylic phosphamide was cyclopropanated to give the cyclopropane 123. N- and O-
deprotection followed by Cbz protection of the amine afforded the alcohols 124a and 124b as a 
separable mixture of diastereomers. The OH group of 124b was oxidised to the carboxylic acid 
functionality to give the δ-amino acid 125 (Scheme 27). 
 
 
Scheme 27: Wipf’s route to cyclopropane δ-amino acids 
 
b. Four-membered ring δ-amino acids 
Very few examples of four-membered ring δ-amino acids can be found in the literature. In this 
field, the Fleet group has been very prolific and has developed syntheses starting from naturally 
occuring and inexpensive sugars like rhamnose and arabinose. The advantage of using sugars as 
starting materials is that complex products can be accessed in a few steps. As an example, they 
recently prepared the 2,4-cis-oxetane δ-amino acid from L-arabinose.45 The key step involved the ring 
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closure of the lactone 127 in basic conditions to obtain the oxetane azide methyl ester 128 which could 
be simply trans-esterified and reduced to afford the corresponding amino acid 129 (Scheme 28). 
 
 
 
Scheme 28: Fleet’s synthesis of oxetane δ-amino acids 
 
Using the same procedure, they could prepare various substituted oxetane amino acids 
starting with L-rhamnose or D-xylose (Scheme 29).46,47 
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Scheme 29: Oxetane δ-amino acids obtained from L-rhamnose and D-xylose 
 
c. Five-membered ring δ-amino acids 
In 1999, Smith et al. published the synthesis of the tetrasubstituted tetrahydrofuran δ-amino 
acid 136.48 The treatment of the open chain triflate 133 with HCl in methanol and subsequent 
protection of the hydroxyl group afforded the substituted furan product 134 which, after substitution of 
the mesylate with sodium azide and reduction, was converted to the cyclic trans-δ-amino acid 136 
(Scheme 30). 
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Scheme 30: Synthesis of tetrasusbtituted tetrahydrofurane δ-amino acid 
 
Chakraborty et al. published another synthesis of a furan amino acid using the hexose 137 as 
a starting material.49 The key step of the synthesis was the cleavage of the sugar ring and formation of 
a terminal aziridine which could then be cyclised selectively affording the N-protected furan amino acid 
141 (Scheme 31). 
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Scheme 31: Synthesis of furanoid δ-amino acid by Chakraborty 
 
Van Well et al. synthesised a locked furan amino acid by the regioselective ring closing of the 
dimesylated compound 146 in basic conditions after prior deprotection.50 The final Staudinger reaction 
and TEMPO oxidation afforded the locked furanoid δ-amino acid 148 (Scheme 32). 
In 2004, Hanessian and Brassard51 published the synthesis of the trans-furan δ-amino acid 
157 by preparing the dehydrobutyrolactone 150 which was selectively vinylated and reduced to the 
corresponding furan 152 with DIBAL-H. Ozonolysis and diastereoselective nitroaldol reaction afforded 
the compound 155 which was protected and reduced before oxidation of the TBDPS protected alcohol 
and esterification with diazomethane to afford the cyclic hydroxyethylene isostere 157 (Scheme 33). 
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Scheme 32: Synthesis of locked furan amino acid 
 
 
 
Scheme 33: Hanessian synthesis of a hydroxyethylene dipeptide isostere 
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d. Six-membered ring δ-amino acids 
The syntheses of six-membered ring δ-amino acids use in many cases natural sugars as 
starting materials due to their large diversity which permits the synthesis of highly functionalised amino 
acids. 
Graf von Roedern et al. synthesised a pyranoid δ-amino acid using glucosamine 158 as a 
starting material,52 in which the amino functionality, after α-bromination of the anomeric hydroxyl group 
and concomitant acetylation of the other hydroxyl groups, was transformed to the β-methoxy NHCbz 
derivative 160. The deprotection of the hydroxyl groups and oxidation of the C6 alcohol afforded the 
cyclic δ-amino acid 162 (Scheme 34). 
 
 
 
Scheme 34: Synthesis of a pyranoid δ-amino acid 
 
In 1999, Overkleeft et al. published the synthesis of a sugar δ-amino acid starting from 3,4,6-
tri-O-acetyl-D-glucal 163.53 It was subjected to a Ferrier rearrangement with trimethylsilyl cyanide and 
a catalytic amount of BF3•Et2O that gave a separable mixture of cyanides. The major isomer 164 could 
be used in two different reaction sequences affording the amino acids 166 and 168 which were 
opposite δ-amino acids regarding the positions of the carboxylic acid and amine moieties (Scheme 35). 
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Scheme 35: Syntheses of two opposite δ-amino acids from the same starting material 
 
Risseeuw et al. proposed in 2007 an original synthesis of an alkylated sugar δ-amino acid.54 
The synthesis started with benzyl protected formyl glucopyranose 169 which, after reaction with (R)- or 
(S)-butanesulfinimide in the presence of Ti(OiPr)4 and subsequent alkylation with MeMgBr afforded the 
adduct 171 with an excellent diastereoisomeric excess. Hydrolysis with HCl in methanol and Fmoc 
protection of the amine followed by the selective deprotection of the OH on the C6 and TEMPO 
oxidation yielded the new sugar δ-amino acid 173 which had the unusual feature of having a chiral 
centre in the δ-position (Scheme 36). 
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Scheme 36: Synthesis of alkylated sugar δ-amino acid 
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III. δ-amino acis in foldamers 
 
 The major application of δ-amino acids can be found in the synthesis of inhibitors since their 
backbone corresponds to an α-dipeptide and their introduction into peptidomimetics as ground state 
analogues in order to inhibit specific targets has been widely investigated. They have found 
applications as enkephalin analogues14,15,50,55,56, human β-secretase inhibitors24,33,35,57,58 as well as in 
the very potent non peptidic renin inhibitor Aliskiren® 59 developed by Novartis which has received the 
approval of the U.S. Food and Drug Administration for the treatment of hypertension. Most of the time, 
the δ-amino acids inserted in inhibitors are placed in strategic domains where they do not participate in 
the secondary structure of the peptidomimetic as their role is limited to inhibiting the cleavage by a 
diverse array of enzymes.  
Nevertheless, δ-amino acids have a great potential for secondary structure induction for the 
same reasons as they have been used in inhibitors: their backbone mimics α-dipeptides and they may 
offer folding properties similar to α-peptides. This potential has been described computationally by 
Hofmann et al. who calculated the possible secondary structures that could be adopted by δ-amino 
acids.60 The calculations revealed that homopeptides of δ-amino acids could adopt a large variety of 
helical structures presenting 8-, 10-, 14-, 16-, 20- and 22-membered rings closed by hydrogen bonding. 
In addition, δ-amino acids can induce β-turns, especially the cyclic analogues which confirmed the 
importance of a blocked conformation of the δ-amino acid for the stabilisation of secondary structures. 
Gellman et al., who prepared the alkene dipeptide isostere 17, investigated its secondary 
structure induction ability by preparing the protected monomer 174 and the tripeptide 175. NMR and 
IR spectroscopic studies in solution showed that both formed a β-hairpin resulting from a ten-
membered ring and that for 175, the flanking α-amino acids were engaged in hydrogen bonding as 
well, therefore initiating a β-sheet (Scheme 37).19 
 
 
 
Scheme 37: β-turn and β-hairpin induced by the alkene isostere 17 
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Still using alkene dipeptide isosteres, they have observed analogous features with a range of 
tetrasubsituted alkene isosteres and non-substituted dipeptide isosteres.20 It was proposed that the 
hairpin structures are stabilised by the avoidance of allylic strain compared to the non substituted 
analogues which exhibited less stable structures.  
Ornithine is a natural linear α-δ-diamino acid and Nowick and coworkers have prepared 
hairpin mimicks using it as a δ-amino acid.61 It was able to induce a β-hairpin in the linear peptide 176 
as well as in the cyclic peptide 177 which was closed with a second ornithine building block (Scheme 
38). 
Still utilising peptides containing δ-ornithine that induced β-hairpin formation, the same authors 
were able to mimic quarternary structures. These quaternary structures could be adopted by a family 
of linear and cyclic peptides.62,63 Peptide 179 was able to form a β-sheet that could dimerise with 
another β-sheet and the cyclic peptide 180 could as well form dimers of β-sheets that could organise 
in a quaternary structure by formation of tetramers (Scheme 39). 
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Scheme 38: β-hairpin structures based on δ-ornithine 
 
Zhao et al. reported the folding of δ-peptides driven by donor-acceptor interactions.64 The 
peptide was composed of L-ornithine which was substituted either by a donor substituent or an 
acceptor substituent. The peptide could adopt a zipper-featured foldamer-like structure since the 
secondary structure was stabilised by pi-stacking between the electron-rich 1,5-dioxynaphtalene (DAN) 
and the electron deficient pyromellitic diimide (PDI). The peptide 181 was named a zipper-featured 
foldamer as the appendages DAN and PDI linked to the α-NH of ornithine were arranged alternatively 
one between each other as in a zipper (Scheme 40). 
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Scheme 39: Nowick’s peptides forming β-sheet dimers 
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Scheme 40: Zipper featured δ-peptide (Reproduction by courtesy o Dr Zhan Ting Li) 
 
Sugar amino acids have also found many applications as their rigid structure, when compared 
to linear δ-amino acids, is more prone to stabilise secondary structures. 
Kessler’s group has investigated the potential of sugar amino acids in inducing secondary 
structures and have showed that the sugar δ-amino acid 18265 could induce a flexible β-turn (Scheme 
41).66 
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Scheme 41: Sugar δ-amino acid inducing a β-turn 
 
Fleet’s group has also prepared a variety of sugar δ-amino acids that adopted secondary 
structures such as 183, whose tetramer and octamer adopted a succession of β-turns.67 The octamer 
of 184 induced a helical secondary structure with a repetition of 16-membered rings68 and the tetramer 
and hexamer of the oxetane amino acid 129 exhibited a β-bend ribbon like structure69 as well as did 
the tetramer of 185 (Scheme 42).70 
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Scheme 42: Fleet’s sugar δ-amino acids inducing diverse secondary structures 
 
When introduced into mixed peptides, δ-amino acids have also shown a significant potential 
for inducing secondary structures as demonstrated by Chakraborty via the preparation of the short α-
δ-peptide 186. A succession of β-turns could be observed in addition to a 9-membered ring at the C 
terminal of the peptide between the terminal leucine and an OH group of the furanoid δ-amino acid.71 
This peptide had the ability of forming organogels in non-polar solvents and displayed interesting 
nanostructures (Scheme 43). 
 
O
OHO
H
O
N
H
O
N O
NH
O
H
N
H
O
HN
OO
OHHO
BocHN
Ph
Ph
186
 
Scheme 43: Mixed α-δ-peptide presenting an alternation of β-turns 
 
 IV. Aim of this work 
 
Previously in our group, a δ-amino acid based on a γ-butyrolactone ring was prepared and 
coupled to a tetramer, CD spectroscopy revealed that it could adopt a helical conformation but no 
other evidence could be collected, especially the 2D-NMR was not very well dispersed. The δ-amino 
acid can be obtained starting from the asymmetric cyclopropanation developed in our group. The 
cyclopropanated compound 189 is then submitted to ozonolysis and Sakurai allylation affording a 
chiral allylated cyclopropane alcohol. This compound can be lactonised very easily to form the 
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corresponding γ-butyrolactonaldehyde 192 on which is added a paramethoxybenzylamine group by 
reductive amination. After Boc protection, PMB cleavage and oxidation can be obtained the δ-amino 
acid 199 ready for peptide coupling. Alternative procedures for the synthesis of the building block have 
been investigated as well as its α-substitution in order to improve the NMR dispersion of the building 
block. The introduction of the building blocks into homopolymers and mixed peptides has been 
investigated for structural characterisation of the resulting peptides. The peptides’ structures were 
characterised by NMR spectroscopy, CD spectroscopy, IR in solution and computational studies 
(Scheme 44). 
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Scheme 44: Retrosynthesis of the building blocks and peptides syntheses
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V. Synthesis of γ-butyrolactonaldehyde 
 
1. Asymmetric cyclopropanation of furan methyl ester 
 
Substituted cyclopropanes are an important class of compounds present in many natural 
products. They are also useful building blocks in organic synthesis as they can give access to diverse 
chiral compounds. Particularly, cyclopropanes vicinally substituted with donor and acceptor moieties 
can be very useful since they are subject to an easy ring opening giving rise to reactive intermediates 
that can be transformed into interesting compounds. 
In our group has been developed the enantioselective cyclopropanation of furan methyl ester 
187 catalysed by Cu(OTf)2. The cyclopropanation of 187 with ethyl diazoacetate in the presence of a 
catalytic amount of Cu(OTf)2, phenylhydrazine and the bis-oxazoline 188 occured regio- and 
enantioselectively.72 The bis-oxazoline, complexed to the copper carbene, allows the approach of the 
substrate only by the less hindered double bond. Then, the positioning of the substrate is controlled by 
the steric hindrance of the isopropyl groups of the bis-oxazoline ligand and the cyclopropanation of the 
double bond is then directed almost only on one face of the substrate. The cyclopropanated 
compound 189 could be obtained in 36% yield and 95% ee. A single recrystallisation permitted to get 
the cyclopropanated furan methyl ester 189 in more than 99% ee. Despite a moderate yield, this 
reaction can be run on a 50 g scale of 187 and can afford in one reaction 30 g of 189 enantiomerically 
pure(Scheme 45).  
 
OMeO2C OMeO2C
H
H
CO2Et O
N N
O
Cu(OTf)2 (0.7 mol%)
188 (0.8 mol%)
N2=CH-CO2Et (1.6 eq.)
DCM, 0°C
36%, 95% ee187 189 188
 
 
Scheme 45: Cyclopropanation of furan methyl ester 
 
2. Ozonolysis 
 
Ozonolysis of 189 could be realised easily in dichloromethane at -78°C. After ozonolysis, 
dimethylsulfide was added and the flask was equipped with a drying tube to avoid entrance of water 
that would react with the peroxide intermediate and oxidise the aldehyde to the carboxylic acid. The 
reaction afforded 190 in 95% yield after simple extraction (Scheme 46). 
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Scheme 46: Ozonolysis reaction 
 
3. Sakurai allylation 
 
The stereoselectivity of addition of nucleophiles to α-chiral carbonyl compound was first 
postulated by Cram73 and its mechanism was improved by Felkin and Anh.74,75 For stereoelectronic 
reasons, cyclopropyl-substituted carbonyl compounds are more stable in bisected conformations. In 
our case, two bisected conformations are possible: s-cis and s-trans. The s-cis conformation should be 
disfavoured because of steric interactions and the anti-Felkin-Anh product 192 should be obtained. But 
the resulting compound which was obtained was in fact the Felkin-Anh product 191 and some 
interactions specific to our product would explain the higher stability of the s-cis compound. The 
reaction of 190 with BF3•Et2O and allytrimethylsilane afforded quantitatively the allylated cyclopropane 
alcohol 191 in a 95/5 ratio (Scheme 47). 
 
 
Scheme 47: Mechanism of the nucleophilic attack of an aldehyde 
 
4. Retroaldol lactonisation 
 
The cyclopropane compound 191 presents many interesting features for further synthetic 
transformations. The free OH group is located in γ-position relatively to the ethyl ester and the 
cyclopropyl-methyl oxalic diester should saponify easily under basic conditions. The retro-aldol 
lactonisation could be realised with barium hydroxide in methanol affording the γ-butyrolactonaldehyde 
194 in good yields (60%) with the same diastereoisomer
Chapter 1: Design, synthesis and structural evaluation of peptidomimetics containing new δ-amino acids 
 45 
lower yields could be observed when the reaction was scaled up to a few grams. Moreover, the 
presence of barium in the separation mixture was creating emulsion problems and long extraction time. 
We investigated on using alternative to this procedure by using another base. The use of strongly 
basic Dowex resin in methanol increased the yield up to 75% on much higher scale (10 g) and with an 
easier workup as a simple filtration of the insoluble resin afforded the crude mixture whose solvent 
was evaporated and the residue immediately purified by column chromatography. The reaction time 
was shortened to two hours. Unfortunately, after having used intensively the resin, yields were 
decreasing and non negligible amounts of the product 193 were found. The compound 193 could be 
purified and fully characterised, it resulted from the rearrangement of the starting material to an acetal 
in a diasteromeric ratio of 80/20. The substitution of the Dowex resin by triethylamine could afford as 
well 194 in 70% yield on high scale (30 g of starting material) still without extraction. The product 193 
could be reused for lactonisation with Dowex resin or Et3N to form 194 but it was impossible to have a 
total conversion suggesting that the formation of 193 was a secondary reaction in equilibrium with the 
lactonisation process (Scheme 48). 
 
 
 
Scheme 48: Lactonisation mechanism and secondary reaction 
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VI. Synthesis of the δ-amino acid 
 
1. Introduction of the nitrogen moiety by reductive amination 
 
The reductive amination of aldehydes is a common reaction to create secondary amines. It 
can be used in order to insert a protected nitrogen which avoids difficult purification. There are very 
few efficient methods of reductive amination of lactonaldehydes.76 The method involves the formation 
of the imine  resulting from the condensation of the aldehyde with the amine, which is then reduced by 
NaBH3CN76, NaBH477, LiAlH4… The imination step releases water and there is an equilibrium between 
the aldehyde and the imine, trapping the water formed can help in having an almost total conversion to 
the imine, a drying agent can be used like activated molecular sieves 4Å or sodium sulphate. The 
reductive amination is usually realised in methanol as a proton source is required to complete the 
reduction. The reductive amination of 194 was first attempted with benzylamine but yields were not 
satisfying and para-methoxy benzylamine was used instead of benzylamine. The reductive amination 
in pure methanol did not afford good yields and the imination step was then performed in 
dichloromethane, methanol and NaBH4 were added only at the reduction step. NaBH4 was found to be 
more effective than NaBH3CN and was preferred for the reaction. The reduction step was performed 
at 0°C as the addition of MeOH and NaBH4 in the reaction mixture is exothermic. Although good yields 
could be obtained on a 400 mg scale, the reaction showed variable yields sometimes affording much 
less product than expected. The scaling up of the reaction was giving even more unexpected yields. 
The isolation of a secondary product 196 could explain the versatility of the reaction. During the 
reduction step, the resulting secondary aminobutyrolactone 195 can rearrange easily to form the more 
stable γ-lactame 196 which has a similar NMR to the aminobutyrolactone 195 as well as their Rf are 
very close by TLC. After investigation, we came to the conclusion that molecular sieves in powder 
which were used as drying agent could make the yield drop dramatically when the reaction was scaled 
up by forming emulsion, Na2SO4 was then used to dry the reaction solution. Moreover, Na2SO4 was 
not provoking emulsion of the extraction solution. The reduction step time had to be reduced in order 
to avoid the spontaneous formation of the lactame 196 and that a column chromatography was not the 
best way to separate the aminobutyrolactone 195 from the lactam. A simple acidic and basic 
extraction could solve the purification problem and slow addition of methanol dropwise to the reaction 
mixture containing NaBH4 avoided local heating in the solution forming the lactame. Thanks to these 
modifications, the reductive amination could be scaled up to a 2 gram scale with 70% yield (Scheme 
49). 
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Scheme 49: Reductive amination mechanism and by-product isolated 
 
2. Boc protection of the secondary amine 
 
The tert-butoxy carbonyl group is an amine protecting group widely used in liquid phase 
peptide synthesis as it can be removed easily under acidic conditions. The Boc protection of 195 could 
be realised efficiently in a mixture of dioxane and a 1M solution of K2CO3 with Boc anhydride affording 
the Boc protected secondary amine 197 in 74% yield. (Scheme 50) 
 
 
Scheme 50: Boc protection of the secondary amine 
 
3. PMB group removal by cerium ammonium nitrate 
 
The PMB group can be selectively removed by oxidation with cerium ammonium nitrate in mild 
conditions by the method of Yoshimura78,79 who published the optimal conditions for the removal of the 
PMB group using CAN. The efficiency of the deprotection is concentration dependant and optimal 
yields can be obtained using 4 equivalents of CAN at a concentration of 0.25 M in a mixture 
acetonitrile/water 3:1 at 0°C. In the same conditions, the PMB removal by CAN on 197 afforded the 
carbamate 198 in 79% yield (Sheme 51). 
 
 
 
Scheme 51: Oxidative PMB removal by CAN 
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4. Oxidation of the allylic double bond 
 
The allylic double bond could be transformed to a carboxylic acid by a ruthenium catalysed 
oxidative cleavage80 with RuCl3•xH2O (7 mol%) and NaIO4 in a mixture Water/CH3CN/CCl4 2:1:1 at 
0°C in two hours. The pure protected amino acid 199 was purified by a simple extraction with diethyl 
ether and washing with water. The reaction afforded 199 in 86% yield (Scheme 52). 
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Scheme 52: Oxidative cleavage of the allylic double bond 
 
VII. Investigations in the α-substitution of the lactone ring 
 
In order to get a better dispersion of the proton signals of our lactone amino acid, α-
substitution was envisaged so that the signals would be splitted and the characterisation of the 
peptidomimetics facilitated. There are many examples of α-subtitution of lactones and we decided to 
prepare methyl and fluorine substituted lactones as the added functionality would not overlap the other 
signals. 
 
1. Monomethylation of the lactone ring 
 
Methylation of lactones is very common in organic synthesis as many examples of 
diastereoselective methylation of lactones can be found in the literature. The reaction is usually 
performed by deprotonation of an α-proton with strong bases like lithium diisopropyl amide (LDA) or 
lithium hexamethylsilylazane (HMDS) forming the lithium enolate which can be then methylated with 
methyl iodide. The methylation can be highly diastereoselective when realised on a chiral lactone 
having bulky substituents at low temperatures.81-83 The methylation step was realised on the 
compound 197 as the fully protected nitrogen would not be methylated and the bulkiness of the 
substituents should help for getting a good diastereoselectivity. Our first attempts with LDA in THF at 
low temperature were successful as we could get the methylated lactone 200 in good yields (70%) and 
excellent diastereoselectivity (d.r.: 93/7) as our compound before methylation was in a 95/5 d.r.  In 
addition, the NMR dispersion was very interesting for further peptide analyses. But the dry THF used 
was purified by a solvent purification system and some degradation of the solvent quality could be 
observed after a few months of service. The THF apparently contained traces of water and we had 
noticed a gel formation when the fresh LDA was added to the reaction mixture, probably coming from 
the presence of water. Moreover, two or three equivalents of LDA were required to complete the 
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reaction and yields were not as satisfying and it was decided to use freshly distilled THF. The first 
visible effect was that no gel formation occured in the reaction mixture and that only one equivalent of 
LDA was enough to complete the reaction in better yields (85%). But, when analysed by NMR, the 
diastereomeric ratio changed drastically from 93/7 to 3/1. The use of cosolvents like DMPU or 
quenching at low temperature did not improve the diastereoselectivity. When the SPS was fixed, the 
use of its THF led to the same d.r. of 3:1. Having the compound 200 in a moderate d.r. was not 
conceivable for further peptidomimetics conformational analyses and the monomethylation was given 
up (Scheme 53). 
 
 
 
Scheme 53: α-methylation of the lactone ring 
 
Nevertheless, our idea to substitute the lactone in α-position was strengthened as the NMR 
dispersion of the substituted product was good.  
 
2. Fluorination of the lactone ring 
 
Fluorination of the lactone ring was envisaged as it was an attractive idea as we would benefit 
from an additional tool for analysing peptides by 19F-NMR. Fluorine being very electronegative 
compared to a proton or a methyl carbon, the fluorination of lactones necessitates specific fluorinating 
reagents that can perform electrophilic fluorination like N-fluorodibenzene sulfonimide (NFSi) which is 
a source of electrophilic fluorine by Umpolung. A few examples of diastereoselective electrophilic 
fluorination of lactone84 can be found and, usually, the reaction is realised with LiHMDS or LDA in THF 
at low temperatures as in the methylation case. The fluorination of 197 was performed in the same 
conditions as for the methylation and the monofluorinated compound 201 could be obtained in 45% 
yield. The 1H-NMR showed a very nice dispersion and 19F-NMR was used to determine the 
diastereomeric ratio and a set of two doublets of doublets could be observed. The signal was a 
doublet of doublet as the fluorine was coupling with the α-proton (2JHα-Fα) and the β-proton (3JHβ-Jα). 
The ratio of both dd was 2/1 meaning that the fluorination was not very diastereoselective and that we 
could not use it for peptide conformational analysis (Scheme 54). 
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Scheme 54: Electrophilic fluorination of the lactone ring 
 
3. Dimethylation of the lactone ring 
 
As it seemed difficult to have an excellent diastereoselectivity in monosubstituting the lactone 
197, we simply decided to dimethylate it as we knew that the methylation could give good yields. The 
lactone 197 was submitted twice to a deprotonation with one equivalent of LDA followed by addition of 
one equivalent of MeI. A third addition of LDA and addition of 3 equivalents of iodomethane was 
required to complete the reaction as some monomethylated compound was still present in the reaction 
mixture and the mono- and dimethylated compound were difficult to separate by flash chromatography. 
The dimethylated lactone 202 could be obtained in 82% yield and exhibited a very well dispersed NMR 
(Sheme 55). 
 
 
 
Scheme 55: Dimethylation of the lactone 
 
4. Synthesis of the dimethylated δ-amino acid 
 
The dimethylated δ-amino acid was prepared by the same procedures as for the non-
methylated lactone. The PMB removal afforded 203 in 87% yield and the ruthenium chloride catalysed 
oxidation yielded the Boc-protected δ-amino acid 204 in 93% yield. All of these steps were performed 
with better yields in comparison to the non-methylated lactone. The final δ-amino acid had a very 
interesting proton NMR and the synthesis of peptide based on the dimethylated and the non-
methylated δ-amino acid could be envisaged (Scheme 56). 
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Scheme 56: Synthesis of the dimethylated δ-amino acid 
 
VIII. Introduction of the δ-amino acid into peptides 
 
Our building blocks being N-Boc protected, the liquid phase strategy was chosen to prepare 
short peptides. The synthesis of homopeptides as well as mixed peptides was investigated to 
determine the secondary structure potential of our building block. 
 
1. Synthesis of the homopeptide of dimethylated amino acid 
 
The synthesis of the tetramer 208 based on the δ-amino acid was envisaged. A stepwise 
synthesis was chosen as the number of steps was the same compared to a fragment condensation of 
two dimers.  
 
a. Benzyl protection of the δ-amino acid 
The protection of the C terminus of 204 was required to initiate peptide elongation. The benzyl 
ester group is a convenient C protecting group as it can be added easily by reaction of the free 
carboxylic acid with benzyl bromide and potassium carbonate in DMF. The removal of the benzyl 
protecting group can be realised with hydrogen at atmospheric pressure with Pd/C in methanol. The 
benzyl protection of 204 in these conditions afforded the protected δ-amino acid 205 in 76% yield 
(Scheme 57). 
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Scheme 57: Benzyl protection of the δ-amino acid 
 
b. Synthesis of the δ-peptides 
For the liquid phase synthesis, the benzyl protected fragment was Boc deprotected in 
TFA/DCM 1:1 affording the corresponding TFA salt after washing and drying. To this TFA salt was 
added the δ-amino acid 204 beforehand activated by coupling reagent like EDC•HCl or HBTU. The 
coupling of the TFA salt of 205 with 204 and HOBt and EDC•HCl in DCM to form the dimer 206 
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proceeded well with 64% yield. The NMR of 206 was very nice regarding the dispersion and the 
coupling to prepare the trimer 207 was realised. At this point were encountered coupling difficulties. 
The coupling with EDC•HCl and HOBt did not work. Substitution of HOBt by HOAt did not afford the 
trimer as well. Dichloromethane was replaced by DMF and still the trimer could not be obtained. Only 
the use of HBTU and HOAt in DMF afforded the trimer 207 in low yield (15%). The trimer was 
particularly insoluble in most solvents and that may be a reason for the difficulties to obtain it. In the 
same conditions, the coupling of the trimer 207 with another amino acid 204 revealed even more 
difficult as a few milligrams of a white product were obtained but this was not the pure compound. 
LC/MS revealed the presence of the tetramer in the white residue but it was impossible to purify it 
completely (Scheme 58). 
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Scheme 58: Synthesis of δ-peptides 
 
2. Synthesis of alternated α-δ-peptides 
 
The conformational analysis of a mixed peptide containing α- and δ-amino acids can be very 
interesting to observe the behaviour of an unnatural amino acid with α-amino acids as it opens 
perspectives for its introduction into natural peptides. The α-amino acid chosen for the synthesis was 
phenylalanine as its signal would not overlap at all with the non-methylated building block. The 
synthesis of an oligomer of four or five amino acids was envisaged as it would reach a sufficient length 
to adopt a secondary structure as an helical structure can be observed when 6 and more α-amino 
acids are coupled together. The synthesis started by coupling the TFA salt of benzyl phenylalanine 
209 and 199 with EDC•HCl and HOBt which afforded the dimer 210 in 85% yield. Addition of Boc-Phe 
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211 to 210 formed the trimer 212 in 68% yield. Addition of a second δ-amino acid afforded the 
tetramer 213 in 62% yield. The last coupling with Boc-Phe allowed the isolation of the pentamer 214 in 
80% yield (Scheme 59). 
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Scheme 59: Synthesis of α-δ-petides 
 
3. Synthesis of a hairpin-like peptide 
 
Our building block presenting two arms relatively close one to each other, it was interesting for 
us to evaluate its potential as a hairpin inducer. In the computational work of Hofmann et al.60, it had 
been demonstrated that cyclic δ-amino acids could induce β-hairpin formation and some hairpin based 
on δ-amino acids have already been described in the literature2,19,20,61,85 confirming the Hofmann’s 
calculations. The synthesis of a heptapeptide hairpin mimic with a central δ-amino acid was envisaged 
using diverse α-amino acids to get the best dispersion possible. For reasons of efficiency, relatively 
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non polar amino acids were selected. A stepwise synthesis was realised initiating with the TFA salt of 
benzyl phenylalanine 209 which was coupled to Boc-Val 215 affording the dipeptide 216 in 87% yield. 
Addition of Boc-serine to this dipeptide gave the tripeptide 217 in moderate yield (42%). The addition 
of 199 proceeded as well in the formation of the tetrapeptide 218 in moderate yield (49%). When trying 
to couple Boc-Ala to 218, the reaction failed to give the expected pentamer. The tetrapeptide was 
actually very polar because of the presence of serine and we decided to replace it by glycine. The 
coupling of Boc-Glyc to the dipeptide 216 afforded the expected tripeptide 219 in 55% yield. The 
addition of 199 to this tripeptide gave the tetrapeptide 220 in 42% yield. Subsequent addition of Boc-
Ala was successful and the pentapeptide 221 could be obtained in 64% yield. The hexapeptide 223 
was obtained in 63% yield by addition of Boc-Phe. The last coupling step afforded the heptapeptide 
224 in low yield (25%) by addition of Boc-Val (Scheme 60). 
 
 
Scheme 60: Synthesis of hairpin-like peptide 
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IX. Conformational analyses of the peptides synthesised 
 
1. Conformational analyses of the α-δ-peptide 
 
The secondary structure of the mixed α-δ-peptide was investigated using typical analyses: 2D-
NMR, CD spectroscopy, IR in solution, molecular dynamics. 
 
a. CD spectroscopy 
CD measurements were realised on the pentamer 214 which showed interesting features 
suggesting a secondary structure. In methanol at the concentration of 0.1 mM, two positive peaks at 
201 nm and 219 nm and a negative peak at 193 nm could be observed suggesting that an organised 
secondary structure was adopted by the pentapeptide 214 (Figure 11). 
 
 
Figure 11: CD spectroscopy of the α-δ-pentamer 214 in MeOH and TFE 
 
On the other hand, the CD spectrum collected in TFE is very different and only the positive 
peak at 220 nm similar to the one in methanol suggested a changing of conformation. Because of the 
lack of data on secondary structures adopted by mixed α-δ-peptides, no comparison with known 
structures could be done. 
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b. IR in solution 
The pentapeptide 214 being soluble in dichloromethane, it was studied by IR in solution in 
order to determine whether hydrogen bonding was taking place in the molecule. The analysis at 4 mM 
in dichloromethane showed two bands in the NH amide absorption area, one at 3420 cm-1, revealing 
the presence of non-hydrogen bonded amide NHs and a band at 3314 cm-1, significant of 
intramolecular hydrogen bonding. This analysis confirmed the folding of the peptide observed by CD 
spectroscopy (Figure 12). 
 
 
Figure 12: IR in solution of 214 at 4 mM in dichloromethane 
 
c. NMR studies 
The pentapeptide was analysed by NMR using temperature variation, proton deuterium 
exchange and 2D-NMR 
 
- Temperature variation 
The pentapeptide was analysed in CDCl3 and MeOH-d3 and the temperature variation 
coefficient (∆δ/∆T) was calculated for both solvents. Unfortunately, in both solvents, some amide 
protons were overlapped and in CDCl3, some amide protons were hidden under the aromatic protons 
on a big range of temperature, making the calculation of their ∆δ/∆T approximative using only two 
points. (Scheme 61 and table 1). 
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In MeOH-d3, the ∆δ/∆T calculated was pretty high, the only amide protons which would be in 
equilibrium between hydrogen-bonded and non hydrogen-bonded state would be the amide protons of 
both lactones with a ∆δ/∆T of 7.39 ppb/K, the other amide protons being at more than 8 ppb/K. 
Methanol being a competitive solvent, these values must be considered with precaution as they do not 
reflect entirely the bonded or non bonded state of the amide protons. In CDCl3, a totally different 
behaviour is observed as all the amide protons had a high ∆δ/∆T suggesting a non-hydrogen bonded 
state except the carbamate which was almost blocked (∆δ/∆T=3.37 ppb/K). 
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Scheme 61: NH numbering of pentapeptide 214 
 
  
Methanol-d3   
NH 1 and 3 2 4 NHBoc 
δ (ppm) at 273 K 8.295 8.475 8.585 6.995 
∆δ (ppb/K) 
-7,39 -8,35 -8 -10,29 
 
    
 
 
CDCl3   
NH 1 or 3 1 or 3 + 2 or 4 2 or 4 NHBoc 
δ (ppm) at 278 K 7,61 7,925 7,10<δ<7,00 5,425 
∆δ (ppb/K) 
-10,8 -12,26 -12 -3,37 
 
Table1: Temperature variation coefficient of the pentapeptide 214’s NHs in MeOH-d3 and 
CDCl3 
 
- Proton exchange with deuterium 
The pentapeptide was dissolved in pure methanol-d4 and the 1H-NMR was realised at different 
moments after the solubilisation in methanol. The phenylalanine NH protons all disappeared after 15 
minutes meanwhile the amide protons of the lactone rings disappeared after 125 minutes as a light 
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signal was still visible. This result is quite surprising as in very harsh conditions, these amide protons 
resisted pretty well to the exchange with deuterium despite a ∆δ/∆T relatively high. This experiment 
demonstrated that the amide protons belonging to the lactones could be involved in relatively strong 
hydrogen bonding (Figure 13). 
 
 
Figure 13: Deuterium proton exchange between 214 and pure methanol-d4 
 
- 2D-NMR 
NOESY and ROESY experiments could be realised in MeOH-d3 and CDCl3. In CDCl3, some 
amide protons were hidden by the aromatic protons and the assignment was impossible. MeOH-d3 
provided a better dispersion despite some amide protons were overlapping, making the assignment 
difficult (Figure 14). 
 
 
Figure 14: NOE contacts observed in methanol-d3 at 6 mM (Assignment by K. Guitot) 
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As the amide 1 and 3 were overlapping, the assignment was difficult but some contacts could 
be observed. Amides 1 and 3 were found to be close to the CHγ of their own butyrolactone ring. In 
addition, the amide 1 had a strong contact with the carbamate of Phe1 meaning a folding in this part. 
Amides 2 and 4 were showing as well contacts with the CHγ of the upper vicinal butyrolactone ring. 
These different contacts could suggest a large helical structure and were used as constraints in 
computational studies.  
 
d. Computational studies 
Using the NOE constraints above, calculations were realised and the minimum found for the 
pentapeptide 214 suggested an extended helical conformation (Figure 15). 
 
 
 
 
Figure 15: Minimum found by computational studies based on NOE constraints (Calculations 
realised by K. Guitot and L. Formicola) 
 
The calculations suggested that the CO of the carbamate could create hydrogen bonding with 
the NH4 thus forming a 22-membered ring and that the amide proton 1 of the lactone would create 
hydrogen bonding with the CO of the benzyl ester forming therefore a 20-membered ring. In the 
computational work of Hofmann,60 these large 20- and 22-membered ring were described as possible 
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features in secondary structures adopted by δ-amino acids. In these calculations, the amide proton 1 
involved in hydrogen bonding corresponds to the most stable amide proton in the deuterium-proton 
exchange analysis. 
 
e. X-ray studies 
To confirm the diverse data collected on the pentapeptide 214, its crystal structure would have 
been of a great help to fully characterise the secondary structure as we would have had some 
common points between the crystal structure and the secondary structure adopted by 214. Some nice 
crystals could be obtained in a solution of pentane and methanol at -20°C in a biphasic system, but, 
unfortunately, the crystals were very unstable when removed from the mother solution for X-ray 
analysis. After a few minutes, they were drying and losing their crystallinity making X-ray analysis 
impossible as only a couple of diffraction points could be collected. Attempts of crystallisation in 
diverse solvents led to the same result and no X-ray data could be collected. Linear peptide crystals 
are usually difficult to obtain and to stabilise as they have a lot of movement freedom and slight 
changes can destroy their structure. 
 
2. Conformational studies of the hairpin-like peptide 
 
The heptapeptide 221 was synthesised in order to investigate on its behaviour when inserted 
in a peptide containing α-amino acids. The closeness of both arms could favour a hairpin like structure 
or a helical structure. The two arms of our building block could induce a hairpin structure by putting 
two chains of amino acids one to each other. Nevertheless, the trans-configuration may disfavour this 
structure but could induce a helical conformation. Its secondary structure was analysed by CD 
spectroscopy, IR in solution and 2D-NMR. 
 
a. CD spectroscopy 
The heptapeptide 221 was first analysed by CD spectroscopy in MeOH at 0.5 mM. The CD 
spectrum showed three negative peaks at 193 nm, a strong one at 200 nm and a small one at 207 nm 
with a shoulder at 213 nm. A positive peak could also be observed at 225 nm (Figure 16). 
The comparison of the CD spectrum of our compound with a β-hairpin induced by δ-amino 
acid prepared by Aguilera et al.85 did not match at all. But the amino acids composing our product and 
the hairpin of this publication are very different and we could not affirm that 221 did not adopt a 
hairpin-like structure. The solvent being different, they might as well have a different spectrum. 
Moreover, CD spectra of secondary structures of δ-peptides are still very scarce and one can not 
deduce a secondary structure just by comparing with reference curves. Nevertheless, the aspect of 
the CD spectrum of 221 and the irregular peak shapes could suggest the presence of more than one 
conformation or a non-defined secondary structure. 
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Figure 16: CD spectroscopy of 221 at 0.5 mM in MeOH 
 
b. IR in solution 
Despite the heptapeptide 221 was not very soluble in dichloromethane, its analysis by IR in 
solution could be realised at a concentration of 1 mM. The IR spectrum exhibited two distinct bands at 
3420 cm-1 and 3326 cm-1 meaning that our heptapeptide presented intramolecular hydrogen bonding 
(Figure 17). 
 
 
 
Figure 17: IR in solution of 221 at 1 mM in DCM 
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c. 2D-NMR 
The heptapeptide was analysed by 2D-NMR in methanol-d3. The low solubility of the 
compound in chloroform prevented NMR analyses in CDCl3. Many NOE contacts could be observed 
and their assignment confirmed that 221 adopted a secondary structure (Figure 18). The NHBoc of 
Val1 showed a contact with amide 1. Amide 2 had a contact with amide 3 and amide 3, like in the 
pentapeptide 214, showed a contact with the CHγ of its own butyrolactone ring. More interesting, the 
amide 4 of Gly 5 showed a long range coupling with the CHα of Phe2, confirming an interstrand 
hydrogen bonding. This suggested the formation of a 13-membered ring between the NH4 of Gly5 and 
the CO of Phe2. It is interesting to notice that a 13-membered ring is a loop of α-helix. Finally, the NH 
5 of Val6 showed a contact with the NH6 of Phe7. The different coupling observed suggest that an 
irregular helical conformation is adopted by the heptapeptide 221.  
 
 
 
Figure 18: NOE contacts observed for the heptapeptide 221 (assignment by K. Guitot and L. 
Formicola) 
 
The diverse contacts observed resulting from the irregular helical structure adopted by the 
heptapeptide can explain the irregular shape of the CD spectrum. The lactone building block seems to 
disorganise the peptide structure, but does not disrupt it. Moreover, the 13-membered ring observed 
constitutes a loop of α-helix, this demonstrates the potential of our scaffold as helix-inducer. 
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X. Conclusion 
 
Based on the synthesis of a new δ-amino acid scaffold in our group, we have improved the 
synthesis by changing the conditions and reagents leading to improved yields and higher scales.  
The synthesis of substituted lactone δ-amino acids gave disappointing results for the 
monomethylation and monofluorination in terms of diastereoselectivity.  
The dimethylation afforded the new δ-amino acid 204 presenting a much more dispersed NMR 
than the non methylated one, making this scaffold an interesting product for the preparation of 
homopeptide. Unfortunately, the synthesis of the homopeptide revealed difficult and the envisaged 
tetramer could not be isolated. 
The introduction of the δ-amino acid 199 into alternated α-δ-peptides has shown interesting 
folding properties although some NOESY data and X-ray crystallography miss to describe the helical 
secondary structure with certainty.  
The introduction of only one δ-amino acid 199 does not induce hairpin structure as supposed 
at the beginning, but an irregular helical secondary structure featuring, among other things, an 
interstrand hydrogen bond forming a 13-membered ring. This 13-membered ring being a loop of α-
helix, we can deduce that our scaffold can be a helix inducer when introduced into peptides containing 
α-amino acids. 
The investigations on this building block demonstrate its ability to induce secondary structures, 
even though their characterisation can be difficult. 
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Chapter 2: Synthesis of rigidically constrained diketopiperazine scaffolds 
towards foldamers 
 
I. Introduction 
 
Diketopiperazines (DKP) are a class of 6-membered-ring compounds containing 2 amide 
functionalities in a 1,4-spatial relationship. They are the smallest cyclic peptides, resulting from the 
cyclisation of two α-amino acids (Figure 19). 
 
 
 
Figure 19: General structure of diketopiperazines 
 
Although known since a hundred years, they have been considered as by-products in peptide 
synthesis for a long time. They have regained interest from chemists and pharmacologists thanks to 
their biological properties. Their characteristic backbone, which can also be found in numerous natural 
products, constitutes a rich source of new biologically active compounds with diverse therapeutic 
applications.86 Their chemical properties, such as their resistance to proteolysis, possibility of 
mimicking pharmacophore peptide groups, their conformational rigidity and the presence of hydrogen 
bonding donors and hydrogen bonding acceptors are extremely valuable for medicinal chemistry. The 
variety of substituents on the cycle’s carbons as well as on the ring’s nitrogens makes them interesting 
scaffolds for drug design and peptide chemistry. To prepare them, natural α-amino acids can be used 
affording disubstituted diketopiperazines but the diversity of the substituents can be extended using 
disubstituted α-amino acids or more complex amino acids. In addition, the relative planarity of the 
cycle and the presence of two potential stereocenters are an advantage for getting rigid structures with 
interesting properties. 
 
1. Diketopiperazines in natural products and biologically active compounds 
 
In nature, diketopiperazines are biosynthesised by different organisms, including mammals 
and are considered as secondary products of terminal peptide cleavage. They can be extracted from 
natural sources, but can as well be synthesised. The number of biologically active DKP based 
compounds biosynthesised is very large and they have many different activities depending on their 
substituents and a small overview can be useful to realise their importance in therapeutics. 
The DKP are known for having antitumor, antiviral, antifungal and antibacterial activities but 
their most known properties are related to the inhibition of plasminogen activator inhibitor-1 (PAI-1) 
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and alteration of cardiovascular and blood-clotting functions. They also have affinities for calcium 
channels and opioid, GABAergic, serotonin-ergic-5-HT1A and oxytocin receptors. 
PAI-1 is the main physiological inhibitor of the serine proteases, urikinase plasminogen 
activator (uPA) and tissue plasminogen activator (tPA). A correlation between PAI-1 and cancer has 
been demonstrated in mice and high levels of circulating PAI-1 led to increased metastases in animals. 
Diketopiperazines are the most potent PAI-1 inhibitors and the metabolite 222, isolated from 
Streptomyces sp., was the first low-molecular-weight inhibitor of PAI-1 and was used as a model for 
designing new inhibitors based on this structure that could be more efficient. Combining bioisosteric 
substitutions and combinatorial chemistry, a new inhibitor containing a diketopiperazine connected to 
the side chains by exocyclic double bonds 223 was found to be particularly active (IC50=3.5 µM). 
Changing the thienyl-thioether group by a phenyl-ether linkage did not cause any loss in the activity. 
The final addition of an alkyl carboxylic group and a heterocyclic substituent on the other arm led to 
the product 224 which had an increased inhibition of PAI-1 (IC50=0.2 µM) (Figure 20). 
 
 
Figure 20: Diketopiperazines inhibitors of PAI-1 
  
Blood clotting is considered to favour metastatic processes and the cyclo[L-His-L-Tyr] 
diketopiperazine 225 increases the clotting time and prevents platelet adhesion and aggregation 
induced by adenosine diphosphate. Some other blood-clotting-inhibiting diketopiperazines have been 
reported. Cyclo[L-His-L-Phe] showed an antitumor activity (Figure 21). In addition to antitumor activity, 
molecules 225 and 226 have displayed a potential activity for the treatment of cardiovascular 
dysfunctions and could be employed as antiarythmic agents and reduce mortality by ventricular 
fibrillation in myocardial infarction. 
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Figure 21: Histidine-containing diketopiperazines having anti-clotting activity 
 
Phenylahistin 227, very similar to 226, isolated from Aspergillus ustus, is involved in 
microtubule depolymerisation in human A459 lung carcinoma and is cytotoxic to several lines of tumor 
cells. Being structurally very different from colchicine 228, it interacts at the same site in tubulin 
provoking microtubule depolymerisation and inhibiting the progression of cellular cycle.87 The 
diketopiperazine 229, an achiral synthetic analogue of 227 also binds to microtubules and has 
exhibited cytotoxic activity against tumor cell lines from prostate, breast, lung, leukaemia and 
colorectal tumors with IC50 from 4.3 to 18 nM. It had also cytotoxic activity against multidrug cell lines. 
It was demonstrated that it was even more potent than colchicine and vincristine that it is being tested 
in preclinical studies (Figure 22). 
 
 
 
Figure 22: Diketopiperazines 227 and 229 act both at the same tubulin site as colchicine 228  
  
2. Syntheses of diketopiperazines 
 
Diketopiperazines can be synthesised easily and synthetic methods are mainly based on 
reactions on dipeptides. These dipeptides can be simply obtained by α-amino acids by conventional 
methodologies. The interest of using α-amino acids is that the diketopiperazines obtained can be 
diversely substituted, opening to many applications in parallel synthesis and solid-phase synthesis.88  
The first diketopiperazine synthesised was a cyclo-[Gly-Gly] which was realised by simply 
heating glycine under a flow of CO2 or HCl.89 The first examples of DKPs containing unnatural amino 
acids were already described in 1888.90 Chemists realised soon that DKPs could be obtained in an 
efficient manner when the spontaneous formation of cyclo-[Gly-Gly] from glycine ethyl ester was 
described.91,92 Diketopiperazines have been used to determine peptide sequences since the controlled 
hydrolysis of peptides was affording DKPs. Most of them being crystalline, it was then easy to 
compare them with a library of synthetic DKPs. The most common and direct syntheses of 
diketopiperazines involve the cyclisation of a dipeptide ester in basic conditions (Scheme 62). This 
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cyclisation can be accompanied by partial epimerisation of the C terminal amino acid.93 In order to 
diminish epimerisation, a concomitant deprotection of the N terminal amine function and cyclisation 
can be performed using for example a Boc-protected dipeptide ester. In boiling isobutanol and toluene, 
the Boc group decomposes itself and lets the N-deprotected dipeptide spontaneously attack the ester 
functionality to form the diketopiperazine scaffold. 
 
 
Scheme 62: Mechanism of dipeptide cyclisation giving the diketopiperazine scaffold 
  
Synthesis of diketopiperazines can also be performed by solid-phase synthesis employing 
linkers based on nitrophenyl,94 p-thiophenyl (with oxidation of the thiol to the sulfone prior to 
cyclization),95 and 4-bromomethyl-3-nitrobenzoylaminobenzyl96 esters. Even standard Merrifield 
peptide synthesis resin can, under optimized reaction conditions, be used to synthesise DKPs.97 
 
The cyclisation of the dipeptide necessitates an isomerisation of the amide bond from the s-
trans-configuration, more stable, to the s-cis-configuration. Studies have shown that in peptides, 
peptide bond in s-cis-configuration is very scarce, less than 2%, and it has been suggested that the 
presence of bulky substituents on the Cα of the amino acids should prevent even more strongly this 
isomerisation making the cyclisation more difficult. The energy barrier of rotation of the amide bond 
between the s-cis and s-trans configuration has been calculated to be 2.5 kcal/mol.98 In fact, the steric 
hindrance of the α-substituents has a negligible effect on the conformation of the amide bond as cis-
amides are less frequent in Gly-Gly sequences. As a consequence, the energy barrier is easily 
surmountable at room temperature making the cyclisation feasible. The nature of the leaving alcohol 
influences the reactivity, methyl esters forming diketopiperazines more easily than longer alkyl chains. 
The cyclisation efficiency is also very dependant on the nature of α-substituents and the Cα 
configuration since formation of trans-DKPs is easier than for the cis-ones. 
A typical example of spontaneous cyclisation with heating is the case of the artificial 
sweetener aspartame 230. This sugar substitute is used by people under diet as it has a high 
sweetening power, 200 times higher than sucrose. It is a dipeptide of aspartic acid and phenylalanine 
methyl ester. When one takes a look at the advices of use, it is suggested on the packaging to 
sweeten cakes after having cooked it in the oven in order to make the cake taste better. The reason is 
pretty simple, under heating, the aspartame will cyclise, forming the corresponding diketopiperazine 
which does not have any sweet taste. Aspartame is also subject to pH-dependant epimerisation.99 
After a long time of storage, diet drinks containing aspartame were presenting traces of 
diketopiperazine 231. According to some studies, this diketopiperazine presents a little toxicity and the 
acceptable daily intake has been fixed to 7.5 mg/kg/day but its toxicity is still very controversed. 
(Scheme 63) 
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Scheme 63: Cyclisation of aspartame resulting in the formation of a diketopiperazine 
 
In our group, the practical synthesis of a cis-DKP formally derived from the cyclisation of 
aspartic acid and serine has been developed. By a Mitsunobu reaction, the hydroxyl group of the 
serine was replaced by an azido functionality, giving birth to the DKP 232 which bore a carboxylic acid 
and an amino functionalities in a cis relationship and could be seen as the cyclisation of aspartic acid 
with 2,3-diaminopropionic acid. Although being prepared from 2 α-amino acids, this new scaffold can 
also be considered as a conformationnally constrained dipeptide formed by two β-amino acids, and in 
articular a β2-amino acid and a β3-amino acid (according to Seebach nomenclature).100 Using L- or D-
serine as starting material could give access to the cis-DKP 232cis or the trans-DKP 232trans (Figure 
23).101  
 
 
 
Figure 23: Diketopiperazine scaffold of Piarulli’s group 
 
3. Diketopiperazines in peptidomimetics 
 
Diketopiperazine scaffolds are interesting building blocks for peptidomimetics synthesis since 
the rigidity of its ring can greatly favour secondary structure formation by limiting the conformational 
freedom of its lateral chains. The cis-conformation is therefore particularly interesting as it would force 
both peptidic arms to stay close one to each other. 
The work of Wennemers demonstrates very well the potential applications of this scaffold in 
peptidomimetics. They have prepared a library of symmetrical diketopiperazine two-armed receptors 
derived from 4-aminoproline where both tripeptide arms were disposed in a cis-relationship (Figure 24). 
The receptor 233 was coupled with a dye in order to see whether a binding was occurring or not.102 
These receptors were screened toward a library of 5000 tripeptides and exhibited high binding affinity 
towards only a few peptide sequences. In addition, every type of receptor had a specifity for a kind of 
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tripeptide. This selective binding property was attributed to the specific turn geometry adopted by the 
receptors.103  
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Figure 24: Diketopiperazine based receptors 
 
Robinson et al. have prepared the bicyclic diketopiperazine scaffold 235 from L-aspartic acid 
and (2S,3R,4R)-diaminoproline 234, a chiral amino acid derived from the transformation of vitamin C. 
This DKP, when introduced into the cyclic peptide 236, stabilised a β-hairpin conformation (Scheme 
64).104 
 
 
Scheme 64: Diketopiperazine inducing a β-hairpin 
 
Recently in our group, the hexapeptide 237 containing the cis-DKP 232cis also exhibited a β-
hairpin secondary structure.101 Conformational analysis was carried out using 1H-NMR spectroscopy, 
IR spectroscopy, CD spectroscopy and molecular modelling and revealed the formation of a β-hairpin 
mimic involving 10-membered, 18-membered and 24-membered rings by hydrogen bonding between 
the two arms of the diketopiperazine (Figure 25). 
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Figure 25: Hexapeptide containing the cis-DKP 237 exhibting a β-hairpin conformation 
 
4. Diketopiperazines as organocatalysts 
 
Peptides play an important role in living organisms, they have a multitude of roles like 
hormones, receptors, extracellular matrix components and enzymes. These enzymes are of great 
importance since they catalyse biochemical reactions with high efficiency and enantioselectivity. For 
centuries, human have taken benefits of enzymes like in the process of vinification for example and 
chemists have also been very interested in using them in chemical processes, i.e resolution of 
racemics. Since it has been found that simple amino acids or short peptides could have the same 
catalytic properties as enzymes, they have attracted a lot of attention105 as they can catalyse reactions 
in very mild conditions as efficiently as metal catalysts and have a much lower toxicity which is an 
advantage for pharmaceutical applications. Furthermore, they are generally much cheaper than the 
metals and ligands used. The catalytic activity can be explained by the secondary structure they can 
adopt which recreates enzymes active site. Nevertheless, there is a need for designing 
organocatalysts in order to get the best efficiency possible. In addition, there are very few polyvalent 
organocatalysts, they are most of the time effective on a kind of reactions with certain substrates and 
the need of new organocatalysts to broaden the scope of applications is very stimulating. 
Diketopiperazine scaffolds are good candidates for organocatalysis since their rigid structure 
can favour turn formation which mimics the active sites of enzymes. Their role as efficient 
organocatalyst is noteworthy in hydrocyanation of aldehydes with the work of Inoue who prepared the 
cyclo[L-Phe-L-His] 238 which exhibited a very high enantioselectivity in the addition of HCN on 
benzaldehyde with a 97% conversion and 97% ee (Scheme 65).106  
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Scheme 65: Hydrocyanation of benzaldehyde catalysed by DKP 238 
 
This catalysis demonstrated the high potential of cis-DKP in organocatalysis and the 
hydrocyanation by DKP 238 is still the most efficient organocatalysed hydrocyanation. 
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Another good example of DKPs as organocatalyst has been reported by Lipton where the 
similar DKP 239 composed of phenylalanine and (S)-norarginine showed exceptional results in 
asymmetric Strecker reaction. In this reaction, HCN could be added to N-benzhydryl aromatic imines 
in 97% yield and >99% ee.107 This reaction afforded, in three steps, (S)-phenylglycine in 97% ee and 
92% overall yield which is an useful unnatural α-amino acid (Scheme 66). 
Nevertheless, these results are still controversial as Kunz et al. repeated the reaction with the 
same diketopiperazine and substrates in the same conditions and found that the conversion was much 
lower (34%) and that the resulting catalysis product was racemic.108 Moreover, the reaction performed 
without 239 afforded the racemic product with a better conversion (42%). 
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Scheme 66: Strecker reaction catalysed by DKP 239 
 
II. Synthesis of the diketopiperazine scaffold 
 
The synthesis of the diketopiperazine 232 was realised following the procedures published a 
few months ago.101 The synthesis of the 232cis and 232trans is exactly the same and yields are 
similar except for one step. 
 
1. Allylation of aspartic acid 
 
The aspartic acid was specifically β-allylated using allyl alcohol as a solvent and adding acetyl 
chloride dropwise at 0°C.109 Maintaining the reaction flask at this temperature during the addition is 
very important as formation of bis-allylated aspartic acid can be observed. The lab temperature is also 
very important since in summer time, more bis-allylated compound formation could be observed. The 
reaction afforded the hydrochloride salt of β-allyl (S)-aspartic acid 240 in 85% yield (Scheme 67). 
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Scheme 67: Allylation of aspartic acid 
 
2. Boc protection of β-allyl aspartic acid 
 
The β-allyl ester of aspartic acid was Boc protected by a conventional procedure using Boc2O 
and triethylamine in a mixture of water/dioxane. Alternatively can be used a mixture water/THF making 
the drying of the product easier. The Boc protected β-allyl aspartic acid 241 could be obtained easily in 
excellent yields (97%) (Scheme 68). 
 
 
 
Scheme 68: Boc protection of β-allyl aspartic acid hydrochloride 
 
3. Methyl esterification of serine 
 
Serine was esterified in the same manner as aspartic acid except that the solvent used was 
methanol. The procedure was a little shorter as after addition of acetyl chloride, the reaction mixture 
was refluxed for 2.5 hours affording the hydrochloride methyl serine salt 242 in 96% yield (Scheme 69). 
To prepare the cis- and trans-diketopiperazines, L-serine and D-serine were used respectively. 
 
 
 
Scheme 69: Methyl esterification of serine 
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4. Reductive amination 
 
The serine methyl ester hydrochloride salt was benzylated on the N terminal by reductive 
amination with benzaldehyde using a known procedure.110 The reaction involved first the formation of 
the benzylimine in methanol which was then reduced using NaBH4. NaBH4 must be added slowly and 
portionwise as its addition in methanol is very exothermic and can lead to partial racemisation of 
serine. The use of freshly distilled benzaldehyde afforded the N-benzylserine methyl ester 243 in 80% 
yield (Scheme 70). 
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Scheme 70: Reductive amination of the serine methyl ester HCl salt 
 
5. Coupling of N-Boc-β-allyl aspartic acid and N-benzyl serine methyl ester 
 
The coupling of the N-protected aspartic acid with N-benzyl serine methyl ester was 
investigated. Attempts with EDC and HOBt led to low yields (40%) probably due to the fact that the 
secondary amine of serine is difficult to couple. The use of HATU in DCM afforded the dipeptide 244 
good yields (72%) and little epimerisation of the serine CHα could be observed. The epimerisation 
comes mainly from the reductive amination step and little from the coupling conditions. More 
epimerisation was observed with dimethylformamide as solvent. The use of HBTU instead of HATU 
with HOBt in dichloromethane led to similar yields at much lower costs. The two diastereoisomers 
could not be separated by flash chromatography (Scheme 71). 
 
 
Scheme 71: Coupling between Boc-aspartic acid and benzyl serine 
 
6. Cyclisation of the dipeptide 
 
The dipeptide 244 was cyclised by first removing the Boc group in a mixture of TFA/DCM at 
room temperature. The TFA salt was then solved in a biphasic mixture of ethyl acetate and saturated 
NaHCO3.111 The diketopiperazine 245 was obtained in good yields (81%) and the diastereomers, 
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which were formed during the previous coupling, could be separated easily affording the pure cis- or 
trans-diketopiperazine (Scheme 72). 
 
 
 
Scheme 72: Dipeptide cyclisation 
 
7. Introduction of the nitrogen moiety by Mitsunobu reaction 
 
The nitrogen moiety was introduced by a Mitsunobu reaction with an hydrazoic acid solution in 
toluene, diisopropylic dicarboxylate (DIAD) and triphenylphosphine following procedures for the 
synthesis of 2,3-diaminopropionic acid.112,113 The reaction was performed in a mixture of toluene and 
dichloromethane at -20°C and gave moderate yields of the azido compound 246 (48%) for the cis-
DKP 245 (Scheme 73). In fact, a competition between the formation of the azido compound and the 
elimination product 247 was found to be responsible for this moderate result. The cis-conformation 
favoured elimination in comparison to the trans-conformation which gave the trans-azido-
diketopiperazine in much higher yield (82%). Formation of 247 was also favoured by temperatures 
higher than -10°C and by higher amounts of dichloromethane in the reaction mixture, which was 
nevertheless required to dissolve the starting material (Scheme 74). 
 
 
 
 
 Scheme 73: Mitsunobu reaction 
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 Scheme 74: Mechanism of the Mitsunobu reaction and by-product formation 
 
8. Reduction of the azide to the protected amine by tandem Staudinger-Boc protection 
reaction 
 
The azido functionality was reduced by Staudinger-like reaction with trimethylphosphine and 
2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON) in dry THF at -20°C allowing the 
isolation of the N-protected diketopiperazine 248 in 78% yield (Scheme 75).114 The reaction goes 
through the formation of a phosphazide which rearranges by liberating N2 to form the 
iminophosphorane. The Boc-ON is then attacked by the iminophosphorane. Reaction with water 
finishes the process liberating the Boc-protected diketopiperazine 248, trimethylphosphine oxide and 
N-hydroxybenzimidoyl cyanide (Scheme 76). 
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Scheme 75: Reduction and concomitant Boc protection of the azide 
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Scheme 76: Mechanism of the Staudinger reaction 
 
9. Deallylation catalysed by Pd(PPh3)4 
 
The diketopiperazine 248 was deallylated by a catalytic amount of palladium 
tetrakis(triphenylphenylphosphine) (4 mol%) and PPh3 (18 mol%) in presence of pyrrolidine in 
dichloromethane at 0°C.115 The catalysis goes through the formation of a pi-allyl complex and oxidative 
addition of the allyl ester to the palladium catalyst. Protons are furnished by the pyrrolidine finishing 
therefore the catalytic cycle by the reductive elimination of the carboxylic acid 232 and N-allyl-
pyrrolidine. The catalysis afforded 232 in 95% yield. (Scheme 77) 
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Scheme 77: Deallylation of the diketopiperazine and proposed mechanism 
 
The diketopiperazine building block was then ready to be used in liquid phase peptide 
synthesis. The synthesis of both cis- and trans-diketopiperazine was performed for this purpose. 
 
III. Introduction of the diketopiperazine building block into peptides and 
conformational analyses 
 
1. β-bend ribbon 
 
The results obtained with the hexapeptide 237 prompted us to consider taking advantage of 
the formation of the ten-membered ring by the DKP scaffold into different peptidomimetics. Actually, 
many secondary structures exhibit ten-membered ring, the most known being the 310 helix. A particular 
type of 310 helix is the β-bend ribbon. It is characterised by a succession of β-turns forming therefore a 
linear peptide with a ribbon-like shape (Figure 26). β-bend ribbons are not so common but they do 
exist in several natural peptides like peptaibol antibiotics zermavicins. Zermavicin IIA is a membrane 
active peptide antibiotic whose crystal structure, first described by Balaram et al.116, exhibited a 
continuous spiral beginning by a 310-helix at the N-terminus, changing to an α-helix for two turns, and 
ending in a spiral of three β-bends in a ribbon. Each of the β-bends contained a proline residue at one 
of the corners. Zermavicin has the particularity to contain α-aminoisobutyric acid (Aib), proline, and 
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polar amino acids like glutamine. A hexadecapeptide analogue of zermavicin, where Gln, Thr and 
hydroxyproline (Hyp) were replaced by Ala, Val and Pro respectively, was synthesised and exhibited 
the same β-bend ribbon structure at the end of the peptide chain. The presence of Aib and Pro was 
proved decisive for the secondary structure stability. 
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Figure 26: Alternation of ten-membered ring in β-bend ribbon 
 
Inspired by this work, Toniolo et al. have prepared protected polymers repeating the sequence 
(L-Pro-Aib)n and have also observed a stable β-bend ribbon which was analysed by crystallography 
and CD spectroscopy (Figure 26).117  
In general, it is considered that a rigid cis-conformation can greatly stabilise a β-bend ribbon 
and most of the examples of synthetic β-bend ribbon verify this observation. But sometimes, peptides 
non having a blocked conformation can as well adopt that kind of secondary structure.118 
Fleet et al. have also observed this structure when preparing the homopolymer 250 of a 
tetrahydrofuran δ-amino acid exhibiting a cis-conformation.70 This peptide adopted a stable 
conformation from 4 building blocks (Figure 27). 
 
 
 
Figure 27: Fleet’s β-bend ribbon 250 based on tetrahydrofuran amino acid building blocks 
 
With this numerous examples, we were prompted to investigate the potential of our scaffold 
for β-bend ribbon formation since the 10-membered ring we had observed in the β-hairpin 237 could 
be repeated in a homopolymer of the diketopiperazine 232cis. The experience of Fleet et al. suggests 
that peptide of at least three building blocks had to be prepared to get a stable secondary structure. 
Thus, we envisaged to prepare homopolymers having at least three or four building blocks. We 
selected the peptide liquid phase synthesis strategy as it is a convenient procedure for short peptides. 
Once the polymers were obtained, they would be studied by 2D-NMR, CD spectroscopy and IR to 
determine whether or not they adopt a β-bend ribbon conformation. 
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2. Synthesis of homopolymers of cis-diketopiperazine 
 
The first reaction of the synthesis was to definitively protect the carboxylic functionality of the 
starting peptide building block. To do so, we decided to couple 232cis with butylamine as it would 
create an additional amide functionality that could participate in the secondary structure. The first 
attempts to couple the diketopiperazine with butylamine were perfomed using EDC. The yields were 
very low (20%) and we decided to use HBTU. Unfortunately, with HBTU, the coupling yield was in the 
same order of magnitude and only the use of HATU in acetonitrile afforded the butylamine-protected 
diketopiperazine 251 in very good yields (87%). The addition of a second building block to 251 after 
having transformed it to its TFA salt also gave low yields of the dimer 252 with EDC and HBTU. The 
best yields were obtained with HATU in DMF but remained moderate (54%). One explanation of this 
low yield could be given by its little solubity and we found out that it aggregated in CDCl3 for 
concentrations higher than 2 mM. The formation of the trimer 253, contrary to the dimer 252, gave 
much higher yields (80%) using HATU in acetonitrile. The synthesis of the tetramer 254 led to some 
reactivity problems as reactions realised in DMF never afforded 254. It was found that the 
spontaneous cleavage of DMF released dimethylamine in the solution which was reacting with the 
diketopiperazine 232cis preventing therefore the coupling with the trimer TFA salt. As we supposed 
the coupling to be difficult, the reaction was performed in acetonitrile with HATU, but we had to avoid 
as well the use of HOAt, even if it should have given best yields, as our HOAt was in DMF solution and 
the small amount of dimethylamine in the HOAt solution was able to inhibit the reaction. Therefore, the 
coupling in acetonitrile with HATU and without HOAt finally gave the tetramer 254 in good yields (71%). 
It was found that the use of collidine instead of DIPEA for the formation of the trimer and tetramer gave 
higher yields (Scheme 78). 
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Scheme 78: Homopolymers syntheses 
 
3. Conformational analyses of the homopolymers 
 
The conformational analyses of the homopolymers of cis-diketopiperazine were studied by 
means of 2D-NMR and CD spectroscopy. The dimer  252 was first analysed, it was found that it 
aggregated in CDCl3 for concentrations higher than 2 mM. Moreover, its 2D-NMR analysis did not 
reveal any interesting NOE contact, therefore, its conformational study will not be exposed in the 
following part. 
 
a. Dilution studies of the trimer 
The trimer’s aggregation was studied in CDCl3 for concentration going from 1 to 5 mM. No 
aggregation could be observed in this range of concentrations and the trimer 253 was then studied at 
the concentration of 5 mM. 
 
b. Temperature variation coefficient of the trimer 
The measurement of the temperature variation coefficient of the trimer’s amide protons in 
CDCl3 revealed that many amide protons were involved relatively strongly in hydrogen bonding. The 
first evidence of hydrogen bonding is the chemical shifts of all NH protons, including the carbamate 
proton which had a chemical shift of 6.16 ppm at room temperature. All the amide protons were 
particularly deshielded showing chemical shifts higher than 8 ppm except the amide A4 with a 
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chemical shift of 7.77 ppm. The most interesting ∆δ/∆T values concerned the extracyclic amide proton 
A4 and the carbamate proton which had values (4.4 and 5.3 ppb/K) much lower than the ∆δ/∆T of A2 
(7 ppb/K) meaning that the NHBoc and the NH4 should be involved in an equilibrium between an 
hydrogen-bonded state and a non-hydrogen bonded state meanwhile NH2 is less involved in 
hydrogen bonding. Low values were found as well for the intracyclic amide protons A1 and A5 (4.9 
and 3.4 ppb/K) and the lowest ∆δ/∆T found was for the intracyclic amide A3 with a value of 2.3 ppb/K 
meaning that it is strongly involved in hydrogen bonding. On the other hand, NH6 had the highest 
∆δ/∆t (8.8 ppb/K) suggesting a totally non-hydrogen bonded state (Table 2 and figure 28).2 
 
 
∆δ/∆T (ppb/K) δ (ppm) 
A1 4.9 8.65 
A2 7 8.07 
A3 2.3 8.63 
A4 4.4 7.77 
A5 3.4 8.43 
A6 8.8 8.43 
NHBoc 5.3 6.16 
 
Table 2: Temperature variation of the NH of the trimer 253 in CDCl3 at 5 mM 
 
δ (ppm)=f(T) in CDCl3
y = -0,0053x + 7,8194
y = -0,0044x + 9,1363
y = -0,007x + 10,198
y = -0,0088x + 11,075
y = -0,0034x + 9,5486
y = -0,0023x + 9,3702
y = -0,0049x + 10,149
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Figure 28: Graph of temperature variation and amide numbering in 253 
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 c. 2D-NMR analysis of the trimer 
The trimer was analysed in CDCl3, DMSO-d6 and methanol-d3. In CDCl3, the dispersion of 
amide protons was not exploitable, some of them being hidden by the aromatic protons. Moreover, 
some of them were overlapping making the assignment impossible. In DMSO-d6, the dispersion was 
more satisfying and some contacts could be seen but the dispersion of the protons “e” made again the 
analysis difficult. In methanol-d3, on the other hand, the dispersion of the amides and protons “e” 
allowed assignment with certainty. The carbamate proton showed a NOE contact with the proton “e1”, 
suggesting that a 10-membered ring was formed on the first building block (Figure 29). For the amide 
proton A2, no NOE contact could be observed with “e2” or with another proton except with “e1” which 
is spatially close to it. Surprisingly, the amide proton A3 had a NOE contact with the proton “d3” 
(Figure 30). The reason of this unusual coupling is unclear but was undoubtedly observed. These 
couplings show clearly that the central building block did not form a 10-membered ring such as the 
upper building block. Finally, the amide A4 had a contact with the proton “e3”, revealing the presence 
of a 10-membered ring in the lower building block. These results taught us that the trimer adopted 
therefore a partial β-bend ribbon, with only the central building block not forming a ten-membered ring 
(Figure 31). 
 
 
 
Figure 29: NOESY expansion showing the contacts of NHBoc and A4 with “e1” and “e3” 
respectively 
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Figure 30: NOESY expansion showing the coupling of A3 with “d3” 
 
 
 
Figure 31: NOE contacts observed for 253 in MeOH-d3 at 5 mM 
 
d. 2D-NMR conformational analysis of the tetramer 254 
The tetramer 254 was analysed by NMR in different solvents but its low solubility in CDCl3 did 
not allow temperature variation studies. The NMR measurement in methanol-d3 showed that the 
intracyclic amide protons were not visible and assignment could not be done. In DMSO-d6, the 
Chapter 2: Synthesis of rigidically constrained diketopiperazine scaffolds towards foldamers 
 84 
dispersion of the amide protons was very nice but the dispersion of the protons “e” was not good 
enough to assign all the amides with certainty. Only one NOE contact could be assigned with certainty, 
it showed that the carbamate proton had a NOE contact with the proton “e1” and so that it was 
involved in a hydrogen bond with the CO of the same building block, forming a ten-membered ring 
typical of β-bend ribbons. For the other extracyclic amides, unfortunately, no assignment could be 
deduced. A 2D-NMR was attempted in a mixture of CDCl3 and DMSO-d6 affording as well a good 
dispersion for the amide protons, but still, no good dispersion was obtained for the protons “e”, making 
assignment impossible. Again, only the contact between the carbamate proton and the proton “e1” 
could be observed revealing the presence of at least one ten-membered ring. In DMSO-d6 and 
methanol-d3, more than one signal was observed for the extracyclic amides, suggesting an equilibrium 
between at least two conformations, one being in great majority. For the intracyclic amides, no 
particular contact could be observed (Figure 32). Since no conclusive proof of a secondary structure 
was obtained by NOE studies, we moved forward and decided get some insights from different 
spectroscopic evidences. 
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Figure 32: NOE contact observed for 254 showing the formation of a ten-membered ring by 
hydrogen bonding 
 
e. Proton exchange analysis on 254 
A proton exchange analysis was realised by adding 0.19mL of methanol-d4 to 0.75 ml of a 5 
mM solution of 254 in DMSO-d6. The 1H-NMR was measured at different moments and different 
exchange times were observed for the amide and carbamate protons. It was found that all the 
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intracyclic amides exchanged almost instantly (7 minutes after the addition). The extracyclic amides 
including the NH belonging to the butylamine fragment disappeared 48 minutes after the addition. The 
NHBoc was the last proton to disappear after 169 minutes. This experiment could allow us to deduce 
that the intracyclic amides are not involved at all in hydrogen bonding meanwhile the extracyclic 
amides showed a much longer resistance to proton exchange, meaning that they must be involved in 
hydrogen bonding (Table 3). 
 
Time stability of the NH protons of the tetramer 254 
NHBoc 169 min. 
Intracyclic NH 7 min. 
Extracyclic NH 48 min. 
NHBu 48 min. 
 
Table 3: Proton exchange time of the NH protons of the tetramer 254 
 
f. CD spectroscopy of the trimer and tetramer 
The trimer 253 and the tetramer 254 were analysed by CD spectroscopy in methanol and TFE 
(Figure 33 and 34). The CD spectrum realised in MeOH at 0.2 mM for both homopolymers showed 
that the trimer and tetramer did not adopt the same structure, the secondary structure of the tetramer 
being much more defined. The tetramer CD spectrum showed an intense negative peak at 198 nm 
and a second negative peak at 220 nm. On the other hand, the trimer exhibited 3 negative peaks, one 
at 197 nm, less intense than the tetramer’s peak at 198 nm and two intense peaks at 208 nm and 221 
nm, revealing therefore a very different secondary structure. Having characterised the trimer by NMR, 
we could affirm that the tetramer’s secondary structure had just a few common points with the trimer’s 
secondary structure. A comparison of the curve shape of the hairpin 237 with the tetramer’s curve 
showed that their CD spectra were very similar.101 The intense peak at 198 nm was attributed to the 
ten-membered ring formed between both arms of the diketopiperazine, suggesting that the tetramer 
254 features as well ten-membered rings. The intensity of the peak at 203 nm of the hairpin 237 was 
around 6500 deg.cm2.dmol-1 at the concentration of 0.2 mM and the intensity of the same peak for the 
tetramer 254 was of 120000 deg.cm2.dmol-1 at the same concentration, this means that there were 
many more ten-membered rings formed (Figure 35). In the literature, β-bend ribbon CD spectra are 
available and they all exhibit similar CD spectra with an intense negative band around 200 nm and 
another one, less intense, around 225 nm (Figure 36 and 37).117,119 In addition the CD spectrum of the 
tetramer in TFE exhibited almost the same curve except an additional shoulder around 205 nm 
revealing that this secondary structure could be adopted in methanol as well as in TFE. The trimer 
exhibited a very different CD curve in TFE compared to its curve in methanol. It had 3 intense negative 
peaks at 197, 204 and 221 nm showing that the secondary structure adopted by the trimer is different 
in methanol and TFE. 
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Figure 33: CD spectroscopy of the trimer and tetramer in MeOH at 0.2 mM 
 
 
Figure 34: CD spectroscopy of the trimer and tetramer in TFE at 0.2 mM 
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Figure 35: CD spectroscopy of the hairpin 237 containing a diketopiperazine 
 
 
Figure 36: β-bend ribbon by Toniolo117 exhibiting the same CD spectrum as 254 
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Figure 37: β-bend ribbon CD spectrum by Tomasini119 et al. 
 
g. Structures of the homopolymers 
The secondary structure of the trimer 253 was characterised by 2D-NMR and it was found to 
adopt a partial β-bend ribbon structure, the central building block not forming the expected ten-
membered ring. The secondary structure of the tetramer 254, on the other hand could not be fully 
characterised by 2D-NMR because of NMR dispersion problems. Nevertheless, the presence of a ten-
membered ring on the N-terminus building block showed that at least one of the building block tended 
to form a β-bend ribbon. The CD spectroscopy analysis showed that the tetramer had a much more 
defined secondary structure than the trimer and that it exhibited CD curve typical of a β-bend ribbon 
structure. 
 
 4. Synthesis of cyclic peptides based on the trans-diketopiperazine building block 
 
The ability of secondary structure induction of peptides based the trans-diketopiperazine 
232trans has been studied in our group.120 Some linear peptides having one trans-diketopiperazine 
coupled to α-amino acid tripeptides have been synthesised. Even if some NOE contacts had been 
observed, no particular secondary structure could be deduced, probably because of the trans-
conformation of both arms which hardly favours secondary structure formation (Figure 38). 
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Figure 38: Linear peptide based on the trans-DKP scaffold 
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Nevertheless, still in our group, the successful synthesis of RGD cyclic peptides based on the 
trans-diketopiperazine scaffold with interesting biological activity against integrins motivated us to 
prepare a simpler cyclic peptide and to study its secondary structure as the trans-conformation should 
favour intramolecular hydrogen bonding and the conformational analysis of a simpler cyclic peptide 
should give precious informations on its preferred conformation which should not be much different 
from the cyclic RGD. We chose as well to prepare a cyclic peptide with the trans-diketopiperazine and 
three α-amino acids to have a similar system. The tripeptide Boc-Val-Ala-Phe-Bn being available, it 
was decided to prepare the cyclic peptide containing this sequence. 
 
a. Coupling of the diketopiperazine with the tripeptide 
The trans-diketopiperazine 232trans was coupled with the TFA salt of the tripeptide 255 using 
HATU and collidine in acetonitrile affording the desired pentapeptide 256 in excellent yields (90%). 
(Scheme 79) 
 
 
 
Scheme 79: Coupling of the trans-diketopiperazine scaffold with the tripeptide 
 
b. Debenzylation of the pentapeptide 
The pentapeptide 256 was debenzylated by hydrogenation mediated by Pd(OH)2/C (10 
mass%) in methanol affording the C-deprotected pentapeptide 257 in 68% yield. (Scheme 80) 
 
 
 
Scheme 80: Debenzylation of the pentapeptide 
 
c. Cyclisation of the peptide 
The pentapeptide 257 was first Boc deprotected with TFA/DCM in a quantitative yield. The 
cyclisation was realised in DMF with HATU and collidine. In order to favour the intramolecular 
cyclisation, the reaction must be performed at low concentration to avoid intermolecular coupling. The 
concentration chosen was 2 mM based on the experience of our group on similar reactions. DMF was 
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prealably degassed by a sequence of vacuum and nitrogen bubbling so that the dimethylamine which 
could be present in the solution would be removed and, as a consequence, would not parasite the 
reaction. Seen the unfavourable trans-conformation, a long reaction time was required to have the 
maximum completion of the reaction. The reaction was run for three-four days and the cyclised 
compound 258 could be obtained in 31% yield. This moderate yield can be explained by the high cycle 
tension in the peptide making the coupling difficult. (Scheme 81) 
 
 
 
Scheme 81: Cyclisation of the pentapeptide 
 
5. Conformational studies of the cyclic peptide 
 
The cyclic pentapeptide 258 was analysed by 2D-NMR, due to its low solubility in CDCl3, 
methanol-d3 was used for conformational studies at a concentration of 5 mM. The dispersion of amide 
protons was satisfying and a NOESY experiment allowed us to define its secondary structure. The 
proton NMR revealed the presence of a major conformation and of at least a second conformation as 
some amide protons presented two peaks corresponding to the same residue, particularly the valine 
residue which had a major peak at 8.52 ppm and a second one at 8.79 ppm. The ratio for both peaks 
was of 77/23. Plenty of NOE contacts could be seen and revealed a close neighbouring between the 
α-amino acid residues. The amide A1 of the diketopiperazine, in addition to the protons “a”, had a 
NOE contact with the amide A2. The intracyclic amide A2 had no long range coupling with protons 
which were not neighbours except the A1 amide. The major amide peak of A3 (Val HN) showed a 
contact with the amide proton A4 (Ala HN). The amide A4 (Ala HN) showed NOE contacts with the 
amide protons A3 major (Val HN) and A5 (Phe HN) as well as with all the protons of the isopropyl group. 
The amide proton A5 (Phe HN) showed a NOE contact with A4 (Ala HN) and the methyl protons “k” of 
the Ala (Figure 39 and 40). All of these NOE couplings show that the cyclic peptide 258 adopts at least 
two conformations, the major one presenting a close neighbouring of the valine, alanine and 
phenylalanine residues, the minor being difficult to analyse because of the little intensity of its amide 
peaks. The structure adopted is very compact due to the trans-configuration of the diketopiperazine 
arms forcing the peptide to adopt a constrained conformation (Figure 41). 
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Figure 39: NOESY expansion in the region of the amide protons 
 
 
Figure 40: NOESY expansion showing the principal couplings between amides and CH3, CH2 
and CH protons 
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Figure 41: NOE contacts observed in the cyclic peptide 
 
Calculations realised in the group of Laura Belvisi in the University of Milano on the cyclic 
peptide cyclo[DKP-Ala-Gly-Ala] revealed that the minimised cyclic peptide conformation should form a 
γ-turn between the CO of the DKP and the Gly HN. Distance measurements on the minimised structure 
revealed that the Val HN and Ala HN was 3.772 Å, the distance between Ala HN and Phe HN was 3.814 
Å and the distance between A1 and A2 would be 4.071 Å. All these distances are in accordance with 
the NOE contacts observed and would confirm the formation of a γ-turn between the CO of the DKP 
linked to Val HN and the Ala HN (Figure 42 and 43). 
 
 
 
Figure 42: Minimised structure of the cyclo[DKP-Ala-Gly-Ala] 
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Figure 43: Second view of the minimised structure of the cyclic peptide 
 
Many rigid cyclic peptides have been developed in the field of RGD sequences and 
conformational studies have been essential for the better understanding of their activity.121 One 
publication of Sewald et al. attracted our attention in particular since it was dealing with the 
conformational preferences of 2 RGD cyclo-pentapeptides, namely cyclo[D-β-Phe-Val-Arg-Gly-Asp] 
and cyclo[D-Phe-β-Leu-Arg-Gly-Asp] containing a scaffold comprising one β-amino acid (either L or D) 
and one α-amino acid (either D or L), as higher homologs of the well known Kessler’s cyclo-
[RGDfV].122 The authors showed, by NMR studies and molecular mechanics calculations, that these 
cyclic peptides were able to adopt a modified γ-turn conformation called Ψγ-turn. In particular, cyclo[D-
β-Phe-Val-Arg-Gly-Asp] presented two turns: a β-turn was adopted by the RGD sequence as well as a 
Ψγ-turn conformation with the β-amino acid in central position. This conformation was essential, 
according to the authors, to establish a good interaction of the pharmacophoric groups with the 
integrin receptors for which these derivatives showed binding values in the nanomolar range. The 
main differences between this peptide and 258, reside in the fact that Sewald’s cyclic RGD contains 
only one β-amino acid thus forming a 16-membered cyclic peptide while our peptide 258 contains 2 β-
amino acids with a 17-membered cyclic peptide. As a consequence, we do not observe exactly the 
same secondary structure. Moreover, the presence of the trans-DKP added more constraints in the 
peptide favouring only the formation of a γ-turn between the CO of the DKP and the Ala HN. The data 
collected by 2D-NMR experiments and computational studies on the cyclo[DKP-Ala-Gly-Ala] are in 
accordance with the presence of a γ-turn in the cyclic peptide 258. By analogy, we can imagine that a 
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cyclic RGD peptide containing the trans-DKP would as well induce a γ-turn between the CO of the 
DKP and Gly HN. 
 
IV. Syntheses of potential organocatalysts based on a diketopiperazine 
scaffold 
 
The potential of diketopiperazines as organocatalysts has been described,106,107 even if some 
results remain controversial.108 In organocatalysis, a lot of efforts are now dedicated to asymmetric 
organocatalysis by simple peptides, especially tripeptides. One of the most notable example is the 
work of Wennemers et al. who have developed a simple tripeptide H-D-Pro-Pro-Glu-NH2 259 which 
exhibited a very high enantioselectivity in Michael addition123 and the tripeptide H-Pro-Pro-Asp-NH2 
260 which was active in asymmetric aldol reaction (Scheme 82).124 The interest of these 
organocatalysts is their ability to catalyse reactions with very low catalyst loading (1 mol%). 
In general, organocatalysts have a specificic activity on a specific substrate and it is relatively 
hard to find polyvalent catalysts. Catalyst 259, very active in Michael addition was also active in aldol 
reaction, but the enantioselectivities observed were lower than with 260. 
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Scheme 82: Wennemers’ tripeptide organocatalysts 
  
Tripeptide organocatalysts containing proline have proved to be very efficient in 
organocatalysis as in the work of Reiser et al. where the tripeptide 261 composed of two prolines and 
a β-amino acid has been described as active in asymmetric aldol reaction. The catalyst loading was 
relatively high (20 mol%) as it is often the case in organocatalysis but it was effective in intermolecular 
aldol reaction between acetone and nitrobenzaldehyde as well as on cyclic ketones with aromatic 
aldehydes and intramolecular aldol reaction with very good yields and ee (Figure 44).125 
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Figure 44: Reiser’s tripeptide organocatalyst for aldol reaction 
 
Tripeptide catalysts have found many applications in organocatalysis and it is normally 
accepted that their prefered turn conformation is responsible for their efficiency. It has also been 
described that these peptides must have a free carboxylic acid and a free amine. Since our 
diketopiperazine scaffold is a rigid and constrained building block and a dipeptide; it would be 
interesting to prepare a tripeptide having a proline residue and test it into catalysed reaction as a turn 
structure could be favoured by the cis-conformation. Moreover, we would easily get the free carboxylic 
acid and the free amine as our building block is Boc protected, giving an easy access to this 
deprotected tripeptide. It was envisaged to prepare two organocatalysts based on the cis-
diketopiperazine coupled by an amide or an ester bond with proline as the changing of the amide bond 
to the ester bond may change the reactivity or the enantioselectity of the organocatalyst. 
 
1. Amide-bonded organocatalyst synthesis 
 
To prepare the organocatalyst having the cis-diketopiperazine linked to the proline by an 
amide bond, the cis-diketopiperazine 248 was used as a starting material. Its TFA salt was coupled 
with proline with HATU and collidine in acetonitrile. The tripeptide 262 was obtained in excellent yields 
(95%). The deallylation of the tripeptide was realised in the same conditions as 232 with Pd(PPh3)4, 
PPh3 and pyrrolidine affording the free C-terminus tripeptide 263 in 95% yield (Scheme 83). 
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Scheme 83: Synthesis of amide-bonded organocatalyst 
 
2. Ester-bonded organocatalyst synthesis 
To prepare the ester-linked organocatalyst, a different starting material and coupling reagent 
had to be used. The reaction started from the hydroxydiketopiperazine 245 to which was coupled 
proline using DCC as a coupling reagent. The proline, DCC, HOBt and DMAP did not dissolve 
themselves very well in the mixture DCM/THF used and the ester-bonded tripeptide 264 could be 
obtained in moderate yields (50%). Then, the deallylation catalysed by Pd(PPh3)4 afforded the C-
terminus free tripeptide 265 in very good yields (86%) (Scheme 84). 
 
 
 
Scheme 84: Synthesis of the diketopiperazine-ester-bonded organocatalyst 
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Work is now in progress to investigate their activity in organocatalysed reactions such as 
enantioselective aldol reaction and Michael addition. 
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Experimental part 
 
I. Instruments and general techniques 
 
1H-NMR spectra were recorded on Bruker AC 250 (250 MHz), Bruker Avance 300 (300 MHz), Bruker 
Avance 400 (400 MHz) and Bruker Avance 600 (600 MHz). The chemical shifts are reporter in δ (ppm) 
relative to chloroform (CDCl3, 7.26 ppm), dimethylsulfoxide (DMSO-d6, 2.49 ppm), methanol-d3 
(CD3OH, 3.34 ppm) with presaturation to eliminate attenuate the OH peak and tetramethylsilane (TMS, 
0.00 ppm) as an internal standard. The spectra were analysed by first order, the coupling constant (J) 
are reported in Hertz (Hz). Characterisation of signals: s= singlet, bs= broad singlet, d= doublet, t= 
triplet, q= quartet, m= multiplet, bm= broad multiplet, dd= double doublet, dt= double triplet, ddd= 
double double doublet. Integration is determined as the relative number of atoms. Diastereoisomeric 
ratios were determined by comparing the integrals of corresponding protons in the 1H-NMR spectra. 
 
13C-NMR spectra were recorded on Bruker AC 250 (62.9 MHz), Bruker Avance 300 (75.5 MHz), 
Bruker Avance 400 (100.6 MHz) and Bruker Avance 600 (150.9 MHz). The chemical shifts are 
reported in δ (ppm) relative to chloroform (CDCl3, 77 ppm), dimethylsulfoxide (DMSO-d6, 39.52 ppm), 
methanol-d3 (CD3OH, 49 ppm) and tetramethylsilane (TMS, 0.00 ppm) as an internal standard. 
 
2D-NMR spectra (COSY, NOESY, ROESY, HETCORR) were recorded on Bruker Avance 400 (400 
MHz) and Bruker Avance 600 (600 MHz). 
 
IR spectra were recorded with a Bio-Rad Excalibur series FT-IR 
 
MS spectra were recorded in the mass spectroscopy departments of Regensburg and Milan 
 
Optical rotations were measured on a Perkin-Elmer-polarimeter 241 with sodium lamp at 589 nm in 
the specified solvent. 
 
CD spectra were measured on a JASCO model J-710/720 at the Institute of Bioanalytic and Sensoric 
of the University of Regensburg at 21°C between 250 and 190 nm in the specified solvent, with 10 
scans. The length of the rectangular cuvette was 0.1 mm, the resolution was 0.2 nm, the band width 
1.0 nm, the sensitivity 10-20 mdeg, the response 2.0 s, the speed 10 nm/min. The background was 
substracted for each spectrum. The absorption value is measured as molar ellipticity per residue 
(deg.cm2.dmol-1). The spectra were smoothed by adjacent averaging algorithm or FFT filter with the 
Origin 6.0 program. 
 
Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel (Merck 
silica gel 60 F 254, layer thickness 0.2 mm) or glass plates coated with flash chromatography silica gel 
(Merck silica gel 60 F 254, layer thickness 0.25 mm). Visualisation was accomplished by UV light 
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(wavelength λ= 254 nm), permanganate solution, ninhydrin/acetic acid solution, vanillin/H2SO4 solution 
and paramethoxybenzaldehyde solution. 
In Regensburg, solvents were purified according to standard laboratory method. THF was distilled 
over sodium/benzophenone before use. After distillation, dry THF was stored in a Schlenk flask under 
nitrogen over molecular sieves 4 Å. BF3•Et2O was distilled under nitrogen and stored in a Schlenk 
flask under nitrogen in the refrigerator. Diethyl ether and dichloromethane were purified by a solvent 
purification system apparatus. In Como, all dry solvents were obtained from sealed bottles under 
nitrogen purchased from Aldrich. DMF was degassed by two sequences of nitrogen bubbling for 15 
minutes and vacuum. All reactions with oxygen or moisture sensitive reactants were performed under 
nitrogen atmosphere. 
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II. Synthesis of compounds 
 
 1. Synthesis of δ-amino acids 
 
H2N
OH
 
 
(L)-amino-3-methylbutan-1-ol 
To a solution of NaBH4 (8.1g, 214 mmol, 2.5 eq.) in dry THF (135 mL) was added L-valine (10.0 g, 
85.3 mmol, 1.0 eq.) under nitrogen atmosphere. The reaction mixture was cooled to 0°C in an ice bath 
and a solution of iodine (21.6 g, 85.3 mmol, 1.0 eq.) in dry THF (50 mL) was slowly added over 1 h, 
resulting in production of hydrogen. After gas ceased, the reaction mixture was refluxed for 20 h and 
then cooled to room temperature. Methanol was added cautiously until the stirred solution became 
clear. The solution was stirred for 30 minutes and concentrated in vacuo to give a white paste, which 
was dissolved in 20% aqueous KOH (50 mL).The solution was further stirred for four hours and 
extracted with DCM (3 x 140 mL). The combined organic layers were dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to afford L-valinol (8.15 g, 92%) as a colourless oil. 
1H NMR (250 MHz, CDCl3): δ = 3.64 (dd, J= 10.6, 8.7Hz, 1H),3.31 (dd, J= 10.6, 8.7 Hz, 1H), 2.57 (ddd, 
J= 8.6, 6.4, 3.9 Hz, 1H), 2.20 (bs, 2H), 1.5-1.7 (m, 1H), 0.93 (d, J= 6.8 Hz, 3H), 0.91 (d, J= 6.8 Hz, 3H). 
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(-)-(S, S)-N,N'-bis-(1-hydroxymethyl-2-methyl-propyl)-2,2-dimethyl-malonamide 
To a cold solution (0°C) of L-valinol (15.4 g, 150.0 mmol, 2.0 eq.) in dry DCM (150 mL) were slowly 
added triethylamine (52.3 mL, 375 mmol, 5 eq.) and a solution of 2,2-dimethylmalonyl dichloride (10 
mL, 75 mmol, 1 eq.) in dry DCM (70 mL). Then, the ice bath was removed and the reaction mixture 
was stirred for 45 minutes to room temperature, resulting in a colorless precipitate which was 
dissolved again by addition of dry DCM (350 mL). After addition of 1M HCl (100 mL), the aqueous 
layer was separated and and extracted with DCM (3 x 50 mL). The combined organic layers were 
washed with saturated NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo. Crystallisation of the crude product from ethyl acetate (100 mL) and 
subsequent recrystallisation of the residue of the mother liquor afforded the dimethylmalonamide 
(18.76 g, 83%) as colourless crystals. 
Rf = 0.26 (SiO2, EA/MeOH 95:5); m.p. = 98-99°C; [ ]20Dα = -6.3 (c=0.50, DCM). 
1H NMR (250 MHz, CDCl3): δ = 6.41 (d, J= 8.8 Hz, 2H), 3.84-3.72 (m, 4H), 3.56-3.48 (m, 2H), 3.21 (bs, 
2H), 1.80 (hept., J= 6.8 Hz, 2H), 1.49 (s, 6H), 0.95 (d, J= 6.74, 6H), 0.92 (d, J= 6.74 Hz, 6H) 
13C NMR (62.9 MHz, CDCl3): δ = 174.6, 64.0, 57.2, 50.1, 29.1, 23.6, 19.7, 18.8 
IR (KBr): υ = 3326, 2963, 2877, 1642, 1543, 1391, 1368, 1287, 1186, 1071, 1024, 899, 651 cm-1 
MS (DCI, NH3): m/z (%) = 304.5 (16), 303.5 (100) [M+H+]. 
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188 
(-)-(S,S)-isopropylbisoxazoline (188): 
To a mixture of (-)-(S, S)-N,N'-bis-(1-hydroxymethyl-2-methylpropyl)-2,2-dimethylmalonamide (18.76 g, 
620.0 mmol, 1.0 equiv.) and 4-dimethylamino pyridine (0.75 g, 6.2 mmol, 0. 1 equiv.) in dry CH2CI2 
(400 mL) was slowly added triethylamine (37.6 mL, 270.0 mmol, 4.4 equiv.) over 15 min. 
Subsequently a solution of tosyl chloride (23.65 g, 124.0 mmol, 2.0 equiv.) in dry CH2CI2 (50 mL) was 
added dropwise via an addition funnel. The reaction mixture was stirred for additional 48 h at room 
temperature where the color changed to yellow and a cloudy precipitate occurred. The precipitate was 
dissolved in CH2CI2 (150 mL). The reaction mixture was then washed with saturated NH4Cl (250 mL) 
followed by water (150 mL) and saturated NaHC03 (200 mL). The combined aqueous layers were 
extracted with CH2CI2 (3x200 mL) and the combined organic layers were dried over Na2SO4. After 
filtration and concentration in vacuo the residue was purified by hot n-pentane extraction to afford 188 
(7.466 g, 44%) as a colorless oil. 
Rf = 0.26 (SiO2, CH2CI2/MeOH 19: 1); [ ]20Dα = -108.1 (c = 1.01, CH2CI2) 
1H NMR (250 MHz, CDCl3): δ = 4.27-4.09 (m, 2 H), 4.04-3.92 (m, 4 H),  1.91-1.72 (m, 2 H), 1.52 (s, 6 
H), 0.92 (d, J= 6.84 Hz, 6 H), 0.85 (d, J= 6.79 Hz, 6 H); 
13C NMR (100.6 MHz, CDCl3): δ = 168.8, 71.5, 69.9, 38.6, 32.2, 24.4, 18.5, 17.3 
IR (Film): υ  = 3411, 3225, 2960, 1660, 1468, 1385, 1352, 1301, 1247, 1146, 1109, 980, 925, 795, 
737 cm-1 
MS (DCI, NH3): m/z (%) = 391.6 (7), 313.5 (7), 268.4 (17), 267.4 (100) [M + NH4+] 
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189 
(1S,5S,6S)-(-)-2-Oxabicyclo[3.1.0]hex-3-ene-3,6-dicarboxylic 6-ethylester-3-methyl ester (189) 
In a three-neck flask equipped with a slow addition funnel under nitrogen at 0°C were added 
successively 53.2 g (421 mmol, 1 eq.) of furan-methylester, 0.88 g (3.32 mmol, 0.008 eq.) of ligand 
188 and 1.08 g (2.98 mmol, 0.007 eq.) of Cu(OTf)2. The inner walls of the flask were rinsed with a few 
millilitres of dry DCM to allow all of the copper to dilute in the solution. After 10 minutes, three drops of 
phenylhydrazine were added in the solution which turned from a deep blue to a dark red colour 
testifying of the reduction of the metal complex. The slow addition funnel was then filled with 500 mL of 
a solution of diazoacetate in DCM (153.97g.L-1, 76.98 g, 675 mmol, 1.6 eq.). After half an hour, the 
solution was added dropwise at the frequency of one drop every 6 seconds and the reaction was let at 
0°C for four days. Once the solution was totally added, the reaction mixture was filtered on a 10 cm 
pad of basic alumina and washed with 500 mL of DCM. The solution was evaporated under vacuum 
and column chromatographed on silica gel with a solution hexanes/Ethyl acetate 5:1 as eluent. The 
fractions were collected and the solvent evaporated under vacuum. The product was obtained as a 
slightly yellow oil and was crystallised in pentane/DCM affording 29.6 g (139.5 mmol, 33%) of 
enantiomerically pure white crystals (ee>99%). 
Rf (PE/EE 5:1)= 0.14; m.p. 42 °C; [ ]20Dα = -272 (c=1.0, CH2Cl2) 
1H NMR (250 MHz, CDCl3): δ = 1.16 (dd, J=2.7, 1.1 Hz, 1H), 1.23 (t, J=7.1 Hz, 3H), 2.87 (ddd, J=5.3, 
2.9, 2.7 Hz, 1H), 3.78 (s, 3H), 4.12 (q, J=7.1 Hz, 2H), 4.97 (dd, J=5.3, 1.1 Hz, 1H), 6.39 (d, J=2.9 Hz, 
1H) 
13C NMR (62.9 MHz, CDCl3): δ = 14.2, 21.5, 31.9, 52.1, 61.0, 67.5, 116.0, 149.3, 159.5, 171.7  
IR (KBr): υ  = 3118, 2956, 1720, 1617, 1428, 1380, 1297, 1166, 1124, 1041, 954, 831, 725 cm-1 
MS (70 eV, EI): m/z (%): 212.1 [M+] (9.8), 153.0 [M+-CO2Me] (11.5), 139.0 [M+-CO2Et] (100), 124.9 
(24.4), 98.9 (28.6), 96.9 (31.7), 78.9 (11.3), 59.0 (13.5), 52.1 (11.5); elemental analysis calcd (%) for 
C10H12O5 (212.2): C 56.60, H 5.70; found C 56.51, H 5.73. 
Experimental part 
 104 
 
CO2Et
CHO
O
O
MeO2C
 
 
190 
(1S,2S,3S)-(-)-Oxalic acid 2-ethoxycarbonyl 3-formyl-cyclopropyl ester methyl ester (190):  
A solution of 189 (2.50 g, 11.78 mmol) in dry CH2Cl2 (125 mL) was cooled to -78°C and treated with 
ozone until the mixture turned blue. Excess ozone was expelled by passing oxygen through the 
solution, followed by addition of dimethyl sulfide (4.3 mL, 58.91 mmol, 5.0 equiv). The reaction mixture 
was allowed to warm to room temperature and stirring was continued for 24 h. Saturated NaHCO3 (10 
mL) was added and layers were separated. The organic layer was washed with water (2x10 mL), dried, 
filtered and evaporated. The residue was recrystallized from Et2O at -27°C to yield 190 as a colourless 
solid (2.70 g, 94%).  
M.p. 52°C; [ ]20Dα =-37.7 (c=1.0, CH2Cl2) 
1H NMR (250 MHz, CDCl3): δ =1.28 (t, J=7.1 Hz, 3H), 2.79 (ddd, J_7.3, 6.0, 4.0 Hz, 1H), 
2.90 (dd, J=6.0, 3.6 Hz, 1H), 3.91 (s, 3H), 4.19 (q, J=7.1 Hz, 2H), 4.83 (dd, J=7.3, 3.6 Hz, 1H), 
9.45 (d, J=4.0 Hz, 1H) 
13C NMR (62.9 MHz, CDCl3): δ =14.1, 26.4, 34.9, 54.0, 58.9, 62.0, 156.6, 156.9, 168.1, 192.7 
IR (KBr): υ = 3066, 3015, 2963, 2892, 1785, 1751, 1735, 1706, 1445, 1345, 1313, 1210, 1167, 1086, 
1011, 963, 867, 790, 715, 613, 495 cm-1 
MS (DCI, NH3): m/z (%): 262.0 [M++NH4] (100), 176.0 (20), 160.0 (55), 120.9 (15); elemental analysis 
calcd (%) for C10H12O7 (244.2): C 49.19, H 4.95; found C 49.22, H 4.99. 
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191 
(1S, 1’S/R,2S, 3S)-Oxalicacid-hydroxy-but-3’-enyl-3-ethoxycarbonyl-cyclopropylester 
methylester (191): 
A solution of 190 (5.00 g, 20.5 mmol) in dry CH2Cl2 (200 mL) was treated with BF3•Et2O (3.0 mL, 20.5 
mmol) at -78°C. After 10 minutes allyltrimethylsilane (5.0 mL, 30.75 mmol, 1.5 equiv) was added and 
stirring was continued for 24 h. The reaction was quenched with saturated NaHCO3 (6.0 mL) and the 
mixture was allowed to warm to 0°C. After separation of the organic layer and drying with MgSO4, the 
solvent was evaporated under vacuum to yield the corresponding alcohol 191 as a colourless oil (5.82 
g, 100% crude yield, dr 95:5). 
1H NMR (250 MHz, CDCl3): δ =1.25 (t, J=7.0 Hz, 3H), 1.81 ± 1.92 (m, 1H), 2.15 (dd, J=6.2, 2.7 Hz, 1H), 
2.31 ± 2.51 (m, 4H), 3.70 (ddd, J=7.3, 7.3, 5.4 Hz, 1H), 3.88 (s, 3H), 4.13 (q, J=7.0 Hz, 2H), 
4.72 (dd, J=7.5, 2.8 Hz, 1H), 5.14 ± 5.22 (m, 2H), 5.76 ± 5. 93 (m, 1H), characteristic signals of the 
diastereomer: δ =4.14 (q, J=7.0 Hz, 2H), 4.67 (dd, J=6.9, 3.0 Hz, 1H). 
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194 
 
(2S/R,3S)-2-Allyl-5-oxotetrahydrofuran-3-carbaldehyde (194): 
A solution of 191 (6.15 g, 21.48 mmol, 1 eq.) in 100 mL dry MeOH was put in an ice bath. 5.96 mL of 
triethylamine (4.35 g, 42.99 mmol, 2 eq.) were then slowly added and the reaction was let at 0°C for 
two hours. The ice bath was then removed and the reaction was warmed to room temperature until no 
more evolution could be seen on TLC. The reaction mixture was evaporated under vacuum and the 
residue was chromatographed on silica gel (hexanes/ethyl acetate 1:1) and afforded 2.21g of 194 
(yield=67%) as a slightly yellow coloured oil with a diastereomeric ratio of 95/5. After the reaction, the 
stable intermediate 193 could be isolated and fully characterised in a diastereomeric ratio of 80/20. 
Rf (hexanes/EA 1:1) = 0.17; [ ]20Dα =-31.7 (c=1.35 in CH2Cl2) 
1H NMR (250 MHz, CDCl3): δ =2.35 ± 2.59 (m, 2H), 2.71 (dd, J1=18.2, J2=9.9 Hz, 1H), 2.89 
(dd, J1=18.2, J2=7.5 Hz, 1H), 3.19 (dddd, J=10.0, 7.3, 6.0, 1.2 Hz, 1H), 4.74 (dd, J=11.9, 6.2 Hz, 1H), 
5.10 ± 5.27 (m, 2H), 5.75 (dddd, J=17.3, 10.0, 7.0, 3.5 Hz, 1H), 9.69 (d, J=1.2 Hz, 1H), characteristic 
signals of the diastereomer (2R): δ = 3.00 (dd, J=17.7, 5.8 Hz, 1H), 9.82 (d, J=1.7 Hz, 1H) 
13C NMR (62.5 MHz, CDCl3): δ = 197.3, 174.0, 130.9, 120.5, 78.0, 51.3, 39.2, 28.9, characteristic 
signals for the minor compound: δ = 198.0, 131.3, 120.0, 49.6, 39.4, 28.7 
IR (film): υ  = 3080, 2980, 2939, 2841, 1774, 1727, 1642, 1419, 1359, 1193, 1111, 1000, 924 cm-1 
MS (EI, 70 eV): m/z (%): 154.2 (5) [M+], 113.1 (100) [M+-C3H5], 85.1 (95), 57.1 (95); elemental analysis 
calcd (%) for C8H10O3 (154.2): C 62.33, H 6.54; found: C 62.36, H 6.83. 
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193 
(2R/S, 3S, 4S, 5S)-5-Allyl-4-formyl-2-hydroxy-tetrahydro-furan-2,3-dicarboxylic acid 3-ethyl 
ester 2-methyl ester (193) 
Rf (hexanes/EA 1:1) = 0.67 
1H NMR (300 MHz, CDCl3): δ =  9.79 (d, J = 1.4 Hz, 0.8H, major), 9.75 (d, J = 1.9 Hz, 0.2H, minor), 
5.83-5.68 (m, 1H), 5.22-5.13 (m, 2H), 4.50 (s, 0.2H, minor), 4.46 (s, 0.8H, major), 4.37-4.07 (m, 3H), 
3.95 (dd, J = 11.5H, J = 1.2 Hz, 1H), 3.87 (s, 2.4H, major), 3.79 (s, 0.6H, minor), 3.65-3.57 (ddd, J = 
1.4 Hz, J = 9.0 Hz, J = 11.5 Hz, 1H), 2.77-2.44 (m, 2H), 1.22-1.17 (t, J  = 7.13 Hz, 3H) 
13C NMR (75 MHz, CDCl3): δ = 198.3, 169.5, 167.3, 132.7, 119.0, 100.3, 80.6, 61.6, 55.9, 53.9, 53.6, 
40.8, 13.9 
MS (LR): m/z (%): 304.2 (100) [M+NH4+], 286.3 (7.35) [M+NH4+-H2O] 
Experimental part 
 108 
 
OO
NHPMB
 
 
195 
(4S,5S)-5-Allyl-4-[(4-methoxy-benzylamino)-methyl]-dihydro-furan-2-one (195): 
To a solution of 194 (880 mg, 5.24 mmol, 1.0 eq.) in dry DCM (50 ml) under nitrogen were added 
sequentially sodium sulfate (1.49 gr, 10.48 mmol, 2.0 eq.) and 4-methoxybenzylamine (750 µL, 5.77 
mmol, 1.1 eq.). The reaction mixture was stirred at room temperature for 3 h. To the resulting slightly 
yellow solution were added NaBH4 (397 mg, 10.48 mmol, 2.0 eq.) and the flask was placed in an ice 
bath. Dry MeOH (15 ml) was then added dropwise to the reaction mixture which was stirred for further 
30 min at 0°C and thereafter filtrated on a celite pad. The solution was cooled to 0°C in an ice bath 
and a 1M solution of HCl was added until the pH solution was 1. The organic phase was separated 
and extracted with 1M solution of HCl (2 x 50 ml). The combined aqueous layers were washed with 
DCM (2 x 50 ml) and cooled at 0°C in an ice bath. Solid sodium hydrogen carbonate was added until 
the pH of the solution was 8. The aqueous phase was then extracted with diethyl ether (3 x 80 mL), 
the combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give 195 
as a slightly yellow oil (1.101 g, 4.00 mmol, 76%) which was used for the next step without further 
purification. The lactame 196 could be identified as a by-product of the reaction and fully characterised. 
Rf = 0.40 (SiO2, ethylacetate); [ ]20Dα = -19.42 (c=1.04, DCM) 
1H-NMR (300 MHz, CDCl3): δ = 7.23 (dd, J = 11.5, 8.5 Hz, 2H), 6.89-6.81 (m, 2H), 5.79 (m, 1H), 5.20-
5.13 (m, 2H), 4.34 (dd, J = 11.7, 5.4 Hz, 1H), 3.80 (s, 3H), 3.71 (s, 2H), 2.73-2.61 (m, 2H), 2.53-2.20 
(m, 5H) 
13C-NMR (75.5 MHz, CDCl3): δ  = 176.4, 158.8, 132.4, 132.0, 129.2, 119.0, 113.9, 83.1, 55.3, 53.3, 
51.4, 39.9, 39.1, 33.2 
IR (KBr): υ  = 3329, 3070, 2924, 2831, 2357, 2057, 1772, 1679, 1611, 1508, 1454, 1288, 1176, 1029, 
985, 819 
MS (CI, NH3): m/z (%) = 276.3 (100) [M+ H+] 
HRMS (EI, 70 eV): Calculated for [C16H21NO3]: 275.1521, found 275.1515 [M+]
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4-(1’-Hydroxy-but-3’-enyl)-1-(para-methoxy-benzyl)-pyrrolidin-2-one (196) 
1H NMR (300 MHz, CDCl3): δ = 7.18-7.15 (d, J = 8.7 Hz, 2H), 6.87-6.84 (d, J = 8.7 Hz, 2H), 5.81-5.68 
(dddd, J = 6.2 Hz, J = 8.2 Hz, J = 10.4 Hz, J = 16.6 Hz, 1H), 5.19-510 (m, 2H), 4.42-4.32 
(d, J = 4.2 Hz, 2H), 3.81 (s, 3H), 3.60-3.53 (m, 1H), 3.29-3.23 (dd, J = 8.4Hz, J = 9.7Hz, 1H), 3.12-
3.06 (dd, J = 6.6Hz, J = 9.8Hz, 1H), 2.54-1.98 (m, 6H) 
13C NMR (75 MHz, CDCl3): δ = 173.9, 159.1, 133.9, 129.5, 128.5, 119.1, 114.1, 71.5, 55.3, 48.6, 45.9, 
39.7, 36.5, 32.9 
MS (LR): m/z (%): 293.2 (9.6) [M+NH4+], 276.2 (100) [M+H+]  
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(2S,3S)-(2-Allyl-5-oxo-tetrahydro-furan-3-ylmethyl)-(4-methoxy-benzyl)-carbamic acid tert-butyl 
ester (197) 
To a solution of 195 (1.28 g, 4.65 mmol, 1.0 eq.) in dioxane / 1M aqueous solution of K2CO3 (12 mL / 
16 mL) was added di-tert-butyldicarbonate (1.52 g, 6.99 mmol, 1.5 eq.). The reaction mixture was 
stirred at RT overnight and extracted with EtOAc (3 x 50 ml). The combined organic layers were 
washed with 10% aqueous solution of citric acid (2 x 30 ml) and brine (2 x 30 ml), dried over Na2SO4, 
filtrated and evaporated in vacuo to give a slightly yellow oil which was purified by column 
chromatography (PE:EtOAc 3:1) to afford 197 (1.294 g, 3.44 mmol, 74%)as a colourless oil. 
Rf = 0.35 (SiO2, PE:EtOAc 3:1) ; [ ]20Dα = -10.37 (c = 0.96, DCM) 
1H-NMR (300 MHz, CDCl3): δ = 7.20-7.11 (m, 2H), 6.92-6.84 (m, 2H), 5.85-5.67  (m, 1H), 5.23-5.10 (m, 
2H), 4.40 (s, 2H), 4.24 (bs, 1H), 3.80 (s, 3H), 3.26 (bs, 2H), 2.59-2.22 (m, 5H), 1.50 (s, 9H) 
13C-NMR (75.5MHz, CDCl3): δ = 175.7, 159.1, 155.8, 132.1, 129.6, 128.8, 119.1, 114.1, 82.5, 80.7, 
55.3, 48.4, 39.9, 38.6, 33.0, 28.4 
IR (film): υ  = 3076, 2976, 2931, 2837, 2372, 1778, 1690 cm-1 
MS (EI, 70 eV): m/z (%) = 375.3 (100) [M+] 
HRMS (EI, 70 eV): Calculated for [C21H29NO5]: 375.2046, found 375.2046 [M+]
Experimental part 
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(2S,3S)-(-)-(2-Allyl-5-oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-butyl ester (198) 
To a cold (0°C) solution of 197 (633 mg, 1.69 mmol, 1.0 eq.) in water / acetonitrile (7mL / 21mL), 
cerium ammonium nitrate (3.70 g, 6.75 mmol, 4.0 eq, c = 0.25 M) was added. The reaction was stirred 
at 0°C for 1 h and then at RT for additional 2 h until total consumption of the starting material. Water 
(30 ml) was added and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined 
organic layers were washed with a saturated solution of NaHCO3 (30 mL), dried with MgSO4, filtrated 
and evaporated in vacuo to give an oil which was purified by column chromatography (PE:EtOAc 3:1) 
to afford 198 (340 mg, 1.33 mmol, 79%) as a colourless solid. 
Rf = 0.29 (SiO2, PE:EtOAc 3:1) ; [ ]20Dα = -21.58 (c = 1.01, DCM) 
1H-NMR (300 MHz, CDCl3): δ = 5.81 (ddd, J= 17.8, 16.5, 7.1 Hz, 1H), 5.25-5.15 (m, 2H), 4.72 (bs, 1H), 
4.31 (dd J =11.8, 5.8 Hz, 1H), 3.33-3.17 (m, 2H), 2.68 (dd J =17.2, 8.1 Hz, 1H), 2.59-2.42 (m, 3H), 
2.34 (dd J=17.3, 7.1 Hz, 1H), 1.41 (s, 9H) 
13C-NMR (75.5MHz, CDCl3): δ = 175.7, 156.0, 131.0, 119.3, 82.3, 80.0, 40.2, 38.7, 38.5, 28.3 
IR (KBr): υ  = 3474, 2976, 2931, 2837, 2372, 1778, 1690, 1168, 910, 855 
MS (CI, NH3): m/z (%) = 273.2 (71.32) [M+NH4+], 256.1 (1.07) [MH+] 
Elementar analysis calcd (%) for [C13H21NO4]: C 61.16, H 8.29, N 5.49; found C 61.04, H 7.86, N 
5.35
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199 
(-)-(2S,3S)-[3-(tert-Butoxycarbonylamino-methyl)-5-oxo-tetrahydro-furan-2-yl]-acetic acid 
(-)-GBA (200) 
To a cold (0°C) solution of 198 (340 mg, 1.33 mmol, 1.0 eq.) in water / acetonitrile / carbon 
tetrachloride (6 mL / 3 mL / 3 mL) were added sodium periodate (1.14 g, 5.32 mmol, 4 eq.) and 
RuCl3•xH2O (25 mg, 0.09 mmol, 0.07 eq.). The solution was stirred for 1 h at 0°C and for 2 h at RT. 
Water (10 ml) was added and the solution was then extracted with diethyl ether (3 x 50 mL). The 
combined organic layers were dried over MgSO4, filtrated through a celite pad and evaporated in 
vacuo to obtain 199 (317 mg, 1.15 mmol, 86%) as a colourless solid. 
Rf = 0.15 (SiO2, EtOAc); [ ]20Dα = -7.41 (c = 1.01, DCM) 
1H NMR (300 MHz, DMSO-d6): δ = 12.75-12.20 (bs, 1H), 7.07 (t J = 5.9 Hz, 1H), 4.55 (m, 1H), 3.15-
2.96 (m, 2H), 2.74-2.25 (m, 5H) 
13C NMR (75.5MHz, DMSO-d6): δ  = 175.8, 171.3, 155.8, 78.9, 77.8, 41.3, 39.8, 39.0, 31.6, 28.0  
IR (KBr): υ  = 3327, 3101, 2989, 2938, 2569, 1783, 1658, 1256 
MS [ESI, DCM/MeOH + 10 mmol/L NH4Ac)NH3]: m/z (%)= 290.8 (100) [M+NH4+], 273.3 (4.7) [MH+] 
Elementar analysis calcd (%) for [C12H19NO6]: C 52.74, H 7.01, N 5.13; found C 52.40, H 6.73, N 
5.03
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202 
(2S, 3S)-(2-Allyl-4,4-dimethyl-5-oxo-tetrahydro-furan-3-ylmethyl)-(4-methoxy-benzyl)-carbamic acid 
tert-butyl ester (202) 
To a solution of 1.138 g of 197 (3.03mmol, 1 eq.) in 30 mL of dry THF at -78°C were added 10 mL of a 
solution of fresh LDA in THF which had been prepared with 1.89 mL of BuLi (0.194 g, 3.03 mmol, 1 eq.) and 
0.47 mL of diisopropylamine (0.337 g, 3.33 mmol, 1.1 eq.) in 8 mL of dry THF at 0°C. The mixture was let at 
-78°C for half an hour and then, 0.19 mL of iodomethane (0.430 g, 3.03 eq.) were added to the mixture. The 
reaction mixture was let reacting half an hour and addition of LDA and iodomethane were repeated twice 
with the same time between each addition. When the reaction was complete, the reaction mixture was 
allowed to warm to room temperature and the solution was diluted in 100 mL of diethyl ether. The organic 
phase was washed twice with demineralised water and brine. The combined aqueous phases were then 
extracted with ether and the combined organic phases were dried with MgSO4, filtered and the solvent was 
evaporated under vacuum. The residue was chromatographed over silica gel using hexanes/ethyl acetate 
4:1 as eluent and by increasing slightly the polarity during the column yielding to a colourless oil  of 202 
(0.999 g, 2.48 mmol, yield=82%). 
Rf (hexanes/EA 3:1)= 0.33, [ ]20Dα = -33.2 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3): δ = 7.24-7.02 (d, J= 8.1Hz, 2H), 6.95-6.76 (m, 2H), 5.92-5.65 (m, 1H), 5.23-4.92 
(m, 2H), 4.53-4.39 (d, J= 15.4 Hz, 1H), 4.38-4.13 (bs, 2H), 3.77 (s, 3H), 3.14-2.98 (dd, J= 14.4 Hz, J= 4.3 Hz, 
1H), 2.59-2.44 (ddd, J= 14.9 Hz, J= 6.1 Hz, J= 2.9 Hz, 1H), 2.24-2.05 (m, 2H), 1.48 (s, 9H), 1.15 (s, 3H), 
1.06 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 180.9, 159.2,155.6, 132.9, 129.2, 118.7, 114.1, 80.7, 60.4, 55.3, 47.7, 42.4, 
28.5, 23.5, 21.1, 18.9, 14.2 
IR (film): υ  = 3200, 2972, 2932, 1771, 1685, 1611, 1512, 1458, 1412, 1395, 1246, 1164, 1032, 984, 918, 877, 
814, 756, 668 cm-1 
MS (CI MS): m/z (%): 421.2 [MNH4+] (100), 404.1 [MH+] (12.35), 365.1 [MNH4+-C4H8] (35.51), 348.0 [MH+-
C4H8] (12.69) 
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203 
(2S, 3S)-(2-Allyl-4,4-dimethyl-5-oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-butyl ester (203) 
To a cold (0°C) solution of 202 (540 mg, 1.34 mmol, 1.0 eq.) in water / acetonitrile (5.3 mL / 15.9 mL), cerium 
ammonium nitrate (2.938 g, 5.35 mmol, 4.0 eq, c = 0.25 M) was added. The reaction was stirred at 0°C for 1 
h and then at RT for additional 2 h until total consumption of the starting material. Water (30 ml) was added 
and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed 
with a saturated solution of NaHCO3 (30 mL), dried with MgSO4, filtrated and evaporated in vacuo to give an 
oil which was purified by column chromatography (PE:EtOAc 3:1) to afford 203 (331 mg, 1.17 mmol, 87%) as 
a colourless oil. 
Rf (hexanes/EA 3:1) = 0.19; [ ]20Dα = -29.6 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3): δ = 5.91-5.77 (td, J = 7.0 Hz, J = 16.9 Hz, 1H), 5.22-5.10 (m, 2H), 4.64-4.50 (bs, 
1H), 4.23-4.16 (m, 1H), 3.34-3.19 (m, 2H), 2.67-2.58 (m, 1H), 2.39-2.30 (m, 1H), 2.17-2.08 (m, 1H), 1.44 (s, 
9H), 1.27 (s, 3H), 1.15 (s, 3H). 
13C NMR (75 MHz, CDCl3): d = 180.90, 132.63, 118.89, 79.94, 60.39, 50.27, 42.52, 38.18, 28.38, 24.45, 
19.18, 14.20 
IR (film): υ  = 3350, 3200, 2974, 2932, 1761, 1693, 1517, 1454, 1390, 1366, 1249, 1163, 1043, 983, 865, 781, 
613 
MS (LR): m/z (%): 301.2 (100) [M+NH4+], 284.1 (2.8) [MH+], 245.1 (21.3) [M+NH4+-C4H8] 
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204 
(2S, 3S)-[3-(tert-Butoxycarbonylamino-methyl)-4,4-dimethyl-5-oxo-tetrahydro-furan-2-yl]-acetic acid 
MGBA (204) 
To a cold (0°C) solution of 203 (303 mg, 1.07 mmol, 1.0 eq.) in water / acetonitrile / carbon tetrachloride          
(5.4 mL / 2.7 mL / 2.7 mL) were added sodium periodate (0.915 g, 4.28 mmol, 4 eq.) and RuCl3•xH2O 
(22 mg, 0.09 mmol, 0.07 eq.). The solution was stirred for 1 h at 0°C and for 2 h at RT. Water (10 ml) was 
added and the solution was then extracted with diethyl ether (3 x 50 mL). The combined organic layers were 
dried over MgSO4, filtrated through a celite pad and evaporated in vacuo to obtain 204 (300 mg, 0.995 mmol, 
93%) as a colourless solid. 
Rf (EA) = 0.13, [ ]20Dα = -19.4 (c=1.00 in CHCl3) 
1H NMR (300 MHz, DMSO-d6): δ = 12.44 (s,1H), 7.08-7.04 (t, J = 5.72 Hz, 1H), 4.49-4.42 (td, J = 9.8 Hz, J = 
2.0 Hz, 1H), 3.33 (bs, 1H), 3.11-3.04 (m, 2H), 2.83-2.77 (dd, J = 16.9 Hz, J = 2.4 Hz, 1H), 2.21-2.13 (dd, J = 
16.8 Hz, J = 7.0 Hz, 1H), 1.38 (s, 9H), 1.13 (s, 3H), 1.07 (s, 3H) 
13C NMR (75 MHz, DMSO-d6): δ = 180.49, 171.28, 167.93, 155.43, 76.43, 49.14, 41.65, 37.14, 28.10, 23.58, 
18.43, 13.89, 
MS (LR): m/z (%): 319.1 (100) [M+NH4+], 301.1 (18.3) ([M+NH4+-H20], 263.1 (42.7) [M+NH4+-C4H8], 245.1 
(11.9) [M+NH4+-H20-C4H8] 
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210 
N-tert-butoxycarbonyl-(-)-GBA-L-Phe-benzyl ester (210) 
A solution of Boc-(L)-Phe-COOBn (297 mg, 1.78 mmol) in DCM/TFA 50:50 (5 ml) was stirred for 1 h at RT. 
The solvent was evaporated in vacuo and the resulting TFA salt was precipitated by addition of diethyl ether. 
The solvent was removed and the resulting colourless salt (247 mg, 0.67 mmol, 1.44 eq.) was dissolved in 
DCM (7 ml) and DIPEA (0.40 mL, 2.3 mmol, 5.0 eq.) was added. Meanwhile, a solution of 199 (127 mg, 0.46 
mmol, 1.0 eq.) and EDC•HCl (134 mg, 0.70 mmol, 1.5 eq.) in DCM (5 mL) was stirred for half an hour at RT 
and added to the phenylalanine solution. After further 5 min, HOBt (107 mg, 0.70 mmol, 1.5 eq.) was added 
and the solution was stirred for 20 h at RT. The solution was diluted with DCM (50 mL) and washed with an 
aqueous solution of KHSO4 1M (2 x 30 mL) and a saturated aqueous solution of NaHCO3 (2 x 30 mL), dried 
over Na2SO4, filtrated and evaporated in vacuo to give a slightly yellow solid which was purified by column 
chromatography (hexanes/EtOAc 1:1) to give 210 as a colourless solid (201 mg, 0.39 mmol, 85%). 
Rf (SiO2, hexanes/EA 1:1) = 0.19; [ ]20Dα = + 8.0 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3): δ = 7.34-7.21 (m, 8H), 7.07-7.01 (m, 2H), 6.40-6.32 (d, J = 7.8 Hz, 1H), 
5.19-5.06 (m, 3H), 4.93-4.4.86 (td, J = 7.7 Hz, J = 5.9 Hz, 2H), 4.62-4.56 (q, J = 6.2 Hz, 1H), 3.28-3.03 
(m, 4H), 2.65-2.55 (m, 2H), 2.51-2.26 (m, 2H), 1.42 (s, 9H) 
13C NMR (75 MHz, CDCl3): δ = 175.1, 171.2, 168.4, 135.4, 134.9, 129.4, 128.71, 128.68, 128.66, 127.2, 79.3, 
67.5, 53.3, 41.1, 41.0, 37.6, 32.4, 28.4 
IR (NaCl): υ  = 3335, 2199, 1779, 1742, 1667, 1523, 1450, 1363, 1251, 1170, 1009, 752, 699 cm-1 
MS (LR): m/z (%): 528.3 (100) [M+NH4+], 511.3 [MH+] 
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212 
N-tert-butoxycarbonyl-L-Phe-(-)-GBA-L-Phe-benzyl ester (212) 
A solution of 210 (220 mg, 0.43 mmol) in DCM/TFA 50:50 (5 ml) was stirred for 1 h at RT. The solvent was 
evaporated in vacuo and the resulting TFA salt was precipitated by addition of diethyl ether. The solvent was 
removed and the resulting colourless salt (220 mg, 0.42 mmol, 1 eq.) was dissolved in DCM (7 ml) and 
DIPEA (0.36 mL, 2.1 mmol, 5.0 eq.) was added. Meanwhile, a solution of Boc-Phe (167 mg, 0.63 mmol, 1.5 
eq.) and EDC•HCl (121 mg, 0.70 mmol, 1.5 eq.) in DCM (5 mL) was stirred for half an hour at RT and added 
to the previous solution. After further 5 min, HOAt (86 mg, 0.63 mmol, 1.5 eq.) was added and the solution 
was stirred for 20 h at RT. The solution was diluted with DCM (50 mL) and washed with an aqueous solution 
of KHSO4 1M (2 x 30 mL) and a saturated aqueous solution of NaHCO3 (2 x 30 mL), dried over Na2SO4, 
filtrated and evaporated in vacuo to give a slightly yellow solid which was purified by column chromatography 
(hexanes/EtOAc 1:1) to give 212 as a colourless solid (189 mg, 0.29 mmol, 68%). 
Rf (hexanes/EA 1:1)= 0.13, [ ]20Dα = +8.1 (C=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3): δ = 7.40-6.95 (m, 15H), 6.85-6.80 (d, 1H), 5.25-5.07 (m, 3H), 4.85-4.75 (dd, J = 
13.2 Hz, J = 7.0 Hz, 1H), 4.40-4.25 (m, 2H), 3.45-3.30 (m, 2H), 3.16-2.92 (m, 5H), 2.65-2.30 (m, 4H), 2.24-
2.12 (dd, J = 16.7 Hz, J = 9.3 Hz, 1H), 1.40 (s, 9H) 
IR (NaCl): υ  = 3306, 2199, 1660, 1531, 1450, 1170, 1018, 750, 698 cm-1 
MS (LR): m/z (%): 658.5 [MH+] 
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213 
N-tert-butoxycarbonyl-(-)-GBA-L-Phe-(-)-GBA-L-Phe-benzyl ester (213) 
A solution of 212 (208 mg, 0.32 mmol) in DCM/TFA 50:50 (5 ml) was stirred for 1 h at RT. The solvent was 
evaporated in vacuo and the resulting TFA salt was precipitated by addition of diethyl ether. The solvent was 
removed and the resulting colourless salt (224 mg, 0.32 mmol, 1 eq.) was dissolved in DCM (7 ml) and 
DIPEA (0.27 mL, 1.58 mmol, 5.0 eq.) was added. Meanwhile, a solution of 199 (125 mg, 0.46 mmol, 1.44 
eq.) and EDC•HCl (91 mg, 0.47 mmol, 1.5 eq.) in DCM (5 mL) was stirred for half an hour at RT and added 
to the previous solution. After further 5 min, HOAt (65 mg, 0.47 mmol, 1.5 eq.) was added and the solution 
was stirred for 20 h at RT. The solution was diluted with DCM (50 mL) and washed with an aqueous solution 
of KHSO4 1M (2 x 30 mL) and a saturated aqueous solution of NaHCO3 (2 x 30 mL), dried over Na2SO4, 
filtrated and evaporated in vacuo to give a slightly yellow solid which was purified by column chromatography 
(EtOAc) to give 213 as a colourless solid (161 mg, 0.20 mmol, 62%). 
Rf (EA) = 0.10, [ ]20Dα = -9.3 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3): δ = 7.40-7.01 (m, 16H), 6.85-6.75 (m, 2H), 5.21-5.05 (m, 3H), 4.89-4.79 (dd, J = 
13.7 Hz, J = 6.6 Hz, 1H), 4.66-4.50 (m, 2H), 4.41-4.36 (dd, J = 12.0 Hz, J = 5.7 Hz, 1H), 3.30-2.90 (m, 8H), 
2.70-2.10 (m, 10H), 1.42 (s, 9H) 
IR (NaCl): υ  = 3418, 2199, 2092, 1644 cm-1 
MS (LR): m/z (%) 830.5 (100) [M+NH4+], 813.4 (43) [M+H+] 
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214 
N-tert-butoxycarbonyl- L-Phe-(-)-GBA- L-Phe-(-)-GBA-L-Phe benzyl ester (214) 
A solution of 213 in DCM/TFA 50:50 (4 ml) was stirred for 1 h at RT. The solvent was evaporated in vacuo 
and the resulting TFA salt was precipitated by addition of diethyl ether. The solvent was removed and the 
resulting colourless salt (115 mg, 0.14 mmol, 1 eq.) was dissolved in DCM (3 ml) and DIPEA (0.12 mL, 0.70 
mmol, 5.0 eq.) was added. Meanwhile, a solution of Boc-L-Phe (55 mg, 0.21 mmol, 1.5 eq.) and EDC•HCl 
(40 mg, 0.21 mmol, 1.5 eq.) in DCM (4 mL) was stirred for half an hour at RT and added to the previous 
solution. After further 5 min, HOAt (28 mg, 0.21 mmol, 1.5 eq.) was added and the solution was stirred for 20 
h at RT. The solution was diluted with DCM (50 mL) and washed with an aqueous solution of KHSO4 1M (2 x 
30 mL) and a saturated aqueous solution of NaHCO3 (2 x 30 mL), dried over Na2SO4, filtrated and 
evaporated in vacuo to give a slightly yellow solid which was purified by column chromatography 
(EtOAc/MeOH 9:1) to give 214 as a colourless solid (107 mg, 0.11 mmol, 80%). 
Rf (EA/MeOH 9:1) = 0.67, [ ]20Dα  = 15 (c=0.1 in CHCl3) 
1H NMR (300 MHz, CDCl3): δ = 7.71-7.61 (m, 1H), 7.40-7.04 (m, 20H), 5.43-5.36 (d, 1H), 5.21-5.08 (m, 3H), 
4.84-4.77 (dd, J = 6.7 Hz, J = 13.2 Hz, 1H), 4.59-4.35 (m, 4H), 3.59-3.38 (m, 2H), 3.18-2.87 (m, 9H), 2.67-
2.35 (m, 8H), 2.26-2.11 (m, 2H), 1.94-1.81 (bs, 1H), 1.39 (s, 9H) 
MS (LR): m/z (%) 960.5 [MH+] 
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205 
[3-(tert-Butoxycarbonylamino-methyl)-4,4-dimethyl-5-oxo-tetrahydro-furan-2-yl]-acetic acid benzyl 
ester (205) 
In 5 mL of DMF were added 100 mg of 204 (0.33 mmol, 1 eq.), 0.06 mL of benzyl bromide (0.53 mmol, 
1.6 eq.) and 82 mg of K2CO3 (0.59 mmol, 1.8 eq.). The reaction was let at room temperature for 36 h. The 
reaction mixture was diluted in diethyl ether and washed with water twice. The aqueous phases were then 
extracted with diethyl ether and the organic layers were dried with MgSO4 and filtered. The solvent was 
evaporated under vacuum and the crude residue purified by column chromatography (PE/EA 3:1) giving 96 
mg of 205 (0.25 mmol, 76%). 
Rf (PE/EA 3:1) = 0.18; [ ]20Dα = -23.6 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3) : δ = 7.38-7.32 (m, 5H), 5.16 (s, 2H), 4.69 (bs, 1H), 4.63-4.56 (ddd, J = 3.9 Hz, J 
= 7.7 Hz, J = 10.0 Hz, 1H), 3.32-3.17 (dd, J = 5.9 Hz, J = 11.7 Hz, 2H), 2.91-2.84 (dd, J = 3.9 Hz, J = 16.6 Hz, 
1H), 2.76-2.68 (dd, J = 7.6 Hz, J = 16.6 Hz, 1H), 2.24-2.16 (td, J = 6.8 Hz, J = 9.9 Hz, 1H), 1.42 (s, 9H), 1.26 
(s, 3H), 1.16 (s, 3H) 
13C NMR (75 MHz, CDCl3) : δ = 180.3, 169.8, 155.8, 135.3, 128.6, 128.4, 128.3, 66.9, 50.6, 47.9, 42.4, 39.2, 
38.3, 35.7, 28.3, 24.2, 19.0 
MS (LR) : m/z (%) 409.0 (100) [M+NH4+], 353.0 (32) [M+NH4+-C4H8] 
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206 
N-tert-butoxycarbonyl-MGBA-MGBA-benzyl ester (206) 
In 5 mL DCM were added 112 mg of MGBA 204 (0.37 mmol, 1.5 eq.) and 37 mg EDC•HCl (0.37 mmol, 1.5 
eq.). The amino acid was activated for 30 minutes and added to a solution of 2 mL containing 100 mg of the 
TFA salt of 205 (0.25 mmol, 1 eq.) and 0.21 mL of  DIPEA (1.24 mmol, 5 eq.). Subsequently, 51 mg of HOAt 
(0.37 mmol, 1.5 eq.) were added and the reaction was stirred for 24h at room temperature. The reaction 
mixture was dissolved in 50 mL DCM and washed with a solution of KHSO4 1M and a saturated solution of 
NaHCO3. The organic phase was then dried over MgSO4, filtered and concentrated under vacuum. The 
residue was chromatographed on silica gel with PE/EA (1:1) and by increasing gradually the eluent mixture 
polarity. After column, the fraction were gathered, evaporated and dried under high vacuum affording 92 mg 
of 206 (0.16 mmol, 64%) as a white powder. 
Rf (EA) = 0.78; [ ]20Dα = -26.6 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3) : δ = 7.38-7.35 (m, 5H), 6.30-6.25 (bs, 1H), 5.17 (s, 1H), 4.85-4.95 (bs, 1H), 4.60-
4.46 (m,2H), 3.51-3.20 (m, 4H), 2.96-2.89 (dd, J = 5.0 Hz, J = 16.6 Hz, 1H), 2.85-2.77 (dd, J = 6.3 Hz, J = 
16.6 Hz, 1H), 2.71-2.63 (dd, J = 3.3 Hz, J = 15.0 Hz, 1H), 2.47-2.37 (dd, J = 7.7 Hz, J = 14.9 Hz, 1H), 2.24-
2.15 (m, 2H), 1.44 (s, 9H), 1.28-1.26 (m, 6H), 1.17-1.14 (d, 6H). 
IR (film) : υ  = 3375, 2975, 2200, 1770, 1531, 1456, 1393, 1366, 1252, 1159, 1133, 1012, 754 cm-1 
MS (LR) : m/z (%) 592.4 (100) [M+NH4+], 575.4 (99) [M+H+], 519.3 (37) [M+H+-C4H8] 
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207 
N-tert-butoxycarbonyl-MGBA-MGBA-MGBA-benzyl ester (207) 
In 3 mL DMF were added 82 mg of MGBA 204 (0.27 mmol, 1.5 eq.) and 103 mg of HBTU (0.27 mmol, 1.5 
eq.). The amino acid was activated for 30 minutes and added to a solution of 1 mL of DMF containing 107 
mg of the TFA salt of 206 (0.18 mmol, 1 eq.) and 0.16 mL of  DIPEA (0.27 mmol, 5 eq.). Subsequently, 37 
mg of HOAt (0.27 mmol, 1.5 eq.) were added and the reaction was stirred for 24h at room temperature. The 
reaction mixture was dissolved in 50 mL DCM and washed with a solution of KHSO4 1M, the aqueous phase 
was then extracted with ethyl acetate and the organic phase were gathered and washed with a saturated 
solution of NaHCO3. The organic phase was then dried over MgSO4, filtered and concentrated under vacuum. 
The residue was chromatographed on silica gel with EA/MeOH (9:1) and the fractions were evaporated and 
dried under high vacuum affording 20 mg of 207 (0.03 mmol, 15%) as a white powder. 
Rf (EA/MeOH 9:1) = 0.29 
1H NMR (300 MHz, DMSO-d6) : δ = 8.13 (bs, 2H), 7.44-7.33 (m, 5H), 7.04 (bt, 1H), 5.14 (s, 2H), 4.57-4.41 (m, 
3H), 3.50-3.40 (m, 2H), 3.24-3.15 (m, 2H), 3.09-2.97 (m, 2H), 2.73-2.57 (m, 4H), 2.38-2.30 (m, 2H), 2.20-
2.14 (m, 3H), 1.37 (s, 9H), 1.14-1.03 (m, 18H) 
MS (LR) : m/z (%) 758.5 (10) [M+H+], 658.5 (100) [MH+-Boc] 
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218 
N-tert-butyloxycarbonyl-(-)-GBA-Gly-Val-Phe benzyl ester (218) 
In a 5 ml of a mixture of DCM/TFA (1:1) was added 320 mg (0.63 mmol) of the peptide Boc-Gly-Val-Phe-Bn 
for half an hour. When the Boc cleavage was achieved, the solvent was evaporated under vacuum and the 
peptide salt was precipitated and washed in Et2O. The salt was filtered and dried in vacuo to give 325 mg 
(0.62 mmol, 1.5 eq.) of the peptide salt as a white powder. In 5 mL DCM were dissolved 113 mg of (-)-GBA 
(0.41 mmol, 1 eq.) and 119 mg of EDC•HCl (0.62 mmol, 1.5 eq.) for half an hour, the solution was added to 
the peptide salt which had previously been dissolved in 3 mL DCM and neutralized with 0.36 mL of DIPEA 
(2.07 mmol, 5 eq.). Then, 84 mg of HOAt (0.62 mmol, 1.5 eq.) were added and the reaction was run for 48 h 
at room temperature. The reaction mixture was diluted in EA (20 mL) and washed subsequently with a 
solution of KHSO4 1M and a saturated solution of NaHCO3. The organic phase was dried with MgSO4, 
filtered and concentrated in a rotary evaporator. The residue was then chromatographed on silica gel with EA 
and afforded 116 mg of 218 (0.17 mmol, 42%) as a white solid. 
Rf (EA) = 0.36; [ ]20Dα = -10.4 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3) : δ = 7.37-7.01 (m, 8H), 7.06-6.99 (m, 2H), 6.75-6.50 (m, 3H), 5.22-5.07 (m, 3H), 
4.95-4.88 (dd, J = 6.2 Hz, J = 14.1Hz, 1H), 4.71-4.62 (dd, J = 6.0 Hz, 1H), 4.35-4.27 (dd, J = 6.6 Hz, J = 8.6 
Hz, 1H), 3.97-3.90 (m, 2H), 3.30-3.15 (m, 2H), 3.13-3.05 (m, 2H), 2.72-2.47 (m, 4H), 2.44-2.33 (dd, J = 7.8 
Hz, J = 16.8 Hz, 1H), 2.10-199 (m, 1H), 1.43 (s, 9H), 0.90-0.81 (dd, J = 6.8 Hz, J = 11.6 Hz, 6H). 
IR (solid) : υ  = 3308, 3068, 2968, 2200, 1776, 1644, 1531, 1450, 1170, 1002, 754, 699 cm-1 
MS (LR) : m/z (%) 684.5 (100) [M+NH4+], 667.5 (47) [M+H+], 611.4 (9) [M+H+-C4H8] 
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219 
N-tert-butyloxycarbonyl-Ala-(-)-GBA-Gly-Val-Phe benzyl ester (219) 
In a 5 ml of a mixture of DCM/TFA (1:1) was added 116 mg (0.17 mmol) of 218 for half an hour. When the 
Boc cleavage was achieved, the solvent was evaporated under vacuum and the peptide salt was 
precipitated and washed in Et2O. The salt was filtered and dried in vacuo to give 122 mg (0.17 mmol, 1 eq.) 
of the peptide salt as a white powder. In 5 mL DCM were dissolved 48 mg of Boc-alanine (0.26 mmol, 1.5 
eq.) and 49 mg of EDC•HCl (0.62 mmol, 1.5 eq.) for half an hour, the solution was added to the peptide salt 
which had previously been dissolevd in 3 mL DCM and neutralized with 0.15 mL of DIPEA (0.85 mmol, 5 eq.). 
Then, 35 mg of HOAt (0.26 mmol, 1.5 eq.) were added and the reaction was run for 48 h at room 
temperature. The reaction mixture was diluted in EA (20 mL) and washed subsequently with a solution of 
KHSO4 1M and a saturated solution of NaHCO3. The organic phase was dried with MgSO4, filtered and 
concentrated in a rotary evaporator. The residue was then chromatographed on silica gel with EA/MeOH 
(9:1) and afforded 80 mg of 219 (0.11 mmol, 64%) as a white solid. 
Rf (EA/MeOH 9:1) = 0.41; [ ]20Dα = -11.2 (c=1.00 in CHCl3) 
1H NMR (300 MHz, CDCl3) : δ = 7.65-7.51 (bs, 1H), 7.36-7.34 (m, 3H), 7.29-7.17 (m, 6H), 7.07-7.00 (m, 2H), 
6.87-6.79 (bd, 1H), 6.78-6.70 (bd, 1H), 5.29-5.20 (bd, 1H), 5.16-5.05 (dd, J = 12.1 Hz, 2H), 4.90-4.84 (dd, J = 
6.3 Hz, 1H), 4.65-4.68 (dd, J = 6.2 Hz, J = 12.3 Hz, 1H), 4.31-4.26 (dd, J = 6.7 Hz, J = 8.3 Hz, 1H), 4.22-4.16 
(m, 1H), 4.05-3.95 (dd, J = 5.7 Hz, J = 16.5 Hz, 1H), 3.80-3.73 (dd, J = 4.6 Hz, J = 16.5 Hz, 1H), 3.51-3.41 
(m, 1H), 3.20-3.03 (m, 3H), 2.80-2.55 (m, 4H), 2.35-2.24 (dd, J = 7.0 Hz, J = 16.3 Hz, 1H), 2.10-1.98 (m, 1H), 
1.42 (s, 9H), 1.32-1.28 (d, J = 7.0Hz, 3H), 0.94-0.85 (dd, J = 7.0 Hz, J = 8.2 Hz, 6H). 
IR (solid) : υ  = 3413, 3300, 3200, 2974, 1743, 1645, 1532, 1454, 1366, 1245, 1175, 1096, 1070, 984, 866, 
739, 554, 489 cm-1 
MS (LR) : m/z (%) 755.5 (100) [M+NH4+], 738.5 (36) [M+H+] 
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220 
N-tert-butyloxycarbonyl-Phe-Ala-(-)-GBA-Gly-Val-Phe benzyl ester (220) 
In 5 mL DCM were dissolved 85 mg of Boc-phenylalanine (0.32 mmol, 1.5 eq.) and 62 mg of EDC•HCl 
(0.32 mmol, 1.5 eq.) for half an hour, the solution was added to the peptide salt of 219 (161 mg, 0.21 mmol, 
1.0 eq.) which had previously been dissolved in 3 mL DCM and neutralized with 0.18 mL of DIPEA 
(1.07 mmol, 5 eq.). Then, 44 mg of HOAt (0.32 mmol, 1.5 eq.) were added and the reaction was run for 48 h 
at room temperature. The reaction mixture was diluted in EA (20 mL) and washed subsequently with a 
solution of KHSO4 1M and a saturated solution of NaHCO3. The organic phase was dried with MgSO4, 
filtered and concentrated in a rotary evaporator. The residue was then chromatographed on silica gel with 
EA/MeOH (9:1) and afforded 117 mg of 220 (0.13 mmol, 63%) as a white solid. 
Rf (EA/MeOH 9:1) = 0.61; [ ]20Dα = -23.1 (c=1.00 in MeOH) 
1H NMR (300 MHz, CDCl3) : δ = 7.39-6.91 (m, 18H), 6.79-6.60 (m, 2H), 5.40-5.25 (bs, 1H), 5.16-5.05 (m, 2H), 
4.93-4.84 (dd, J = 7.0 Hz, J = 12.7 Hz, 1H), 4.63-4.22 (m, 4H), 3.99-3.85 (m, 2H), 3.60-3.31 (m, 2H), 3.19-
2.95 (m, 5H), 2.77-2.48 (m, 2H), 2.32-2.17 (m, 1H), 2.13-1.93 (m, 3H), 1.39 (s, 9H), 1.28-1.26 (d, J = 7.2 Hz, 
3H), 0.93-0.83 (m, 6H). 
IR (solid): υ  = 3286, 3200, 1777, 1737, 1643, 1525, 1454, 1168, 1009, 748, 697, 566, 495 cm-1 
MS (LR): m/z (%) 885.4 (16) [M+H+], 785.5 (100) [M-C5H8O2+H+] 
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221 
N-tert-butyloxycarbonyl-Val-Phe-Ala-(-)-GBA-Gly-Val-Phe benzyl ester (221) 
In 5 mL DCM were dissolved 41 mg of Boc-alanine (0.19 mmol, 1.5 eq.) and 36 mg of EDC•HCl (0.19 mmol, 
1.5 eq.) for half an hour, the solution was added to the peptide salt of 220 (114 mg, 0.13 mmol, 1.0 eq.) 
which had previously been dissolved in 3 mL DCM and neutralized with 0.11 mL of DIPEA (0.63 mmol, 5 eq.). 
Then, 26 mg of HOAt (0.19 mmol, 1.5 eq.) were added and the reaction was run for 48 h at room 
temperature. The reaction mixture was diluted in EA (20 mL) and washed subsequently with a solution of 
KHSO4 1M and a saturated solution of NaHCO3. The organic phase was dried with MgSO4, filtered and 
concentrated in a rotary evaporator. The residue was then chromatographed on silica gel with EA/MeOH 
(9:1) and afforded 32 mg of 221 (0.03 mmol, 25%) as a white solid. 
Rf (EA/MeOH 9:1) = 0.27 
1H NMR (300 MHz, DMSO-d6) : δ = 8.55-8.53 (d, 1H), 6.22-8.10 (m, 2H), 8.00-7.77 (m, 3H), 7.36-7.14 (m, 
15H), 6.68-6.65 (d, 1H), 5.09-4.99 (q, 2H), 4.65-4.48 (m, 3H), 4.27-4.15 (m, 2H), 3.83-3.67 (m, 3H), 3.07-
2.95 (m, 3H), 2.80-2.72 (m, 1H), 2.65-2.26 (m, 5H), 195-1.76 (m, 2H), 1.37 (s, 9H), 1.24-1.03 (m, 6H), 0.88-
0.56 (m, 12H) 
IR (solid) : υ  = 3280, 3200, 2962, 2927, 1778, 1740, 1638, 1526, 1455, 1390, 1244, 1213, 1167, 1088, 1011, 
928, 874, 800, 740, 696, 567 
MS (LR): m/z (%) 984.3 (50) [M+H+], 884.3 (100) [M+H+-Boc] 
Experimental part 
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(S)-β-allyl aspartic acid hydrochloride (240) 
In a round bottom flask cooled at 0°C were diluted 4.160 g (31.2 mmol, 1eq.) of L-aspartic acid in 45 mL of 
allylic alcohol. Acetyl chloride (8.74 mL, 122.95 mmol, 3.9 eq.) were then slowly added dropwise with a 
dropping funnel into the reaction mixture. Once the addition was finished, the reaction flask was removed 
from the ice bath and let react at room temperature for 18 h. The reaction mixture was diluted in Et2O making 
the product precipitate entirely. The salt was filtered through a glass filter and washed twice with more Et2O. 
The salt was recovered and dried under vacuum affording 5.542 g (26.44 mmol, 85%) of the monoallylated 
aspartic acid hydrochloride 240 as a white salt. 
[ ]20Dα = +22.7° (MeOH, c=1.00) 
1H NMR (D2O, 400 MHz): δ= 6.05-5.85 (m, 1H), 5.36-5.25 (m, 2H), 4.63 (d, 2H, J=5.74 Hz), 4.48 (m, 1H), 
3.26-3.3.20 (dd, 1H, J1=5.5 Hz, J2=18 Hz), 3.14-3.08 (dd, 1H, J1=4.8 Hz, J2=18.4 Hz) 
Experimental part 
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241 
N-Boc-(S)-β-allyl aspartic acid (241) 
In a round bottom flask were solved 5.54 g (26.4 mmol, 1 eq.) of allyl aspartic acid hydrochloride 240 in 150 
mL of THF/water 1:1 solution. The reaction flask was put in an ice bath and 10.99 mL (79.28 mmol, 3 eq.) of 
triethylamine were added. Then, 6.860 g (31.7 mmol, 1.2 eq.) of Boc2O were added and the reaction was let 
at room temperature for 24 h. The reaction mixture was diluted in 200 mL of EtOAc and washed with KHSO4 
1M solution and brine. The organic phase was dried over Na2SO4, filtered and concentrated under reduced 
pressure. The product was then dried under high vacuum for a few hours affording 7.046 g (25.8 mmol, 97%) 
of the pure expected product 241 as a pale viscous yellow oil. 
[ ]20Dα = +33.3° (CHCl3, c=1.00) 
1H-NMR (CDCl3, 400 MHz): δ= 5.80-5.93 (m, 1H), 5.59 (d, 1H, J=8.8), 5.19-5.32 (m, 2H), 4.52- 4.60 (m, 3H), 
3.01 (dd, 1H, J1=4.4 Hz, J2=17.0 Hz), 2.87 (dd, 1H, J1=4.9Hz, J2=17.3 Hz), 1.41 (s, 9H) 
 
 
 
Experimental part 
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242 
Serine methyl ester hydrochloride (242) 
In a round bottom flask at 0°C were dissolved 6 g (57.09 mmol, 1 eq.) of serine in 45 mL MeOH. Acetyl 
chloride (16.2 mL, 228 mmol, 4 eq.) was added dropwise in the reaction mixture. Once the addition was 
done, the reaction flask was equipped with a condenser and refluxed for 2.5 h. Reflux was then stopped and 
the flask was cooled to room temperature. 200 mL of Et2O were added provoking the precipitation of the 
resulting salt which was filtered on a glass funnel and dried under vacuum affording 8.57 g (55.08 mmol, 
96%) of serine methyl ester hydrochloride 242 as a white powder. 
R: [ ]20Dα = -3.98° (MeOH, c=1.00) 
S: [ ]20Dα = +3.98° (MeOH, c=1.00) 
1H NMR (D2O, 400 MHz): δ= 4.20-4.22 (t, 1H, J=7.6 Hz), 4.01-4.06 (dd, 1H J1=4.3 Hz, J2=12.5 Hz), 3.91-
3.95 (dd, 1H, J1=3.4 Hz, J2=12.5 Hz), 3.69 (s, 3H) 
Experimental part 
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243 
N-benzyl-serine methyl ester (243) 
In 18 mL MeOH were added successively 2.54 g (16.3 mmol, 1eq.) of serine methyl ester hydrochloride, 3.2 
mL (22.8 mmol, 1.4 eq.) of Et3N and 1.65 mL (16.3 mmol, 1 eq.) of freshly distilled benzaldehyde. The 
reaction was stirred  for 4 hours. The reaction flask was put in an ice bath and 1.23 g (32.6 mmol, 2eq.) of 
NaBH4 were added portionwise during 30 min. The reaction mixture was again let react for half an hour, then, 
reaction was quenched by adding at 0°C HCl 4 M until no more gas formation was observed. The mixture 
was washed 3 times with Et2O. The organic phases were combined and extracted with HCl 4 M twice. The 
aqueous phases were then combined and neutralised by careful addition of saturated NaHCO3 solution until 
a pH=8 was reached. The aqueous phase was then extracted 4 times with Et2O. The organic phase was 
separated and dried over Na2SO4, filtered, concentrated under reduced pressure and dried under vacuum 
affording 2.73 g (13.04 mmol, 80%) of benzyl serine methyl ester 243 as a white oil. 
R: [ ]20Dα = +39.4 (CHCl3, c=1.00) 
S: [ ]20Dα = -39.4 (CHCl3, c=1.00) 
1H-NMR (CDCl3, 400 MHz): δ= 7.26-7.37 (m, 5H), 3.79-3.83 (m, 1H), 3.75 (s, 3H), 3.78 (s, 1H), 3.64-3.68 (dd, 
1H, J1=6.2 Hz,  J2=10.8 Hz), 3.44-3.47 (m, 1H), 2.69 (s, 2H),  
Experimental part 
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244 
(S)-N-Benzyl-3-tert-butoxycarbonylamino-N-[(S)-2-hydroxy-1-methoxycarbonyl-ethyl]-succinamic 
acid allyl ester (244) 
 To a solution of β-allyl (2S)-N-(tert-butoxycarbonyl)aspartate ester 241 (328 mg, 1.2 mmol, 1 equiv) in 
CH2Cl2 (8 mL), under nitrogen atmosphere and at 0 ºC, was added HATU (524 mg, 7.9 mmol, 1.1 equiv) and 
DIPEA (417 µL, 2.4 mmol, 2 equiv). After 30 min, a solution of (S) or (R) -N-benzylserine methyl ester 243 
(250 mg, 1.2 mmol) in CH2Cl2 (1.6 mL) was added and the reaction was stirred at 0 ºC for 1 h and at r.t. for 
24 h. The mixture was then diluted with AcOEt (100 mL) and the organic phase was washed in order with: 1 
M KHSO4 (2×20 mL), aqueous NaHCO3 (2×20 mL) and brine (2×20 mL), dried over Na2SO4 and volatiles 
were removed under reduced pressure. The residue was purified by flash chromatography on silica gel 
(Petroleum ether/AcOEt, 75:25) to afford the desired product 244 as a yellow oil (401 mg, 72%). 
Rf (Hex/EA 6:4)= 0.31; S,S: [ ]20Dα = -2.65 (CHCl3, c=1.00); S,R: [ ]20Dα = +11° (CHCl3, c=1.00) 
Cis: 
1H NMR (CDCl3, 400 MHz): δ= 7.24-7.34 (m, 5H), 5.83-5.93 (m, 1H), 5.48 (d, 1H, J=8.2 Hz), 5.30 (d, 1H, 
J=17.2 Hz), 5.23 (d, 1H, J=10.4 Hz), 4.51-4.61 (m, 3H), 4.32-4.48 (m, 2H), 3.88 (d, 1H, J=13.1 Hz), 3.75 (s, 
3H), 3.73 (d, 1H, J=13.1 Hz), 3.55 (t, 1H, J=4.7 Hz), 2.99 (dd, 1H, J1=17.0 Hz, J2=4.3 Hz), 2.85 (dd, 1H, 
J1=17.0 Hz, J2=4.7 Hz), 2.21 (br s, 1H), 1.45 (s, 9H).  
Two set of signals were observed in the 13C spectrum due to the presence of two rotational isomers A:B 
(20:1 ratio): 
13C NMR (CDCl3, 100 MHz) δ= 172.8 (A), 172.1 (B), 171.0 (A), 170.3 (B), 155.7 (A), 155.0 (B), 139.6 (A), 
138.9 (B), 132.1 (A), 131.4 (B), 128.9 (A), 128.7 (A), 128.1 (B), 127.9 (B), 127.6 (A), 126.9 (B), 119.1 (A), 
118.4 (B), 80.6 (A), 79.9 (B), 66.2 (A), 66.1 (A), 65.5 (B), 65.4 (B), 59.5 (A), 58.8 (B), 52.7 (A), 52.2 (A), 51.9 
(B), 51.4 (B), 50.3 (A), 49.6 (B), 37.1 (A), 36.4 (B), 28.7 (A), 27.9 (B); 
IR (film): υ =  3438, 3338, 3026, 2983, 2953, 2857, 1739, 1500, 1453, 1378, 1341, 1279, 1247, 1176 cm-1. 
HRMS (ESI) m/z calcd for [C23H33N2O8]+: 465.22314 [M+H]+; found: 465.22326; Elemental analysis calcd% 
for C23H32N2O8: C 59.47, H 6.94, N 6.03; found C 59.07, H 7.01, N 5.91. 
Trans: 
1H-NMR (CDCl3, 400 MHz) δ= 7.26-7.34 (m, 5H), 5.89 (ddd, 1H, J3=5.8Hz, J2=11.0Hz, J1=16.3Hz), 5.48 (d, 
1H, J=8.3Hz), 5.28 (dd, 2H, J2=13.8Hz, J1=26.7Hz), 4.46 (dd, 1H, J2=4.6Hz, J1=10.9Hz), 4.34 (dd, 1H, 
J2=4.8Hz, J1=10.9Hz), 3.88 (d, 1H, J=13.1Hz), 3.73 (d, 1H, J=17.7Hz), 3.54 (t, 1H, J=4.7Hz), 3.00 (dd, 1H, 
J2=4.3Hz, J1=17.1Hz), 2.85 (dd, 1H, J2=4.7Hz, J1=17.1Hz), 1.45 (s, 9H) 
13C-NMR (CDCl3, 100 MHz): δ= 172.8, 171.0, 170.9, 155.6, 139.6, 132.0, 129.1, 128.8, 128.6, 128.4, 127.0, 
119.0, 80.5, 66.3, 59.4, 52.6, 52.2, 50.3, 37.1, 28.6 
Experimental part 
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245 
[(2S,5S)-4-Benzyl-5-hydroxymethyl-3,6-dioxo-piperazin-2-yl]-acetic acid allyl ester (245) 
A solution of the dipeptide 244 (1.94 g, 4.2 mmol) in TFA/DCM 1:1 (32 mL) in a tarred flask was stirred for 30 
minutes. The solvent was evaporated and dried under vacuum. A few milliliters of diethyl ether were added 
to wash and precipitate the TFA salt of the dipeptide, the solvent was removed with a filtrating Pasteur 
pipette and the salt was dried under vacuum affording the TFA salt as a white solid. This salt was dissolved 
in a mixture of saturated aqueous NaHCO3/EtOAc (0.1 M, 1:1 v/v) and stirred at room temperature for 48 h. 
Subsequently, the layers were separated and the aqueous layer was extracted with EtOAc (4×). The 
combined organic layers were washed with brine, dried over Na2SO4 and volatiles were removed under 
reduced pressure. The residue was purified by flash chromatography on silica gel (EA/PE, 8:2) to afford the 
desired product 245 as a white solid (1.13 g, 81%). 
Cis: 
Rf (SiO2, EA) = 0.44; Mp 118-120 ºC; [ ]20Dα = -72.1 (c= 1.00, CHCl3) 
1H NMR (CDCl3, 400 MHz): δ= 7.25-7.37 (m, 5H), 7.05 (br s, 1H), 5.84-5.94 (m, 1H), 5.25-5.34 (m, 3H), 
4.55-4.66 (m, 2H), 4.49-4.51 (m, 1H), 4.07 (d, 1H, J= 15.0 Hz), 3.98 (d, 1H, J= 11.1 Hz), 3.85-3.89 (m, 2H), 
3.21 (dd, 1H, J1= 17.5 Hz, J2= 2.8 Hz), 3.16 (br s, 1H); 3.13 (dd, 1H, J1= 17.5 Hz, J2= 10.4 Hz); 
13C NMR (CDCl3, 100 MHz) δ= 171.9, 167.0, 166.3, 135.6, 131.9, 129.5, 128.6, 119.5, 66.4, 61.3, 60.5, 52.8, 
47.6, 40.7; 
IR (film): υ = 3388, 3275, 3031, 3017, 2945, 1728, 1680, 1452, 1379, 1336, 1276, 1183, 1124 cm-1. MS 
(FAB+) m/z (%) 333 (80) [M+H]+, 275 (11), 154 (57), 136 (48), 91 (100); Elemental analysis calcd% for 
C17H20N2O5: C 61.44, H 6.07, N 8.43; found C 61.23, H 5.97, N 8.24. 
Trans: 
Rf (SiO2, EA) =0.19; [ ]20Dα == -35.3° (CHCl3, c=1.00) 
1H-NMR (CDCl3, 400 MHz): δ= 7.26-7.35 (m, 5H), 5.91 (qd, 1H, J1= 5.8 Hz, J2= 10.7 Hz), 5.26-5.36 (m, 2H), 
4.68 (dd, 1H, J1= 3.4 Hz, J2= 8.8 Hz), 4.63 (d, 1H, J= 5.8 Hz), 4.05 (dd, 1H, J1= 1.4Hz, J2= 11.6 Hz), 3.90 (dd, 
1H, J1= 3.2 Hz, J2= 11.7 Hz), 3.85 (s, 1H), 3.30 (dd, 1H, J1= 3.5 Hz, J2= 17.5 Hz), 2.83 (dd, 1H, J1= 8.9 Hz, 
J2= 17.5 Hz) 
13C-NMR (CDCl3, 100 MHz) δ= 171.2, 168.8, 167.0, 135.8, 131.9, 129.3, 128.4, 119.2, 66.2, 62.0, 61.7, 51.4, 
47.6, 37.4 
Experimental part 
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Preparation of hydrazoic acid 
In a three-necked flask were dissolved 3 g of NaN3 in 3 mL H2O. Once totally diluted, 20 mL of toluene were 
added and the reaction flask was put in an ice bath under vigorous stirring. When the solution was at 0°C, 
1.2 mL of concentrated H2SO4 were added extremely slowly in order not to exceed 10°C for the solution 
temperature. The reaction was let one hour at 0°C and was then filtered on cotton wool. The salt residue was 
washed twice with more toluene. The toluene solution was titrated by diluting 1 mL of the toluene solution in 
distilled water in a total volume of 50 mL. Titration was realised by addition of 0.1 M NaOH controlled with a 
pH meter allowing to calculate the HN3 concentration in the mother solution when the equivalence volume 
was reached. 
Experimental part 
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246 
[(2S,5S)-5-Azidomethyl-4-benzyl-3,6-dioxo-piperazin-2-yl]-acetic acid allyl (246) 
To a solution of HO-cis-DKP-COOAllyl 245 (559 mg, 1.7 mmol) in CH2Cl2/toluene (6.6 mL/12.2 mL), under 
nitrogen atmosphere and at -20 ºC, was added PPh3 (535 mg, 2.0 mmol, 1.2 equiv) and the mixture was 
stirred until a solution was obtained. Hydrazoic acid (0.45 M in toluene, 7.5 mL, 3.4 mmol, 2 equiv) was 
added followed by dropwise addition of DIAD (0.42 mL, 2.0 mmol, 1.2 equiv) and the reaction was stirred at -
20ºC during 3.5 h. The reaction mixture was put on silica gel without previous evaporation and a quick 
chromatography (petroleum ether/AcOEt, 6:4) was performed to remove the hydrazine and the resulting 
crude residue was then purified by flash chromatography on silica gel (CH2Cl2/MeOH, 99:1) to afford the 
desired product 246 as a colourless oil (291 mg, 48% for the cis compound, 82% for the trans compound). 
The cis-azido DKP can also be separated in one long column in modified flash chromatography condition 
using 45 cm of silica and Hex/EA 3:2 as eluent. 
Cis: 
Rf (DCM/MeOH 97:3)= 0.36, elimination Rf=0.31; [ ]20Dα = -72.7 (CHCl3,c=1.90) 
1H NMR (CDCl3, 400 MHz) δ 7.26-7.39 (m, 5H), 6.91 (br s, 1H), 5.89-5.99 (m, 1H), 5.36 (d, 1H, J=17.2 Hz), 
5.30 (d, 1H, J=10.4 Hz), 5.18 (d, 1H, J=15.0 Hz), 4.62-4.71 (m, 2H), 4.51-4.54 (m, 1H), 4.20 (d, 1H, J=15.0 
Hz), 3.95 (br s, 1H), 3.89 (dd, 1H, J1=12.7 Hz, J2=1.7 Hz), 3.68 (dd, 1H, J1=12.7 Hz, J2=3.4 Hz), 3.31 (dd, 1H, 
J1=17.7 Hz, J2=2.2 Hz), 3.08 (dd, 1H, J1=17.7 Hz, J2=11.2 Hz) 
13C NMR (CDCl3, 100 MHz): δ= 171.6, 165.7, 165.1, 135.3, 131.8, 129.6, 128.8, 128.6, 119.6, 66.5, 58.8, 
52.6, 51.1, 48.0, 40.7 
IR (film): υ = 2984, 2929, 2853, 2119, 1734, 1686, 1667, 1451, 1336, 1274, 1181 cm-1 
MS (FAB+) m/z (%) 358 (12) [M+H]+, 330 (2), 149 (16), 109 (27), 91 (100); Elemental analysis calcd% for 
C17H20N2O5: C 57.14, H 5.36, N 19.60; found C 57.39, H 5.28, N 19.25 
 
Trans: 
Rf (Hex/EA 3:2)= 0.13; [ ]20Dα = = -55.9 (CHCl3, c=1.00) 
1H-NMR (CDCl3, 400 MHz): δ=  7.26-7.38 (m, 5H), 5.92 (ddd, 1H, J3= 5.8 Hz, J2= 10.6 Hz, J1= 22.9 Hz), 5.32 
(dd, 1H, J2= 13.8 Hz, J1= 26.9 Hz), 5.16 (d, 1H, J= 15.1 Hz), 4.63-4.66 (m, 2H), 4.26 (d, 1H, J= 15.1 Hz), 
3.96 (t, 1H, J= 2.6 Hz), 3.89 (dd, 1H, J2= 2.2 Hz, J1= 12.7 Hz), 3.66 (dd, 1H, J2= 3.4 Hz, J1= 12.7 Hz), 3.30 
(dd, 1H, J2= 3.5 Hz, J1= 17.5 Hz), 2.83 (dd, 1H, J2= 9.0 Hz, J1= 17.5 Hz),  
13C-NMR (CDCl3, 100 MHz) δ= 170.8, 167.0, 166.5, 135.6, 131.9, 129.4, 128.6, 128.4, 119.2, 66.2, 59.5, 
52.0, 51.3, 48.2, 37.4 
Experimental part 
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[(2S,5S)-4-Benzyl-5-(tert-butoxycarbonylamino-methyl)-3,6-dioxo-piperazin-2-yl]-acetic acid allyl ester 
(248) 
To a solution of the azide 246 (269 mg, 0.75 mmol) in THF (2.5 mL), under nitrogen atmosphere and at -
20ºC, was added Me3P (828 µL of 1 M solution in THF, 0.83 mmol, 1.1 equiv) and 2-(t-
butoxycarbonyloxyimino)-2-phenylacetronitrile (Boc-ON, 206 mg, 1.1 equiv). After stirring for 5 h at r.t., 60 
mL of CH2Cl2 were added and the solution was extracted with H2O (3×30 mL) and brine, the organic phase 
was dried over Na2SO4 and volatiles were removed under reduced pressure. The residue was purified by 
flash chromatography on silica gel (CH2Cl2/MeOH, 99:1) to afford the desired product 248 as a white solid 
(253 mg, 78%). 
Cis: 
Rf (DCM/MeOH 95 :5)=0.43; Mp 57-58 ºC; [ ]20Dα =-123.7 (CHCl3, c=1.00); 
1H NMR (CDCl3, 400 MHz): δ= 7.28-7.36 (m, 5H), 7.06 (br s, 1H), 5.86-5.96 (m, 1H), 5.56 (d, 1H, J= 15.1 
Hz), 5.25-5.36 (m, 3H), 4.60-4.69 (m, 2H), 4.48-4.51 (m, 1H), 4.09 (d, 1H, J= 15.1 Hz), 3.80-3.86 (m, 2H), 
3.45-3.49 (m, 1H), 3.27 (dd, 1H, J1= 17.6 Hz, J2= 1.7 Hz), 2.85 (dd, 1H, J1= 17.6 Hz, J2= 11.1 Hz), 1.46 (s, 
9H) 
13C NMR (CDCl3, 100 MHz): δ= 171.5, 166.7, 164.9, 156.2, 135.6, 131.8, 129.4, 128.9, 128.5, 119.3, 80.8, 
66.4, 59.2, 52.4, 47.2, 40.8, 40.6, 28.7 
IR (Nujol) υ =3323, 3308, 1716, 1684, 1658, 1339, 1272, 1167, 1127. 
MS (FAB+) m/z (%) 432 (12) [M+H]+, 376 (49), 332 (41), 302 (16), 91 (100); Elemental analysis calcd% for 
C22H29N3O6: C 61.24, H 6.77, N 9.74; found C 61.47, H 7.03, N 9.56. 
 
Trans: Rf (DCM/MeOH 95:5) = 0.32; [ ]20Dα =+16.9 (CHCl3, c=1.00) 
1H-NMR (CDCl3, 400 MHz) δ= 7.27-7.37 (m, 5H), 5.92 (ddd, 1H, J3= 5.8 Hz, J2= 11.0 Hz, J1= 16.3 Hz), 5.51 
(d, 1H, J= 15.2 Hz), 5.32 (dd, 2H, J2= 13.8 Hz, J1= 26.0 Hz),  4.95 (m, 1H), 4.65 (d, 2H, J= 5.8 Hz), 4.49 (dd, 
1H, J2= 2.8 Hz, J1= 9.6 Hz), 4.10 (d, 1H, J= 15.0 Hz), 3.56 (ddd, 1H, J3= 2.2 Hz, J2= 6.1 Hz, J1= 14.5 Hz,), 
3.37 (dd, 1H, J2= 3.1 Hz, J1= 17.6 Hz), 2.78 (dd, 1H, J2= 9.7 Hz, J1= 17.6 Hz), 1.46 (s, 9H) 
13C-NMR (CDCl3, 100 MHz) = 171.0, 168.2, 165.7, 156.4, 135.9, 131.9, 129.3, 128.7, 128.3, 119.2, 80.5, 
66.2, 59.8, 51.2, 47.4, 40.9, 37.9, 28.7 
Experimental part 
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232 
[(2S,5S)-4-benzyl-5-(tert-butoxycarbonylamino-methyl)-3,6-dioxo-piperazin-2-yl]-acetic acid (232) 
To a solution of Boc-DKP-allyl 248 (242 mg, 0.56 mmol) in CH2Cl2 (3.0 mL), under nitrogen atmosphere and 
at 0 ºC, was added pyrrolidine (56 µL, 0.67 mmol, 1.2 equiv), PPh3 (26 mg, 0.10 mmol, 0.18 equiv) and then 
[Pd(PPh3)4] (24 mg, 0.02 mmol, 0.04 equiv). After stirring for 1 h at 0 ºC, EtOAc (25 mL) was added and the 
solution was extracted with aqueous NaHCO3 (4×10 mL). The combined aqueous phases were acidified to 
pH 2 with a 1 M KHSO4 solution and then extracted with CH2Cl2. The resulting organic phase was dried over 
Na2SO4 and the solvent evaporated to afford the desired product 232 as a fluffy white solid (209 mg, 95%). 
Cis: 
Mp 85-86 ºC; [ ]20Dα = -69.9 (c 1.0, CHCl3) 
1H NMR (CDCl3, 400 MHz, 50ºC) δ= 10.02 (br s, 1H), 8.05 (br s, 1H), 7.25-7.37 (m, 5H), 5.59 (d, 1H, J= 14.2 
Hz), 5.36 (br s, 1H), 4.52 (d, 1H, J=  11.4 Hz), 4.03 (br s, 1H), 3.88 (s, 1H), 3.79-3.85 (m, 1H), 3.49-3.54 (m, 
1H), 3.28 (dd, 1H, J1= 17.7 Hz, J2= 2.3 Hz), 2.74 (dd, 1H, J1= 17.7 Hz, J2= 11.4 Hz), 1.50 (s, 9H) 
13C NMR (CDCl3, 100 MHz, 50ºC) δ= 175.1, 168.1, 164.9, 157.0, 135.4, 129.4, 128.8, 128.6, 81.4, 59.5, 
52.4, 47.3, 40.9, 40.6, 28.7 
IR (Nujol): υ = 3382, 3325, 3227, 1715, 1659, 1647, 1272, 1162, 1125 
HRMS (ESI) m/z calcd for [C19H25N3NaO6]+ : 414.16356 [M+Na]+; found: 414.16367.  
Trans: 
[ ]20Dα =+5.42° (CHCl3, c=1.00) 
1H-NMR (CDCl3, 400 MHz) : δ= 7.23-7.37 (m, 5H), 5.49 (t, 1H, J= 13.8 Hz), 5.21-5.25 (m, 1H), 4.53 (t, 1H, J= 
9.6 Hz), 4.11 (d, 1H, J= 17.1 Hz), 3.91 (d, 1H, J= 15.0 Hz), 3.61 (m, 1H), 3.83 (s, 1H), 3.41-3.50 (m, 1H), 
2.64-2.75 (m, 1H), 1.45 (s, 9H) 
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251 
tert-butyl ((2S,5S)-1-benzyl-5-(2-(butylamino)-2-oxoethyl)-3,6-dioxopiperazin-2-yl)methylcarbamate 
(251) 
In a Schlenk tube under nitrogen containing 56 mg (0.14 mmol, 1 eq.) of cis-DKP 232cis in 2 mL acetonitrile 
were added at 0°C 82 mg of HATU (0.21 mmol, 1.5 eq.) and 0.074 mL of DIPEA (0.43 mmol, 3 eq.). After 
stirring for 30 minutes, 0.021 mL of butylamine (0.21 mmol, 1.5 eq.) were added and the reaction mixture 
was stirred for 24 hours at room temperature. The reaction mixture was then diluted in EtOAc and washed 
with KHSO4 1 M, saturated NaHCO3 and brine. The organic phase was then dried with Na2SO4 and filtered. 
The solvent was evaporated and the crude mixture was purified by flash chromatography (EA) affording 54 
mg (0.12 mmol, 87%) of 251 as a colourless oil. 
Rf (SiO2, EA)= 0.32; [ ]20Dα = -99.91° (CHCl3, c=0.56) 
1H NMR (CDCl3, 400 MHz): δ= 7.36-7.7.27 (m, 5H), 6.77 (bs, 1H), 6.32 (bs, 1H), 5.95 (bs, 1H), 5.54 (d, 1H, 
J= 15.1 Hz), 4.49 (m, 1H), 4.10 (d, 1H, J= 14.5 Hz), 3.87 (m, 1H), 3.75 (m, 1H), 3.27 (m, 2H), 3.09 (m, 1H), 
2.66 (m, 1H), 1.49 (m, 2H), 1.46 (s, 9H), 1.35 (m, 2H), 0.94 (t, 3H, J= 7.2 Hz) 
13C NMR (CDCl3, 100 MHz): δ= 170.5, 166.2, 165.2, 135.4, 129.5, 128.9, 128.6, 59.1, 52.9, 47.5, 47.1, 41.6, 
40.9, 40.2, 39.8, 31.8, 28.8, 20.5, 14.1 
IR (KBr): υ = 3427, 3321, 2962, 1649, 1541, 1452, 1385, 1367, 1336, 1273, 1168, 1062, 985, 846, 738, 702, 
518, 420 cm-1 
MS (ESI): m/z (%): 446.2 (28) [M+], 445.2 (100) [M+-H], 328.2 (60) 
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252 
Boc-(cis-DKP)2-NHBu (252) 
In 10 mL of DCM/TFA were added 57 mg (0.13 mmol, 1 eq.) Boc-cis-DKP-butylamide 251 and stirred for 30 
minutes. Solvent was evaporated and the crude mixture was dried under vacuum. Washing with a few mL of 
Et20 provoked the precipitation of the TFA salt. The solvent was removed with a Pasteur pipette capped with 
cotton wool and the salt was dried under vacuum affording the corresponding white TFA salt in a quantitative 
yield. In a Schlenk tube under nitrogen, 54 mg (0.13 mmol, 1 eq.) of Boc-cis-DKP-COOH 232cis were solved 
in dry DMF and  58 mg of HATU (0.15 mmol, 1 eq.) and 0.074 mL of DIPEA (0.54 mmol, 3 eq.) were added 
at 0°C. After 30 minutes, the TFA salt solved in a few mL of DMF was added to the mixture and the reaction 
was let reacting for 24h at r.t. The reaction mixture was dissolved in Et2O and H20 and the phases were 
separated in a dropping funnel. The aqueous phase was extracted a second time with Et2O and the organic 
phases were combined. The Et2O phase was subsequently washed with aqueous KHSO4 1M, saturated 
NaHCO3 solution and brine. The organic phase was then dried over Na2SO4 and concentrated with a rotary 
evaporator. The crude mixture was dried under vacuum and purified by a flash chromatography with 
EA/MeOH 95:5 as eluent affording the dimer of diketopiperazine 252 as a white solid in 54% yield (50 mg, 
0.07 mmol). 
Rf (SiO2, EA/MeOH 95:5) = 0.24, [ ]20Dα = -95.4° (CHCl3, c=0.23) 
1H-NMR (CDCl3, 400 MHz): δ= 8.28 (bs, 1H), 7.99 (bs, 1H), 7.80 (bs, 1H), 7.56 (bs, 1H), 7.56-7.22 (m, 10H), 
6.00 (bs, 1H), 5.57 (d, 1H, J=15.4 Hz), 5.49 (d, 1H, J=15.3 Hz), 4.27 (m, 2H), 4.11 (d, 1H, J=15.4 Hz), 4.02 
(d, 1H, J=15.3 Hz), 3.96 (m, 1H), 3.30-3.09 (m, 6H), 2.99 (m, 2H), 2.85 (m, 2H), 1.39 (m, 2H), 1.28 (m, 2H), 
1.07 (s, 9H), 0.81 (t, 3H, J=7.2 Hz) 
13C NMR (CDCl3, 100 MHz): δ= 172.5, 170.8, 166.8, 166.5, 166.2, 165.5, 168.2, 135.6, 135.4, 129.5, 129.4, 
128.7, 128.3, 80.2, 60.8, 59.3, 58.4, 53.9, 52.7, 47.3, 46.6, 42.8, 42.4, 40.2, 39.5, 38.2, 31.7, 28.2, 20.2, 14.2 
MS (ESI): m/z (%): 718.1 (100), 644.1 (44), 601.1 (44), 389.0 (37), 314.9 (12), 272.0 (5) 
IR (KBr): υ = 3450, 3076, 2951, 2930, 2862, 1641, 1560, 1452, 1385, 1275, 1167, 1064, 700, 443 cm-1 
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253 
Boc-(cis-DKP)3-NHBu (253) 
In a Schlenk tube under nitrogen were dissolved 17 mg (0.042 mmol, 1.5 eq.) of Boc-cis-DKP-COOH 232cis 
in acetonitrile and 16 mg (0.042 mmol, 1.5 eq.) of HATU and 0.015 mL of collidine (0.114 mmol, 4 eq.) were 
added at 0°C. After 30 minutes, 21 mg (0.029 mmol, 1 eq.) of the dimer 252 TFA salt were dissolved in a few 
mL of acetonitrile and added to the reaction mixture which was let at room temperature for 24 h. The reaction 
mixture was then dissolved in Et2O and H20 and the phases were separated in a dropping funnel. The 
aqueous phase was extracted a second time with Et2O and the organic phases were subsequently washed 
with aqueous KHSO4 1M, saturated NaHCO3 solution and brine. The organic phase was then dried over 
Na2SO4 and concentrated with a rotary evaporator. The crude mixture was dried under vacuum and purified 
by a flash chromatography with DCM/MeOH 95:5 as eluent affording the trimer of diketopiperazine 253 as a 
white solid in 80% yield (23 mg, 0.023 mmol). 
Rf (SiO2, DCM/MeOH 9:1) = 0.46, [ ]20Dα = -241.5° (CHCl3, c=0.23) 
1H-NMR (DMSO-d6, 400 MHz): δ= 8.40 (t, 1H, J=4.8Hz), 8.31 (t, 1H, J=5.6Hz), 8.25 (d, 1H, J=2.6Hz), 8.23 (d, 
1H, J=1.7Hz), 8.09 (d, 1H, J=2.0Hz), 7.99 (t, 1H, J=5.4Hz), 7.36-7.25 (m, 15H), 7.04 (t, 1H, J=5.8Hz), 5.16 (d, 
1H, J=6.9Hz), 5.13 (d, 1H, J=6.9Hz), 5.08 (d, 1H, J=15.4Hz), 4.31-4.23 (m, 3H), 4.20 (d, 1H, J=10.2Hz), 4.17 
(d, 1H, J=9.9Hz), 4.05 (d, 1H, J=15.2Hz), 3.87-3.84 (m, 2H), 3.75-3.64 (m, 3H), 3.61-3.50 (m, 4H), 3.12-3.03 
(m, 2H), 2.79-2.61 (m, 6H), 1.38 (m, 2H), 1.34 (s, 9H), 1.30-1.23 (m, 2H), 0.85 (t, 3H, J=7.3Hz) 
13C NMR (DMSO-d6, 100 MHz): δ= 170.77, 170.64, 169.80, 166.85, 166.64, 166.38, 166.08, 165.96, 165.85, 
137.42, 129.46, 128.58, 128.27, 79.07, 58.88, 58.69, 53.19, 52.74, 52.53, 47.58, 39.28, 31.96, 29.01, 20.46, 
14.54, 
MS (ESI): m/z (%): 991.3 (100), 939.3 (12), 684.2 (8)662.2 (6) 
IR (KBr): = 3493, 3304, 3098, 2952, 1669, 1550, 1457, 1339, 1288, 1254, 1206, 1168, 1127, 736, 700 
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254 
Boc-(cis-DKP)4-NHBu (254) 
In a Schlenk tube under nitrogen were dissolved 32 mg (0.082 mmol, 1.5 eq.) of cis-DKP 232cis in 
acetonitrile and 31 mg (0.082 mmol, 1.5 eq.) of HATU and 0.024 mL of collidine (0.218 mmol, 4 eq.) were 
added at 0°C. After 30 minutes, 55 mg (0.055 mmol, 1 eq.) of the trimer 253 TFA salt were dissolved in a few 
mL of acetonitrile and added to the reaction mixture which was let at room temperature for 24 h. The reaction 
mixture was then dissolved in Et2O and H20 and the phases were separated in a dropping funnel. The 
aqueous phase was extracted a second time with Et2O, reextracted with EA and the organic phases were 
subsequently washed with aqueous KHSO4 1M, saturated NaHCO3 solution and brine. The organic phase 
was then dried over Na2SO4 and concentrated with a rotary evaporator. The crude mixture was dried under 
vacuum and purified by a flash chromatography with DCM/MeOH 95:5, then, the eluent polarity was 
increased using a mixture DCM/MeOH 9:1. Finally, the use of EA/MeOH 85/15 afforded the tetramer of 
diketopiperazine 254 as a white solid in 71% yield (49 mg, 0.039 mmol). 
Rf (SiO2, DCM/MeOH 95:5)= 0.32; [ ]20Dα = -53.9° (MeOH, c=0.36) 
1H NMR (DMSO-d6, 400 MHz): δ= 8.42 (t, 1H, J=5.4Hz) 8.32 (m, 2H), 8.29 (d, 1H, J=2.5Hz), 8.25 (bs, 1H), 
8.23 (d, 1H, J=2.1Hz), 8.11 (bs, 1H), 8.00 (t, 1H, J=5.6Hz), 7.35-7.25 (m, 20H), 7.05 (t, 1H, J=6.1Hz), 5.16-
5.06 (m, 4H), 4.31-4.12 (m, 7H), 4.05 (d, 1H, J=15.5Hz), 3.90-3.81 (m, 4H), 3.73-3.68 (m, 3H), 361-3.50 (m, 
4H), 3.37-3.34 (m, 1H), 3.12-2.99 (m, 2H), 2.98 (bs, 1H), 2.91 (d, 1H, J=4.9Hz), 2.87 (bs, 1H), 2.74-2.63 (m, 
5H), 1.42-1.36 (m, 2H), 1.34 (s, 9H), 1.25 (m, 2H), 0.85 (t, 3H, J=7.3Hz) 
13C NMR (DMSO-d6, 100 MHz): δ= 170.33, 170.17, 169.75, 169.40, 166.55, 166.43, 166.31, 166.18, 165.98, 
165.74, 165.54, 165.44, 165.36, 156.03, 137.02, 136.96, 129.04, 128.19, 128.15, 127.85, 78.66, 59.11, 
58.46, 58.38, 58.22, 52.77, 52.36, 52.27, 52.12, 51.94, 47.28, 47.17, 41.73, 41.32, 41.06, 40.77, 38.88, 
37.11, 35.44, 31.55, 28.61, 20.05, 14.13 
MS (ESI): m/z (%) 1264.5 (100), 985.4 (17), 963.4 (12) 
IR (KBr): υ = 3469, 3298, 3241, 3083, 2935, 2872, 1667, 1639, 1556, 1546, 1458, 1335, 1287, 1253, 1168, 
1127, 1070, 736, 700 
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256 
(S)-benzyl 2-((S)-2-((S)-2-(2-((2S,5R)-4-benzyl-5-((tert-butoxycarbonylamino)methyl)-3,6-
dioxopiperazin-2-yl)acetamido)-3-methylbutanamido)propanamido)-3-phenylpropanoate (256) 
In a Schlenk tube under nitrogen were solved 97 mg (0.25 mmol, 1 eq.) of Boc-trans-DKP-COOH 232trans 
in 2 mL acetonitrile. At 0°C were added 141 mg of HATU (0.37 mmol, 1.5 eq.) and 0.131 mL of collidine 
(0.99 mmol, 4 eq.) and the reaction was run for 30 minutes. Then, 200 mg of TFA•Val-Ala-Phe-OBn (0.37 
mmol, 1.5 eq.) were dissolved in acetonitrile and DCM because of its low solubility and added to the reaction 
mixture. After two days, the reaction mixture was solved in EtOAc and washed successively by KHSO4 1M, 
saturated NaHCO3 and brine. The organic phase was dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography with DCM/MeOH 97:3 as eluent affording 
180 mg of the expected product 256 (0.225 mmol, 90%). 
Rf (SiO2, DCM/MeOH 95:5)=0.33 
1H NMR (CDCl3, 400 MHz): δ= 7.70 (bs, 1H), 7.49 (bs, 1H), 7.36-7.00 (m, 17 H), 5.69 (bs, 1H), 5.43 (d, 1H, 
J=15.1 Hz), 5.13-5.02 (m, 2H), 4.83 (dd, 1H, J1=6.7 Hz, J2=13.4 Hz), 4.64 (m, 1H), 4.51-4.43 (m, 2H), 4.06 (d, 
1H, J=15.0 Hz), 3.74-3.68 (m, 1H), 3.50-3.45 (m, 1H), 3.28-3.21 (m, 1H), 3.12-2.97 (m, 3H), 2.67 (m, 1H), 
2.03 (m, 1H), 1.40 (s, 9H), 1.30 (d, 3H, J=7.0Hz), 0.89 (d, 6H, J= 6.8Hz) 
13C NMR (CDCl3, 100 MHz): δ= 172.1, 171.1, 170.9, 170.7, 169.7, 167.5, 166.2, 156.1, 135.7, 135.3, 135.0, 
129.3, 128.9, 128.6, 127.9, 127.0, 67.2, 59.9, 58.4, 53.5, 51.4, 48.7, 47.3, 37.7, 31.4, 28.3, 19.3, 18.3 
MS (ESI): m/z (%) 821.4 (100) [M+Na+], 524.4 (57) 
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257 
Boc-trans-DKP-Val-Ala-Phe-OH (257) 
In 10 mL MeOH in a Schlenk tube under nitrogen were dissolved 170 mg (0.21 mmol) of Boc-trans-DKP-Val-
Ala-Phe-Bn 256 and 17 mg (10 mass%) of Pd(OH)2. The Schlenk tube was then put under vacuum and 
flushed 3 times by a sequence vacuum-hydrogen. The Schlenk tube was then filled with H2 (1 atm.) and 
agitated for 24h. The solution was then filtered on a celite pad and washed with 200 mL MeOH. The solution 
was condensed under reduced pressure and dried under vacuum affording 101 mg (0.14 mmol, 68%) of the 
debenzylated product 257 as a white amorphous solid. 
[ ]20Dα = +19.23° (MeOH, c=0.60) 
1H NMR (CD3OH, 400 MHz): δ= 8.26 (bs, 1H), 8.22 (d, 1H, J= 7.3 Hz), 8.11 (d, 1H, J= 8.2 Hz), 7.73 (d, 1H, 
J= 7.3 Hz), 7.35-7.16 (m, 10H), 7.02 (t, 1H, J= 6.1 Hz), 5.31 (d, 1H, J= 15.3 Hz), 4.55 (m, 1H), 4.38 (t, 1H, J= 
7.1 Hz), 4.26 (dd, 1H, J1= 6.1 Hz, J2= 7.8 Hz), 4.00 (d, 1H, J= 15.4 Hz), 3.77-3.47 (m, 3H), 3.23-3.18 (m, 1H), 
3.07-3.02 (m, 2H), 2.87 (ddd, 2H, J1= 5.9 Hz, J2= 15.4 Hz, J3= 20.5 Hz), 2.22-2.14 (m, 1H), 1.43 (s, 9H), 1.32 
(d, 3H, J= 7.0 Hz), 0.93 (dd, 1H, J1= 6.8 Hz, J2= 10.6 Hz) 
13C NMR (CD3OH, 100 MHz): δ= 174.19, 172.95, 172.15, 170.95, 168.03, 167.42, 156.86, 137.22, 135.83, 
129.23, 128.49, 127.90, 127.70, 127.46, 126.23, 79.30, 63.75, 59.90, 58.63, 54.73, 51.26, 49.32, 48.58, 
40.95, 40.23, 38.79, 37.10, 31.23, 29.86, 27.37, 18.48, 16.65, 
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258 
Cyclic trans-DKP-Val-Ala-Phe (258) 
In a tarred flask were reacted 31 mg (0.044 mmol, 1 eq.) of Boc-trans-DKP-Val-Ala-Phe-OH 257 in 5 ml 
DCM/TFA 1:1 for 30 minutes. Once the deprotection completed, the solvent mixture was evaporated under 
reduced pressure and the flask was then dried under vacuum. A few mL of Et2O were added resulting in the 
precipitation of the TFA salt. Et2O was removed using a Pasteur pipette capped with cotton wool and the salt 
was dried under vacuum. After weighing to control whether the mass of TFA salt corresponded to a 
quantitative Boc deprotection, the flask was put under nitrogen and 22 mL of degassed DMF were added 
(substrate concentration 2 mM). The flask was put in an ice bath and 0.023 mL (0.175 mmol, 4 eq.) of 
collidine were added followed by addition of 33 mg (0.087 mmol, 2 eq.) of HATU. Two more equivalents of 
HATU were added after one day of reaction. Reaction was let at r.t. for 3 days. The reaction mixture was 
mixed to 50 mL of water and 150 mL of Et2O, the organic phase was collected and the aqueous phase was 
extracted a second time with EtOAc. The organic phases were gathered and washed with KHSO4 1M, 
NaHCO3 sat. and brine. The organic phase was dried with Na2SO4, filtered and concentrated under vacuum. 
The crude residue was purified by flash chromatography with DCM/MeOH 95:5 and afforded 8 mg (0.0135 
mmol, 31%) of the cyclised product. 
Rf (SiO2, DCM/MeOH 9:1)=0.45 
1H NMR (CD3OH, 400 MHz): δ= 8.83 (d, 0.23H, J= 5.4 Hz), 8.60 (dd, 1H, J1= 3.8 Hz, J2= 9.2 Hz), 8.53 (d, 
0.77H, J= 6.1 Hz), 8.32 (s, 1H), 8.12 (d, 1H, J= 9.1 Hz), 7.52 (d, 1H, J= 6.8 Hz), 7.38-7.13 (m, 10H), 5.28 (d, 
1H, J= 15.4 Hz), 4.78 (m, 1H), 4.48 (dd, 1H, J1= 7.1 Hz, J2= 9.3 Hz), 4.33-4.31 (m, 1H), 4.25 (dd, 1H, J1= 7.8 
Hz, J2= 15.0 Hz), 4.10 (d, 1H, J= 15.7 Hz), 4.01 (dd, 1H, J1= 6.2 Hz, J2= 12.3 Hz), 3.81 (d, 1H, J= 5.2 Hz), 
3.26-3.06 (m, 3H), 2.97 (dd, 1H, J1= 9.7 Hz, J2= 12.9 Hz), 2.37 (dd, 1H, J1= 2.7 Hz, J2= 13.0 Hz), 2.18 (m, 
1H), 1.37 (d, 3H, J= 7.3 Hz), 1.04 (dd, 6H, J1= 4.3 Hz, J2= 6.9 Hz) 
13C NMR (CD3OH, 100 MHz): δ= 173.24, 172.72, 172.21, 169.39, 169.12, 137.16, 135.93, 128.82, 128.57, 
128.03, 127.60, 126.34, 70.13, 61.52, 59.21, 57.39, 52.14, 38.66, 38.33, 35.93, 28.89, 18.21, 16.93, 16.79, 
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262 
Boc-Pro-cis-DKP allyl ester (262) 
In 10 mL of DCM/TFA were added 271 mg (0.63 mmol, 1 eq.) of Boc-cis-DKP-allyl ester 248 and stirred for 
30 minutes. Solvent was evaporated and the crude mixture was dried under vacuum. Washing with a few mL 
of Et20 provoked the precipitation of the TFA salt. The solvent was removed with a Pasteur pipette capped 
with cotton wool and the salt was dried under vacuum affording the corresponding white TFA salt in a 
quantitative yield. A Schlenk tube under nitrogen was put in an ice bath were added 195 mg (0.91 mmol, 1.5 
eq.) of Boc-(S)-proline, 344 mg (0.91 mmol, 1.5 eq.) of HATU and 0.32 mL (2.42 mmol, 4 eq.) of collidine in 
10 mL acetonitrile. The reaction was let running for 30 minutes and then the TFA salt was dissolved in a few 
mL of acetonitrile and added to the reaction mixture. After 24 h of reaction, the reaction mixture was solved 
in EtOAc and washed successively by KHSO4 1M, saturated NaHCO3 and brine. The organic phase was 
dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified by flash 
chromatography with DCM/MeOH 95:5 as eluent affording 302 mg of the expected product 262 (0.57 mmol, 
95%). 
Rf (DCM/MeOH 95:5)= 0.36, [ ]20Dα = -120.11 (CHCl3, c=1.00) 
1H NMR (CDCl3, 400 MHz): δ= 7.36-7.30 (m, 6H), 6.71 (bs, 1H), 5.92 (tdd, 1H, J1= 5.9 Hz, J2= 10.5 Hz, J3= 
16.4 Hz), 5.55 (d, 1H, J= 14.2 Hz), 5.32 (dd, 2H, J1= 13.8 Hz, J2= 25.6 Hz), 4.65 (dq, 2H, J1= 6.0 Hz, J2= 
13.2 Hz), 4.48 (td, 1H, J1= 2.5 Hz, J2= 11.0 Hz), 4.30 (bs, 1H), 4.13 (d, 1H, J= 15.0 Hz), 3.94 (m, 1H), 3.84 
(bs, 1H), 3.67-3.62 (m, 1H), 3.50-3.21 (m, 4H), 3.08-2.99 (m, 1H), 2.37 (bs, 1H), 1.88 (bs, 2H), 1.45 (s, 9H) 
13C NMR (CDCl3, 100 MHz): δ= 172.9, 165.5, 164.4, 135.1, 131.4, 128.9, 128.6, 128.1, 119.1, 80.7, 66.1, 
60.1, 57.8, 52.0, 47.3, 46.9, 39.5, 38.7, 28.4, 28.2, 24.5 
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263 
Boc-Pro-cis-DKP-COOH (263) 
In a Schlenk tube under nitrogen were dissolved 300 mg (0.57 mmol, 1 eq.) of Boc-Pro-cis-DKP-COOAllyl 
262 in 4 mL of DCM. At 0°C were added subsequently 0.056 mL (0.68 mmol, 1.2 eq.) of pyrrolidine, 27 mg 
(0.102 mmol, 0.18 eq.) of PPh3 and 26 mg (0.023 mmol, 0.04 eq.) of Pd(PPh3)4. Reaction was run for 2 h 
and the reaction mixture was then dissolved in 50 mL EtOAc and was extracted twice with a saturated 
solution of NaHCO3. The aqueous phase was washed a second time with EtOAc and acidified to pH=2 with 
KHSO4 1M. The aqueous phase was then extracted with 100 mL DCM (3 times). The organic phase was 
then dried with Na2SO4, filtered and condensed under reduced pressure. The expected product 263 could be 
obtained after drying under vacuum as a white solid (256 mg, 0.54 mmol, 95%). 
[ ]20Dα = -48.22 (MeOH, c=1.00) 
1H NMR (DMSO-d6, 400 MHz): δ= 12.65 (s, 1H), 8.28 (dd, 1H, J1= 1.9 Hz, J2= 13.4 Hz), 8.15 (bs, 1H), 7.35-
7.26 (m, 5H), 5.05 (d, 1H, J= 15.2 Hz), 4.29 (m, 1H), 4.15 (d, 1H, J= 15.0 Hz), 4.11-4.04 (m, 1H), 3.79-3.65 
(m, 2H), 3.43-3.38 (m, 3H), 2.74 (m, 2H), 2.06-2.01 (m, 1H), 1.86-1.67 (m, 3H), 1.28 (s, 9H) 
13C NMR (DMSO-d6, 100 MHz): 174.97, 172.83, 166.72, 166.19, 154.54, 135.97, 128.49, 127.77, 127.49, 
80.07, 60.13, 58.17, 51.91, 46.45, 39.77, 38.04, 31.09, 27.24, 23.24 
MS (ESI): m/z (%) 999.0 (100) [2M+Na+], 511.2 (88) [M+Na+], 303.4 (40) 
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264 
Boc-Pro-COO-cis-DKP allyl ester (264) 
In a Schlenk tube under nitrogen at 0°C were dissolved in DCM/THF 271 mg (1.26 mmol, 1.5 eq.) of Boc-
(S)-Proline, 260 mg (1.26 mmol, 1.5 eq.) of DCC, 170 mg (1.26 mmol, 1.5 eq.) of HOBt and 308 mg (2.52 
mmol, 3 eq.) of DMAP. After 30 minutes were added 279 mg (0.84 mmol, 1 eq.) of HO-DKP-COOAllyl 245 
and the reaction was run for two days. The reaction mixture was solved in EtOAc and washed successively 
by KHSO4 1M, saturated NaHCO3 and brine. The organic phase was dried over Na2SO4 and concentrated 
under reduced pressure. The crude product was purified by flash chromatography with DCM/MeOH 95:5 as 
eluent affording 225 mg of the expected product 264 (0.42 mmol, 50%). 
Rf (DCM/MeOH 95 :5)= 0.40, [ ]20Dα = -87.29 (CHCl3, c=1.13) 
1H NMR (CDCl3, 400 MHz): δ= 7.35-7.19 (m, 5H), 6.97 (bd, 1H), 5.94-5.84 (m, 1H), 5.34-5.23 (m, 3H), 4.68-
4.57 (m, 3H), 4.52 (d, 1H, J= 9.4 Hz), 4.33 (m, 2H), 4.15 (dd, 1H, J1= 3.4 Hz, J2= 8.5 Hz), 4.04-3.94 (m, 2H), 
3.53-3.34 (m, 2H), 3.27-3.23 (m, 1H), 2.87 (ddd, 1H, J1= 10.9 Hz, J2= 17.3 Hz, J3= 27.9 Hz), 2.19 (m, 1H), 
1.89 (m, 2H), 1.43 (s, 9H) 
13C NMR (CDCl3, 100 MHz): δ= 172.6, 170.6, 165.3, 164.4, 154.3, 153.5, 134.6, 131.5, 129.13, 128.30, 
119.4, 80.3, 66.2, 62.3, 58.7, 57.5, 52.1, 47.3, 46.6, 40.2, 30.9, 29.9, 28.4, 24.4, 23.7 
 
 
Experimental part 
 147 
N
NH
COOH
O
O
Bn O
O N
Boc
 
 
265 
Boc-Pro-COO-cis-DKP-COOH (265) 
In a Schlenk tube under nitrogen were dissolved 225 mg (0.57 mmol, 1 eq.) of Boc-Pro-COO-cis-DKP-
COOAllyl 264 in 3 mL of DCM. At 0°C were added subsequently 0.042 mL (0.51 mmol, 1.2 eq.) of pyrrolidine, 
20 mg (0.076 mmol, 0.18 eq.) of PPh3 and 20 mg (0.017 mmol, 0.04 eq.) of Pd(PPh3)4. Reaction was run for 
2 h and the reaction mixture was then dissolved in 50 mL EtOAc and was extracted twice with a saturated 
solution of NaHCO3. The aqueous phase was washed a second time with EtOAc and acidified to pH=2 with 
KHSO4 1M. The aqueous phase was then extracted with 100 mL DCM (3 times). The organic phase was 
then dried with Na2SO4, filtered and condensed under reduced pressure. The expected product 265 could be 
obtained after drying under vacuum as a white solid (177 mg, 0.36 mmol, 86%). 
[ ]20Dα = -20.87 (MeOH, c=1.00) 
1H-NMR (CD3OH, 400 MHz): δ= 8.29 (s, 1H), 7.35-7.28 (m, 5H), 4.81 (bs, 1H), 4.62 (d, 1H, J= 15.2 Hz), 
4.52-4.47 (m, 2H), 4.41 (dq, 1H, J1= 2.8 Hz, J2= 12.0 Hz), 4.28-4.20 (m, 2H), 3.49-3.44 (m, 1H), 3.41-3.35 (m, 
1H), 3.04 (ddd, 1H, J1= 4.0 Hz, J2= 8.8 Hz, J3= 16.6 Hz), 2.91 (ddd, 1H, J1= 5.2 Hz, J2= 8.9 Hz, J3= 16.5 Hz), 
2.31-2.21 (m, 1H), 1.91-1.82 (m, 3H), 1.36 (s, 9H) 
13C-NMR (CD3OH, 100 MHz): δ= 172.50, 172.17, 166.80, 165.33, 154.19, 136.22, 128.54, 127.57, 80.35, 
63.22, 59.26, 58.78, 52.36, 46.04, 40.32, 30.26, 27.28, 27.14, 23.10 
MS (ESI): m/z (%) 1001.0 (25) [2M+Na+], 512.2 (100) [M+Na+], 456.2 (11), 303.4 (33) 
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Summary 
 
The efficient synthesis of a γ-butyrolactone based δ-amino acid was realised starting from furan methyl ester. 
Its enantioselecive cyclopropanation by copper triflate and a chiral bis-oxazoline led to the formation of an 
enantiopure cyclopropanated furan product which could be subjected to ozonolysis affording a cyclopropane 
aldehyde having three chiral centers. A Sakurai allylation was performed efficiently in high d.r. The 
lactonisation of the allylated cyclopropane alcohol could be realised with barium hydroxide. This reaction 
could be scaled up using triethylamine in the same conditions. The reductive amination of the resulting 
lactonaldehyde could be realised in good yields in mild conditions. The Boc protection of the secondary 
amine and the PMB cleavage were performed affording the lactone with a protected primary amine. The 
allylic double bond could be oxidised by ruthenium chloride and sodium periodate affording the δ-amino acid 
199 in good yields (Scheme 85). 
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 Scheme 85: Synthesis of the δ-amino acid 
 
Modification of the lactone by α-substitution was investigated to obtain a better NMR dispersion. The α-
methylation with LDA and methyl iodide led to poor diastereoselectivities (d.r. 3/1). The α-fluorination was 
not diastereoselective as well (d.r. 2/1) and yields were poor. The α-dimethylation of the lactone could be 
performed in good yields and the resulting δ-amino acid showed an excellent NMR dispersion for further 
foldamers studies (Scheme 86). 
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 Scheme 86: α-substitution of the lactone ring and new δ-amino acid synthesis 
 
The liquid-phase synthesis of the desired tetramer of dimethylated δ-amino acid could not be performed, 
even by using efficient coupling reagents. The synthesis of mixed α-δ-peptides with the non-methylated 
building block was realised. First, an alternated α-δ-pentapeptide containing L-Phe and the lactone building 
block was efficiently synthesised and its secondary structure analysed by various techniques. Despite 
overlapping of some protons in NMR spectroscopy, some NOE contacts could be observed and allowed 
computational studies using NOE constraints. The calculations predicted an extended loop conformation of 
the pentapeptide and other analyses such as IR in solution or CD spectroscopy are in favour of 
intramolecular hydrogen bonding. CD spectra refences missing for that type of alternated peptide, no 
comparison could be done with similar peptides. The secondary structure could not be determined with 
certainty and attemps to crystallise the peptide in a stable form failed (Scheme 87). 
 
Summary 
 150 
OO
NH
NH
CO2Bn
O
NH
OO
NH
O
O
NHBoc
O
Ph
Ph
Ph
214
 
 
 Scheme 87: Alternated α-δ-peptide 
 
Secondly, a heptapeptide containing only one δ-amino acid was synthesised in order to know whether this 
building block could induce hairpin secondary structures. IR in solution revealed the presence of 
intramolecular hydrogen bonding and CD spectroscopy showed interesting features suggesting the presence 
of a stable secondary structure although its CD spectrum looked a little disorganised. Its 2D-NMR analysis 
revealed interstrand contacts and showed that this heptapeptide was forming, among other things, a 13-
membered hydrogen-bonded ring. As a consequence, we came to the conclusion that it did not adopt a 
hairpin conformation but a disorganised helicoidal structure (Scheme 88). 
 
 
 
 Scheme 88: Heptapeptide containing one δ-amino acid scaffold 
 
For the second part of this project, the ability of cis-DKP in β-bend ribbon structure was investigated. The 
trimer of DKP could be synthesised and fully characterised and revealed a partial β-bend ribbon 
conformation. The tetramer, on the other hand, could not be fully characterised by 2D-NMR, but its CD 
spectrum showed the presence of a stable secondary structure and comparison with other β-bend ribbon CD 
spectra in the literature showed a similar behaviour in terms of shapes and intensities. The CD data collected, 
in addition to proton-deuterium exchange analysis are in favour of a stable β-bend ribbon secondary 
structure (Scheme 89). 
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 Scheme 89: Trimer and tetramer of the diketopiperazine scaffold 
 
A short cyclic peptide based on a trans-DKP scaffold was successfully synthesised and fully characterised by 
2D NMR spectroscopy. The presence of a γ-turn in the peptide was detected and confirmed preliminary 
computational studies realised on a similar peptide. It is very probable that a pentapeptide containing a RGD 
sequence and the trans-DKP scaffold would as well induce a γ-turn, whose presence is primordial for its 
activity against integrins αvβ3 (Scheme 90). 
 
 
 
 Scheme 90: Cyclic peptide containing a trans-DKP building block 
 
Finally, two potential tripeptidic organocatalysts were synthesised, each of them containing a cis-DKP and 
being linked by an amide or an ester bond to a proline. Their investigation in organocatalysed aldol reaction 
and Michael addition is now in progress (Scheme 91). 
 
 
 Scheme 91: Potential organocatalysts containing the cis-DKP scaffold
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 157 
(1S,5S,6S)-(-)-2-Oxabicyclo[3.1.0]hex-3-ene-3,6-dicarboxylic 6-ethylester-3-methyl ester (189) in CDCl3 
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 158 
(1S,2R,3S)-2-(ethoxycarbonyl)-3-formylcyclopropyl methyl oxalate (190) in CDCl3 
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 159 
(1S,2R,3R)-2-(ethoxycarbonyl)-3-((S)-1-hydroxybut-3-enyl)cyclopropyl methyl oxalate (191) in CDCl3 
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 160 
(2S/R,3S)-2-Allyl-5-oxotetrahydrofuran-3-carbaldehyde (194) in CDCl3 
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 161 
(2R/S, 3S, 4S, 5S)-5-Allyl-4-formyl-2-hydroxy-tetrahydro-furan-2,3-dicarboxylic acid 3-ethyl ester 2-
methyl ester (193) in CDCl3 
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 162 
(4S,5S)-5-Allyl-4-[(4-methoxy-benzylamino)-methyl]-dihydro-furan-2-one (195) in CDCl3 
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 163 
4-(1’-Hydroxy-but-3’-enyl)-1-(para-methoxy-benzyl)-pyrrolidin-2-one (196) in CDCl3 
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 164 
(2S,3S)-(2-Allyl-5-oxo-tetrahydro-furan-3-ylmethyl)-(4-methoxy-benzyl)-carbamic acid tert-butyl ester 
(197) in CDCl3 
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 165 
(2S,3S)-(-)-(2-Allyl-5-oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-butyl ester (198) in CDCl3 
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 166 
(-)-(2S,3S)-[3-(tert-Butoxycarbonylamino-methyl)-5-oxo-tetrahydro-furan-2-yl]-acetic acid (200) in 
DMSO-d6 
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 167 
tert-butyl-((2S,3S,4R)-2-allyl-4-methyl-5-oxotetrahydrofuran-3-yl)methyl(4-methoxybenzyl) carbamate 
(200) in CDCl3 
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 168 
tert-butyl ((2S,3S,4R)-2-allyl-4-methyl-5-oxotetrahydrofuran-3-yl)methylcarbamate in CDCl3 
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 169 
2-((2S,3S,4R)-3-((tert-butoxycarbonylamino)methyl)-4-methyl-5-oxotetrahydrofuran-2-yl)acetic acid in 
DMSO-d6 
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 170 
tert-butyl ((2S,3S,4R)-2-allyl-4-fluoro-5-oxotetrahydrofuran-3-yl)methyl(4-methoxybenzyl) carbamate 
(201) in CDCl3: 1H and 19F NMR 
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 171 
(2S, 3S)-(2-Allyl-4,4-dimethyl-5-oxo-tetrahydro-furan-3-ylmethyl)-(4-methoxy-benzyl)-carbamic acid 
tert-butyl ester (202) in CDCl3 
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 172 
(2S, 3S)-(2-Allyl-4,4-dimethyl-5-oxo-tetrahydro-furan-3-ylmethyl)-carbamic acid tert-butyl ester (203) 
in CDCl3 
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 173 
(2S, 3S)-[3-(tert-Butoxycarbonylamino-methyl)-4,4-dimethyl-5-oxo-tetrahydro-furan-2-yl]-acetic acid 
(204) in DMSO-d6 
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 174 
[3-(tert-Butoxycarbonylamino-methyl)-4,4-dimethyl-5-oxo-tetrahydro-furan-2-yl]-acetic acid benzyl 
ester (205) in CDCl3 
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 175 
Boc-(DiMeLac)2-Bn (206) in CDCl3 
 
 
 
Boc-(DiMeLac)3-Bn (207) in DMSO-d6 
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 176 
Boc-Lac-Phe-Bn (210) in CDCl3 
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 177 
Boc-Phe-Lac-Phe-Bn (212) in CDCl3 
 
 
 
Boc-Lac-Phe-Lac-Phe-Bn (213) in CDCl3 
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 178 
Boc-Phe-Lac-Phe -Lac-Phe-Bn (214) in CD3OH 
 
 
 
Boc-Lac-Gly-Val-Phe-Bn (218) in CDCl3 
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 179 
Boc-Ala-Lac-Gly-Val-Phe-Bn (219) in CDCl3 
 
 
 
Boc-Phe-Ala-Lac-Gly-Val-Phe-Bn (220) in CDCl3 
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 180 
Boc-Val-Phe-Ala-Lac-Gly-Val-Phe-Bn (221) in CD3OH 
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 181 
(S)-N-Benzyl-3-tert-butoxycarbonylamino-N-[(S)-2-hydroxy-1-methoxycarbonyl-ethyl]-succinamic 
acid allyl ester (244) in CDCl3 
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 182 
[(2S,5S)-4-Benzyl-5-hydroxymethyl-3,6-dioxo-piperazin-2-yl]-acetic acid allyl ester (245) in CDCl3 
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 183 
[(2S,5S)-5-Azidomethyl-4-benzyl-3,6-dioxo-piperazin-2-yl]-acetic acid allyl ester(246) in CDCl3 
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 184 
[(2S,5S)-4-Benzyl-5-(tert-butoxycarbonylamino-methyl)-3,6-dioxo-piperazin-2-yl]-acetic acid allyl ester 
(248) in CDCl3 
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 185 
[(2S,5S)-4-benzyl-5-(tert-butoxycarbonylamino-methyl)-3,6-dioxo-piperazin-2-yl]-acetic acid (232cis) 
in CDCl3 at 50°C 
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 186 
[(2S,5R)-4-Benzyl-5-hydroxymethyl-3,6-dioxo-piperazin-2-yl]-acetic acid allyl ester (245) in CDCl3 
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 187 
Allyl 2-((2S,5R)-5-(azidomethyl)-4-benzyl-3,6-dioxopiperazin-2-yl)acetate (246trans) in CDCl3 
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 188 
[(2S,5R)-4-Benzyl-5-(tert-butoxycarbonylamino-methyl)-3,6-dioxo-piperazin-2-yl]-acetic acid allyl ester 
(248) in CDCl3 
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 189 
2-((2S,5R)-4-benzyl-5-((tert-butoxycarbonylamino)methyl)-3,6-dioxopiperazin-2-yl)acetic acid 
(232trans) in CDCl3 at 50°C 
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 190 
Boc-(cis-DKP)2-NHBu (252) in CDCl3 
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 191 
Boc-(cis-DKP)3-NHBu (253) in CDCl3 
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 192 
Boc-(cis-DKP)4-NHBu (254) in DMSO-d6 
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 193 
Boc-trans-DKP-Val-Ala-Phe-Bn (256) in CDCl3 
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 194 
Boc-trans-DKP-Val-Ala-Phe-OH (257) in CD3OH 
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 195 
Cyclo[trans-DKP-Val-Ala-Phe] (258) in CD3OH 
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 196 
Boc-Pro-cis-DKP allyl ester (262) in CDCl3 
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 197 
Boc-Pro-cis-DKP-COOH (263) in CD3OH 
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 198 
Boc-Pro-COO-cis-DKP allyl ester (264) in CDCl3 
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 199 
Boc-Pro-COO-cis-DKP-COOH (265) in CD3OH 
 
 
 
 
 
 
